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ABSTRACT
The pathogenesis of portal hypertension in patients with cirrhosis is
poorly understood and current treatment modalities are unsatisfactory.
Transjugular intrahepatic portosystemic stent-shunt (TIPSS) is an
interventional radiological technique involving the creation of a communication
between the hepatic and the portal veins that is kept open using an
expandable metal stent. Its introduction reduces the portal pressure which (a)
helps in the management of portal hypertension and (b) allows us to study the
contribution of portal pressure to the syndrome of cirrhosis.
The purpose of this thesis was to evaluate
(i) the effect of TIPSS on the natural history of cirrhosis
(ii) the changes in shunt function following its insertion and study the potential
pathogenic mechanisms
(iii) the place of TIPSS in the management of variceal haemorrhage in patients
with cirrhosis and
(iv) the use of TIPSS as a 'model' to study the pathogenesis of sodium
retention in patients with cirrhosis.
The thesis aims to answer these questions by studying defined cohorts of
patients with cirrhosis and portal hypertension undergoing TIPSS insertion for
a variety of indications. The thesis is divided into various sections which deal
with the above questions. The first section deals with the outcome of patients
with cirrhosis treated with TIPSS and assesses the factors predicting mortality,
rebleeding, encephalopathy and shunt insufficiency. It also prospectively
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assesses changes in liver function, neuropsychological profile, haematological
profile and appraises their relationship with changes in the portal pressure.
Studies in the next section were designed to evaluate the methods for
assessment of shunt function and to study the pathogenesis of shunt
insufficiency. The place ofTIPSS in the management ofvariceal haemorrhage
in patients with cirrhosis is evaluated in a randomised and controlled study in
comparison with variceal band ligation. The last section looks at the
mechanisms of sodium retention in cirrhosis particularly with reference to the
'hepatorenal reflex'. The final chapter is dedicated to discussing the findings of
this study in the light of the available literature and define the areas of
deficiency in our understanding and to outline future perspectives.
In conclusion, TIPSS is an exciting innovation which is relatively safe
and can be performed in the vast majority of patients with cirrhosis with a very
low procedure related mortality. Although its place in the management of
uncontrolled variceal haemorrhage appears certain, further controlled studies
are needed to assess its role in the secondary prophylaxis of variceal
haemorrhage and in refractory ascites.
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LEGENDS TO FIGURES
Figure 1.1: Schematic representation of factors involved in the initiation and
maintenance of sodium retention in patients with cirrhosis.
Figure 1.2: An approach to the management of ascites in patients with
cirrhosis. OLT-Orthotopic Liver Transplantation, TIPSS-Transjugular
intrahepatic portosystemic stent-shunt.
Figure 1.3: Schematic representation of the various factors involved in the
pathogenesis of chronic hepatic encephalopathy.
Figure 1.3 (inset): Proposed mechanisms of neurotoxicity of NH3. Ammonia
inhibits the cellular chloride channels which contribute to the depression of the
CNS. Ammonia was thought to combine with a-ketoglutarate, thereby
depleting the CNS of intermediates of the citric acid cycle. This is unlikely
because ammonia is metabolised in the brain by combination with glutamate
to form glutamine but may affect energy metabolism by disturbing the malate-
aspartate shuttle. Ammonia facilitates the cerebral uptake of tryptophan which
is a substrate for the generation of various neuroactive metabolites including
serotonin. Ammonia reduces glutamatergic neurotransmission, causing
neurodepression.
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Figure 2.1. This figure shows the steps involved in the insertion ofTIPSS. (a)
the guide wire is advanced into the middle hepatic vein (b) the stylet is
advanced over the transjugular needle to puncture a branch of the portal vein
and a guide wire is introduced into the splenic vein (c) an angioplasty balloon
is used to dilate the track, the two waists represent the junction of the hepatic
parenchyma and the hepatic and portal veins respectively, (d) a Wallstent has
been deployed.
Figure 2.2. Kaplan Meier analysis of rebleeding in patients having TIPSS with
the Palmaz stent or the Wallstent.
Figure 2.3. A dislocated Palmaz stent.
Figure 2.4. A Palmaz stent that has migrated from the parenchymal track into
the trunk of the portal vein.
Figure 2.5. Hepatic vein stenosis producing recurrence of varices.
Figure 2.6. Intimal hyperplasia within a Wallstent.
Figure 2.7. A broken fragment of an angioplasty balloon stuck within the frame
work of the Palmaz stents. This has been secured to the wall by insertion of a
Wallstent within the Palmaz stents.
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Figure 2.8. Kaplan Meier analysis of mortality according to severity of liver
disease.
Figure 2.9. Kaplan Meier analysis of shunt dysfunction according to the initial
pressure gradient (p<0.01).
Figure 2.10. Kaplan Meier analysis of shunt dysfunction according to the type
of stent used.
Figure 2.11. Changes in the portal pressure gradient in the patients with
TIPSS enrolled in the 'neuropsychology study.
Figure 2.12. Changes in alanine transaminase after TIPSS.
Figure 2.13. Changes in bilirubin after TIPSS.
Figure 2.14. Changes in Indocyanine clearance after TIPSS.
Figure 2.15. Changes in haemoglobin after TIPSS
Figure 2.16. Changes in reticulocytes in three patients with significant
hemolysis
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Figure 2.17. Change in the portal pressure gradient and spleen size after
TIPSS
Figure 2.18. Change in platelet count after TIPSS
Figure 3.1. This figure depicts the relationship between the portal pressure
gradient and peak systolic velocity of blood in the portal vein.
Figure 3.2. Radiograph showing endocopy biopsy forceps introduced into the
shunt through the sheath for obtaining biopsies of the occluding material.
Figure 3.3. Changes in portal pressure gradient in the group A patients.
Figure 3.4. Changes in the portal pressure in the group B patients.
Figure 3.5. Radiograph showing occluded Palmaz stents and a parallel
Wallstent inserted through another hepatic vein.
Figure 3.6. Changes in portal pressure gradient in the Group C patients who
were managed initially managed by balloon angioplasty and then by insertion
of a parallel stent. Long term patency was obtained after insertion of the
parallel stent.
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Figure 3.7. Changes in the portal pressure gradient in the Group C patients
who were managed solely by balloon angioplasty. Note that there is
predictable rise in the portal pressure gradient at subsequent assessment of
shunt function.
Figure 3.8. Radiograph of an occluded stent where contrast fills the biliary
system on forcible injection of contrast.
Figure 3.9. Cholangiogram of an explant liver demonstrating cicatrisation of
the bile ducts in the vicinity of the shunt.
Figure 3.10. Photomicrograph of the histopathological appearance of a biopsy
specimen obtained from an occluded shunt demonstrating biliary epithelium
(positive staining for cytokeratin).
Figure 3.11. An endoscopic view of the shunt obtained from an explanted liver
showing the continuous pseudo-intima.
Figure 3.12. Photomicrograph of the lining of the shunt showing the
pseudointima.
Figure 3.13. Photograph of a shunt that has been dissected out of the liver
showing that a major bile duct has been transected.
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Figure 3.14. Photograph of a shunt which has been dissected out and opened
to demonstrate the occluding material. The arrow represents the primary
thrombus that overlies the transected bile duct.
Figure 3.15 and 3.16. Photomicrograph of the histopathological appearance of
the thrombus which overlies the transected bile duct demonstrating
granulomatous inflammation and bile impregnation.
Figure 4.1. The outcome of patients with uncontrolled variceal haemorrhage in
the TIPSS and oesophageal transection groups. Numbers within brackets
refer to the number of patients.
Figure 4.2. Kaplan Meier analysis of survival in the TIPSS and transection
groups. p<0.05.
Figure 4.3. Kaplan Meier analysis showing significantly less rebleeding
(p<0.0006) in the TIPSS group compared with the variceal band ligation
group.
Figure 4.4. Kaplan Meier analysis of survival in the variceal band ligation and
TIPSS groups (p=ns).
Figure 4.5. Kaplan Meier analysis of shunt insufficiency after TIPSS
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Figure 5.1. Changes in urinary sodium following TIPSS.
Figure 5.2. Changes in creatinine clearance following TIPSS.
Figure 5.3. Changes in plasma renin activity following TIPSS.
Figure 5.4. Changes in Angiotensin II following TIPSS.
Figure 5.5. Changes in cyclic Guanosine mono phosphate (cGMP) following
TIPSS
Figure 5.6. Changes in Atrial natriuretic peptide (ANP) following TIPSS.
Figure 5.7. Changes in Lithium Clearance following TIPSS.
Figure 5.8. The computer set-up and the thermodilution system that was used
to measure renal and portal blood flow.
Figure 5.9. X-ray showing an inflated angioplasty balloon in the shunt inserted
through the internal jugular vein and a reverse thermodilution catheter in the
right renal vein inserted through the femoral vein.
Figure 5.10. Graph showing the changes in the renal blood flow prior to and
following shunt occlusion.
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Figure 5.11. Graph showing the changes in cardiac output following shunt
occlusion.
Figure 5.12. Relationship between portal blood flow and renal blood flow.
Figure 5.13. Relationship between changes in portal pressure gradient and
changes in renal blood flow.
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1.1 HISTORY OF PORTAL HYPERTENSION
Stahl (Stahl et.al. 1748) was the first to describe a syndrome where
the porta! vein was diseased, the spleen was enlarged and there were large
haemorrhoids. The association between bleeding from oesophageal varices
and cirrhosis was first described by Fauvel (Fauvel et.al. 1858). Power (1840,
quoted by Preble 1900) had however described bleeding from oesophageal
varices before Fauvel, but he failed to recognise its association with liver
disease. Preble (Preble et.al. 1900) reviewed 60 cases of fatal gastro¬
intestinal haemorrhage due to cirrhosis and constructed the hypothesis that
the fibrotic liver was the major cause of obstruction of portal circulation and
that this is what led to increased pressure in the collateral circulation. Fie
also made the fundamental observation that a third of these patients died of
the first episode of variceal haemorrhage and that bleeding in the patients
who survived was usually recurrent.
Fierrick (Herrick et.al. 1907) studied the relationship between the
hepatic arterial pressure and the portal pressure in animal models with
normal and cirrhotic livers. Fie observed that portal pressure became
elevated only when the arterial pressure was increased to 100 mmFIg in the
animals with normal liver. On the other hand in animals with cirrhotic livers, a
similar increase in portal pressure was observed when the arterial pressure
was increased to 30 mmFlg. Fie concluded that the high pressure in the
hepatic artery was responsible for changes in the portal pressure.
23
Mclndoe (Mclndoe et.al. 1928) first coined the term portal
hypertension. Using techniques involving the injection of gelatin and Indian
ink into the portal system he concluded that there was a progressive
dissociation between the portal venous and hepatic arterial systems which
resulted in the diversion of portal blood flow into the collateral channels. The
hepatic artery therefore remained as the major blood supply of the
hepatocytes which was progressively divorced from the normal portal blood
supply. From these studies he concluded that the portal hypertension could
be explained entirely on a physical basis due to a porto-hepatic venous
outflow obstruction. Rousselot (Rousselot et.al. 1936) first described the
existence of portal hypertension as a definite clinical entity by measuring
the splenic venous pressure in a patient with Banti's disease.
1.2 ANATOMY OF THE PORTAL VENOUS SYSTEM
The portal system comprises of the veins that collect blood from the
intra-abdominal part of the gastrointestinal tract, the spleen, the pancreas
and the gallbladder. The portal vein is formed by the union of the splenic and
the superior mesenteric veins, is approximately 6-8 cm long and enters the
liver at the porta-hepatis as two main branches supplying the right and the
left lobes. Inside the liver the portal veins are distributed segmentally.
The splenic vein is formed by the union of numerous splenic veins and
the short gastric veins. This is then joined by the left gastro-epiploeic vein
behind the body of the pancreas and then by numerous tributories draining
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the pancreas. The inferior mesenteric vein carries blood from the left part of
the colon and the rectum and usually drains into the middle third of the
splenic vein. The left gastric vein usually joins the main portal vein at its
origin but may occasionally enter the splenic vein. The superior mesenteric
vein is derived from numerous veins which drain the right side of the colon,
the small intestine and the head of the pancreas.
Portal blood flow in man averages about 1 litre per minute and
supplies about 60% of the oxygen demand of the liver (Tygstrup et.al. 1962).
The rest of the liver blood flow is from the hepatic artery with a rate of flow of
about 350 ml per minute. The normal pressure in the portal venous system
is about 5-7 mmHg. The splenic pulp pressure, which is an indirect measure
of the pressure in the portal venous system is about 7-13 mmHg and that in
the hepatic veins is between 4 and 6 mmHg (Richard PDI and Withrington
PG, 1981b).
The collateral circulation of portal hypertension
When the pressure rises above 7 mmHg, the collateral circulation
starts to develop between the high pressure portal system and the
neighboring veins which are at a lower pressure, thereby permitting a
diversion of portal blood into the systemic circulation. The actual site for the
development of portal collateral vessels are those areas where veins
draining into the portal system are in immediate juxtaposition to veins
draining into the superior and inferior vena cava. These areas are the
submucosa of the oesophagus and stomach, the submucosa of the rectum,
the anterior abdominal wall and the left renal vein. Studies using cast
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erosion and radiological techniques have provided evidence that the
collateral circulation that develops is due to the opening of pre-existing
vasculature rather than a consequence of angiogenesis (Kitano et.al 1986,
Vianna et.al. 1987).
1.3 THE PATHOPHYSIOLOGY OF PORTAL HYPERTENSION
Portal pressure is dependent upon the portal venous blood flow and
the resistance offered by the hepatic sinusoids. Therefore, alteration to
either the portal venous flow and/or the intrahepatic resistance would
produce portal hypertension. The former is regulated by the splanchnic
blood flow and the latter by neurohumoral mechanisms (Granger et.al. 1980).
In the normal situation, physiological stimuli such as ingestion of food,
exercise or Valsalva maneuver may alter splanchnic blood flow and
therefore influence portal blood flow (Chou CC and Kvietys PR, 1981,
Richard PDI and Withrington PG, 1981a). Sudden changes in portal pressure
due to an increase in portal blood flow are prevented by homeostatic
mechanisms that involve neurohumoral factors which serve to maintain the
portal pressure within the normal range by modulating the portal vascular
resistance (Richard PDI and Withrington PG, 1981b).
When these homeostatic mechanisms are disturbed by changes either
in the portal venous inflow (forward hypothesis) or in the resistance
(backward hypothesis), portal hypertension results (Witte CL and Witte MM,
1983). In order to decompress the portal system, portosystemic collaterals
develop. Despite this, portal pressure remains elevated due to the
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development of a hyperdynamic splanchnic and systemic circulation that
serves to maintain the enhanced portal venous inflow. It can therefore be
appreciated that the forward and backward hypotheses are somewhat
simplistic and that portal hypertension is the result of complex interplay
between increased portal vascular resistance and blood flow. Factors
contributing to changes in resistance and the hyperdynamic circulation of
cirrhosis are described below.
1.31. Portal Vascular Resistance
This has a static and a dynamic component.
1.311. Static Phenomenon
The proposed pathogenic mechanisms involved in the development of
the static or the fixed component of portal hypertension has evolved over the
years. Mclndoe et.al. (Mclndoe et.al. 1928) suggested that portal
hypertension was due to diffuse hepatic fibrosis. It was then hypothesised
that it resulted from the displacement of intrahepatic vasculature by cirrhotic
nodules (Hart GF and Lisa GR, 1937, Kelty et.al. 1950, Popper et.al. 1952)
and finally fibrosis in the space of Disse was observed (Popper et.al. 1961).
In alcoholic subjects the degree of fibrosis of the space of Disse has been
shown to correlate directly with the severity of portal hypertension (Orrego
et.al. 1979, Orrego et.al. 1981). Another theory proposes that hepatocyte
enlargement as a result of excessive intracellular water and fat accumulation
may be responsible for increased intrahepatic sinusoidal pressure (Blendis
et.al. 1982, Crossley et.al. 1985). This hypothesis is supported by the
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observation that portal pressure fluctuates widely with alcohol intake or
abstinence (Leevy et.al 1970, Reynolds et.al. 1960).
When the hepatocyte enlargement theory and the collagenisation of
the space of Disse theory, were put to test in alcoholic and non alcoholic
subjects the results favored the hepatocyte enlargement theory as the
primary factor (Blendis et.al. 1982), although the interaction between these
two mechanisms are almost inseparable as an elevation in intrahepatic
pressure is associated with cell ballooning which may in fact stimulate
fibrogenesis (Crossley et.al. 1985).
1.312. Dynamic Phenomena
The demonstration that there is a dynamic component of intrahepatic
portal hypertension opened up exciting prospects for treatment. The hepatic
vasculature is richly endowed with adrenergic receptors and this is subject to
complex neurohumoral control (McClain et.al. 1989, MacMathuna et.al.
1990a, Biolac-Sage et.al. 1990). Studies using calcium channel antagonists
(Reichen J and Le M, 1986) and clonidine (a2 agonist) (Willet et.al. 1986) in
isolated rat liver and in cirrhosis showed that intrahepatic resistance was
amenable to pharmacological manipulation. The action of these
neurohumoral substances may be exerted at the level of the myo-fibroblasts
present within the capillarised sinusoids, the receptors on the blood vessels
or even on the sinusoid cells (Bhathal PS and Groszmann RJ, 1985). The
response to neurohumoral substances in health is very different from that
seen in liver disease primarily because the disease tends to alter receptor
function and modifies the response to vasoactive agents (Ballet et.al. 1988,
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Marteau et.al. 1989). This observation is further supported by the relatively
contradictory finding of the opposing actions of noradrenaline on the portal
system (predominantly vasoconstrictive), and upon the systemic circulation
where there is a markedly reduced sensitivity to the circulating noradrenaline
(Kiel et.al. 1985).
The initial finding of alteration in intrahepatic vascular resistance with
the use of calcium channel antagonists was not confirmed in later studies
(Marteau et.al. 1989). This discrepancy may in part be explained by a
compensatory mechanism whereby any reduction in intrahepatic vascular
resistance due to verapamil is neutralised by an increase in portal venous
flow as a result of systemic vasodilatation. Nitrates have been shown to
reduce intrahepatic vascular resistance in cirrhotic rat models (Blei et.al.
1988) and this has been confirmed by Navasa and his colleagues using
isosorbide mononitrate in patients with cirrhosis (Navasa et.al. 1988). This
action of nitrates is probably mediated by nitric oxide which acts via
stimulation of cyclic GMP (Murad et.ai. 1986). The role for other important
vasoconstrictors such as platelet activating factor (Richardson PDI and
Withrington PG, 1976) and endothelin (Benoit et.al. 1986, Lee et.al. 1988,
Pizcueta et.al. 1990) has been observed both in animal models and in the
cirrhotic patient.
1.32. Hyperdynamic Circulation
The systemic circulation in patients with cirrhosis is characterised by
peripheral vasodilatation occurring as a result of a reduction in splanchnic
vascular resistance and an increase in the cardiac output which contributes
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to increase in the portal venous inflow. This increase in the portal venous
inflow may therefore contribute to the portal hypertension (forward
hypothesis).
This hyperdynamic state is probably due to a combination of increased
levels of circulating endogenous vasodilators and a reduced vascular
sensitivity to vasoconstrictor compounds.
1.321. Vasodilatation
Glucagon concentration is elevated in the circulation of patients with
cirrhosis and reduces vascular sensitivity to vasopressor agents and
increased splanchnic blood flow. It does this by activating adenylate cyclase
(Richard PDI and Withrington PG, 1976, Lee et.al. 1988, Pizcueta et.al.
1990). Inability to reduce portal blood flow using glucagon antiserum
suggests that glucagon is not the only factor which is responsible for the
circulatory abnormalities (Benoit et.al. 1986).
Portosystemic shunting induces endotoxaemia in patients with
cirrhosis and this could induce nitric oxide synthase activity in the
endothelium and vascular smooth muscle cells. Nitric oxide is formed from
catabolism of L-arginine which acts by stimulation of cyclic guanosine
monophosphate (cGMP) (Vallance P and Moncada S, 1991, Moncada S and
Higgs A, 1993). In addition to its constitutive activity in the endothelium
which is involved in the regulation of normal vascular tone, in vitro studies
have implicated nitric oxide in the vascular hyporeactivity of portal
hypertension (Seiber CC and Groszmann RJ, 1992, Seiber et.al. 1993,
Castro et.al. 1993) and studies in animal models have shown that portal
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blood flow and pressure are reduced following inhibition of nitric oxide
synthase activity (Pizcueta et.al. 1992a, Pizcueta et.al. 1992b). Experiments
in patients with cirrhosis and controls using measurement of forearm blood
flow after inhibition of nitric oxide synthase showed no significant difference
in vascular responses (Calver et.al. 1994). These observations suggest that
nitric oxide mediated tone is not solely responsible for the changes in the
portal circulation.
Adenosine has been implicated in the circulatory disturbances of
cirrhosis and is formed by dephosphorylation of adenosine triphosphate
(ATP) which is often co-released with noradrenaline from the nerve endings.
It acts via the adenosine II receptor. An increase in cyclic GMP activity in the
vascular smooth muscle cells and the endothelial cells initiates nitric oxide
production (Moritoki et.al. 1990, Rose'Meyer RB and Hope W, 1990).
Blockade of adenosine receptors in animal models of cirrhosis reduces
portal blood flow but does not produce any change in the portal pressure
(Lee et.al. 1992). It appears unlikely that adenosine is the sole determinant
of the initiation of the vasodilatation in cirrhosis although it may play a role in
its maintenance (MacMathuna et al 1990b).
Atrial natriuretic peptide is produced in response to atrial stretch as a
result of increasing blood volume and vasodilates through its action on
guanylate cyclase leading to increased formation of cGMP (Epstein et.al.
1988). Changes in the levels of cGMP measured in patients with cirrhosis is
inconsistent (Hayes et.al. 1992, Burghardt et.al. 1986). A recent study has
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however shown a good correlation between the haemodynamic changes of
cirrhosis and levels of measured cGMP (Burghardt et.al. 1986).
Prostacyclin is a potent dilator of the peripheral vasculature and has
been shown to be elevated in patients with cirrhosis (Guarner et.al. 1992). It
is produced by the action of cyclooxygenase on arachidonic acid. It is
released from the endothelium in response to portal vein distension,
endotoxin and vasopressors (Wu et.al. 1991, Guarner et.al. 1992). Inhibition
of cyclooxygenase activity reduces portal blood flow and pressure although
do not reach normal levels (Wu et.al. 1993, Oberti et.al. 1993). Vasoactive
intestinal peptide and substance P have been shown to be elevated in
various studies, but their role in the pathogenesis of the hyperdynamic
circulation of cirrhosis is not clear (Hunt et.al. 1979, Ring-Larsen et.al. 1986).
Bile acids have vasodilatory properties and are elevated in patients with
cirrhosis and seem to play an important role in the development of the
hyperdynamic circulation, although no correlation has been observed
between its concentration and the severity of circulatory derangement
(Ohkibuda et.al. 1984). Similarly, tumour necrosis factor has been thought to
be an important mediator of the vascular changes but its inhibition did not
shown any significant change in portal pressure (Soupison et.al. 1994). Both
gamma-aminobutyric acid and opioids are known to be potent vasodilators
and their concentrations have been found to be elevated in cirrhosis. Their
role in the vasodilatation of portal hypertension remains unclear because of
variable effects from their inhibition (Lee et.al. 1987, Minuk et.al. 1988).
1.322. Vascular hyperreactivity
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In vivo and in vitro studies have shown that the vascular smooth
muscle in cirrhosis is hyporeactive to noradrenaline and angiotensin II,
implying that the defect lies either at the receptor level or at the post receptor
level in the smooth muscles (Keil et.al. 1985, MacGilchrist et.al. 1991).
Measurement of noradrenaline in the serum reflects sympathetic
nerve activity (Henriksen et.al. 1984). Patients with cirrhosis clear
noradrenaline from their plasma normally, therefore the elevated levels
reflect over-production and enhanced sympathetic activity (Henriksen et.al.
1984). The action of noradrenaline on the smooth muscles is through the
alpha-1 and alpha-2 receptors. These are more important in the veins than in
the arteries. The number of alpha-2 receptors in patients with cirrhosis is
normal. Therefore it is difficult to explain why there is an inhibition of the
action of noradrenaline despite increased levels of noradrenaline with normal
numbers of receptors.
Angiotensin II is a potent vasoconstrictor, and acts on the angiotensin
I receptors on the smooth muscles. Its concentration in cirrhosis is known to
be elevated and the use of its antagonists produces dramatic reduction in
blood pressure. Very little is known about the status of its receptors in
cirrhosis.
Endothelin, is also a potent vasoconstrictor and is produced by the
endothelium of the blood vessels in response a number of stimuli. Its
concentration is elevated in patients with cirrhosis and ascites and may also
be elevated in patients without ascites (Asbert et.al.1993, Moller et.al.1993).
It acts through its receptors (endothelin receptor A and B, ETA, ETB) and the
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status of these receptors in patients with cirrhosis is unknown. Use of
endothelin antagonists has been shown to reduce portal pressure probably
by reducing intrahepatic resistance (Asbert et.al. 1993, Moller et.al.1993).
Serotonin is an arterial vasodilator and acts through the 5 hydroxy
tryptamine-1 receptor on the endothelial cells. Its actions on the veins is
quite different because it acts through the 5 hydroxy tryptamine-2 receptor
and produces venous constriction (Peroutka et.al. 1990, Vanhoutte et.al.
1990). Administration of ketanserin (a 5H2 antagonist) causes reduction in
the portal pressure gradient and reduction in collateral blood flow (Hadengue
et.al. 1987). Chronic administration of this drug produces reduction in portal
pressure gradient but does not return it to normal levels (Vorobioff et.al.
1989).
Vasopressin is released non osmotically from the hypothalamus and
acts upon the vascular smooth muscles via its receptors to cause
vasoconstriction. It has been shown to be elevated in patients with cirrhosis
probably as a compensatory mechanism for the reduced systemic vascular
resistance (Claria et.al. 1991).
Platelet activating factor increases hepatic vascular resistance and
may contribute to portal hypertension. Its effects have not been fully studied
in patients with cirrhosis (Lapointe et.al. 1989).
In summary, despite marked activation of the vasopressor system the
peripheral circulation remains vasodilated and this has been thought either to
be related to a defect at the receptor level which seems unlikely or to an
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alteration In the mechanisms of signal transduction following the interaction
of vasopressor with its receptor. The major control of signal transduction
following receptor binding is through cyclic nucleotides such as cyclic
adenosine monophosphate (cAMP) and cGMP or through phosphatidyl
inositol turnover. A study of cyclic nucleotides in the platelets (reflects
vascular smooth muscle activity) from cirrhotic patients indicated an excess
of cAMP and of cGMP with impairment of phosphatidyl inositol degradation
(Laffi et.al. 1993). Further studies are required to characterise the nature of
these defects.
1.4. COMPLICATIONS OF PORTAL HYPERTENSION
The most important complications of portal hypertension in patients
with cirrhosis are
1. Variceal haemorrhage
2. Sodium retention, ascites and hepatorenal failure
3. Chronic hepatic encephalopathy
4. Hypersplenism
The following section deals with the pathogenesis, natural history,
prognosis and the presently available modalities of treatment that are
available to manage this condition at this present time.
1.41 VARICEAL BLEEDING
1.411. Development of varices
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The rise in portal pressure is associated with the development of
collateral circulation which allows the portal blood to be diverted into the
systemic circulation in an attempt to decompress the portal system. These
spontaneous shunts occur a) at the cardia through the intrinsic and extrinsic
gastro-oesophageal veins b) in the anal canal where the superior
haemorrhoidal vein belonging to the portal system anastomoses with the
middle and inferior haemorrhoidal veins which belong to the system
circulation c) in the falciform ligament of the liver through the paraumbilical
veins which are the remains of the umbilical circulation of the foetus, d) in the
abdominal wall and the retroperitoneal tissues, where veins and abdominal
organs are in juxtaposition including veins from the liver to the diaphragm,
veins in the splenorenal ligament, in the omentum and lumbar veins, and e)
blood diverted from diaphragm, gastric, pancreatic, splenic, and adrenal may
drain into the left renal vein (Mikkelson et.al. 1965).
There are considerable data in the literature which suggest that
varices develop and enlarge with time. Christensen (Christensen et.al. 1981)
followed a cohort of 532 patients with cirrhosis over 12 years and showed
that the cumulative percentage of patients with varices over this period
increased from 12%-90%. In a study involving 80 patients followed for 16
months Cales (Cales et.al. 1989) showed that 20% patients who did not have
varices developed new varices and 42% patients with small varices showed
definite enlargement. Czaja (Czaja et.al. 1979) on the other hand showed
that the prevalence of varices increased from 8%-13% over 5 years in a
cohort of patients with chronic active hepatitis treated with prednisolone.
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The two factors that appear to determine the development of varices
are continued hepatic injury and the degree of portosystemic shunting.
Evidence for the former is derived from studies in which varices were shown
to regress with time. Baker (Baker et.al. 1959) followed a cohort of 112
patients with oesophageal varices and showed that varices had disappeared
in 9 patients, regressed in 7 and remained unchanged in 96. He concluded
that the disappearance and regression of varices may be related to
abstinence from alcohol. This observation was confirmed in a study by
Dagradi (Dagradi et.al. 1972) who followed a cohort of patients with alcoholic
cirrhosis over 3 years and showed a reduction in variceal size in 12 of the 15
patients with alcoholic cirrhosis who stopped drinking and an enlargement in
variceal size in 17 patients who continued to drink. Cales (Cales et.al. 1989)
showed that 16% of patients with alcoholic cirrhosis who continued to imbibe
alcohol showed regression in varices.
1.412. Risk factors for first variceal bleeding
The factors that predispose to and precipitate variceal haemorrhage
are still not clear, although the venous anatomy, portal pressure, intravariceal
pressure, variceal size, endoscopic appearances of the varices (red spot,
weals), tension on the variceal wall and severity of the underlying liver
disease have been blamed. The most important factors that are thought to
increase the risk of variceal bleeding are (i) pressure within the varix (ii)




In most cases, the portal pressure reflects the intravariceal pressure
(Dawson et.al. 1985) and a hepatic venous pressure gradient greater than 12
mmHg is necessary for the development of and bleeding from oesophageal
varices although no linear relationship exists between the severity of portal
hypertension and the risk of variceal haemorrhage (Lebrec et.al. 1980,
Garcia-Tsao et.al. 1985). However, the HVPG tends to be higher in the
bleeders as well as in patients with larger varices. In a prospective study
comparing propranolol with placebo for the prevention of first variceal
haemorrhage, Grosszmann (Grosszmann et.al. 1990) showed that bleeding
from varices did not occur if the portal pressure gradient could be reduced to
less than 12 mmHg. This pressure has since been accepted as the aim of
pharmacological therapy of portal hypertension.
Variceal Size
This is best assessed endoscopically and variable results in the
literature are because of the lack of definition regarding the distinction
between large and small varices. Numerous studies (Lebrec et.al. 1980,
Vinel et.al. 1986) have shown that the risk of variceal haemorrhage
increases with the increase in the size of varices (Palmer and Brick 1956).
Varix Wall Structure and Tension
Polio and Grosszmann (Polio J and Grosszmann RJ, 1986) using an
in vitro model showed that rupture of varices was related to the tension on
the variceal wall. The tension depends upon the radius of the varix. In this
model, increasing the size of the varix and decreasing the thickness of the
variceal wall caused variceal rupture. Therefore the tension on the variceal
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wall was increased by variceal pressure, size of the varix and a decrease in
wall thickness.
Endoscopic features such as "red spots" and "weal" markings were
first described by Dagradi (Dagradi et.al. 1972). They have been described
as being important in the prediction of variceal haemorrhage. These features
represent changes in variceal wall structure and tension associated with the
development of microtelangiectasias. In a retrospective study by the
Japanese Research Society for Portal Hypertension Beppu et.al. (Beppu
et.al. 1981) showed that 80% patients who had blue varices or cherry red
spots bled from varices suggesting that this was an important predictor of
variceal haemorrhage in cirrhosis.
Severity of liver Disease and Bleeding indices
Two independent groups assessed factors predicting first variceal
haemorrhage in cirrhosis prospectively. First, the North Italian Endoscopic
Club (NIEC) (NIEC 1988) reported their findings in 1988 and was followed in
1990 by data from the Japanese (Inokuchi, 1990). Both these studies
showed that bleeding risk was based upon 3 factors. These were severity of
liver disease as gauged by Child class, variceal size and red weal markings.
NIEC study showed a very wide range in the risk of bleeding from 6%-76%
depending upon the presence or the absence of the different factors. This
index was prospectively validated in a study by Prada (Prada et.al. 1994).
Using the same variables the NIEC index was simplified by DeFranchis
(DeFranchis et.al. 1991) and shown to correlate with the original index.
Further studies showed that the HVPG and intravariceal pressure were also
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independent predictors of first variceal haemorrhage when analysed in
conjunction with the NIEC index (Merkel et.al. 1992).
In summary, the risk of first bleed from varices in cirrhosis is
dependent predominantly upon the portal pressure, tension on the variceal
wall, presence or the absence of the red sign and the severity of liver
disease. Unfortunately, these data have been derived from studies that
assess changes at one given time point only. There are very few studies on
the evolution with time. It has been suggested from looking back at the old
shunt trials that ascites increases the risk of bleeding.. Continued alcohol
abuse and the rate of deterioration in the severity of liver disease also
increases the risk of bleeding (Burroughs et.al. 1989, Cales et.al. 1989,
Dagradi et.al. 1972).
1.413. Risk of first variceal bleed
Data describing the overall risk of bleeding from varices must be
viewed with caution and has some pitfalls in interpretation. The natural
history of patients who have varices diagnosed as a part of their work up is
different from patients who have complications of liver disease. Patients in
trials may represent a different population from the patients who have had
documented varices and not bled during follow up. Most studies do not
comment upon either the severity of liver disease or upon whether patients
with alcoholic cirrhosis are continuing to drink or not as both these factors
have a significant effect upon the risk of variceal haemorrhage.
Most studies report bleeding from varices in about 20-50% during the
period of follow up. Baker (Baker et.al. 1959) reported variceal bleeding in 33
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of the 115 patients that he followed for a mean of 3.3 years with a mortality of
48% from first variceal haemorrhage. These data were confirmed by
Christensen (Christensen 1981). About 70% episodes of bleeding occur
within 2 years of diagnosis.
Prophylactic propranolol trials also show results similar to those of the
shunt trials with most of the episodes of bleeding occurring within the first 2
years of follow up. In these studies the rate of first variceal haemorrhage
varied from 22% to 61% (Pascal et.al. 1987, Ideo et.al. 1988, Lebrec et.al.
1988, IMPP 1989, Conn 1991). This vast difference in the rate of first bleed
relates almost certainly to the number of patients with severe liver disease
included in the study (Pascal, Child C-46%, bleeding-61 %; IMPP, Child C-
6%, bleeding-32%; Conn, Child C-6%, bleeding-22%). Mortality varied from
24% to 49% over 2 years (Pascal, mortality-49%; IMPP, mortality-24%;
Conn, bleeding-24%). This was also almost certainly related to the severity of
liver disease.
1.414. Prophylaxis from variceal haemorrhage
As stated earlier 30 to 50% of patients with portal hypertension will bleed
from varices and about 50% will die from the effects of the first bleed and it
seems rational to develop prophylactic regimes to prevent the development
of and bleeding from these varices. One factor that emerges very clearly
from looking at the trials of prophylaxis of variceal haemorrhage in cirrhosis is
that most of the published trials do not have sufficient power to identify
favorable treatment effects. Based upon the expected bleeding and death
rates in the control group the minimum number of patients needed to detect a
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50% reduction in bleeding would be 270 patients, and 850 patients to detect
the same reduction in mortality.
Surgery
Portacaval shunts: There are 4 trials in the literature which have
randomised a total of 302 patients (Conn et.al. 1965, Jackson et.al. 1968,
Resnick et.al. 1969, Conn et.al. 1965) either to prophylactic shunt surgery or
to non-active treatment. A meta-analysis of these studies showed a
significant benefit in the reduction of variceal bleeding (odds ratio (OR) 0.31,
95% confidence intervals (CI) 0.17-0.56), significantly greater risk of hepatic
encephalopathy (HE) (OR 2, 95%CI 1.2-3.1) and of mortality (OR 1.6, 95%CI
1.02-2.57) in patients treated with shunt surgery (D'Amico et.al. 1995).
Devascularisation procedures: Inokuchi (Inokuchi et.al. 1990) showed
that there was a significant reduction in variceal bleeding and in mortality in
patients treated with a variety of devascularisation procedures. There are
however, numerous problems with the interpretation of this study because of
the use of different procedures in each of the 22 centres. These results need
confirmation in a further study.
Pharmacologic therapy
The mainstay of pharmacologic approach to the primary prophylaxis of
variceal haemorrhage has been propranolol which reduces the portal
pressure gradient (Reichen J, 1990), reduces azygos blood flow and also
variceal pressure (Bosch et.al. 1984). It achieves this by causing splanchnic
vasoconstriction, and reducing cardiac output.
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There are 9 randomised trials assessing its effectiveness; 7 are fully
published papers and 2 are in the abstract form (Pascal et.al. 1987, Ideo et.al.
1988, Lebrec et.al. 1988, IMPP 1989, Andreani et.al. 1990, Conn et.al. 1991,
PROVA 1991, Strauss et.al. 1988, Colman et.al. 1990). The risk of variceal
bleeding was lower in 7 studies (Pascal et.al.1987, Ideo et.al. 1988, Lebrec
et.al. 1988, IMPP 1989, Andreani et.al. 1990, Conn et.al. 1991, Strauss et.al.
1988), significantly lower in 4 studies (Ideo et.al. 1988, IMPP 1989, Andreani
et.al. 1990, Conn et.al. 1991) and unchanged in 1 study (PROVA 1991).
There was a higher incidence of bleeding in the propranolol group in 1 study.
This was a small study and unbalanced randomisation is likely because of a
very low bleeding rate in the control group (Colman et.al. 1990). Mortality
was reduced in 7 trials (Pascal et.al. 1987, Ideo et.al. 1988, IMPP 1989,
Andreani et.al. 1990, Conn et.al. 1991, PROVA 1991, Strauss et.al. 1988)
significantly in 1 (Pascal et.al.1987) and unchanged in 2 (Lebrec et.al. 1988,
IMPP 1989). A meta-analysis showed that the risk of rebleeding was
significantly lower (OR 0.54, 95% CI 0.39-0.74) although no significance was
detected in differences in mortality (OR 0.75, 95% CI 0.57-1.06) (D'Amico
et.al. 1995).
Interest in the use of vasodilators such as iso-sorbide mononitrate has
grown since the demonstration that it reduces portal pressure as effectively
(Navasa et.al. 1989) as propranolol. A trial comparing iso-sorbide
mononitrate with propranolol showed no significant difference between these
agents (Angelico et.al. 1993).
Endoscopic therapy
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Sclerotherapy: There are 19 trials comparing endoscopic variceal
sclerotherapy with no treatment of which 4 are in the abstract form (Andreani
et.al. 1990, PROVA. 1991, Strauss et.al. 1988, Paquet et.al. 1982, Witzel
et.al. 1985, Koch et.al. 1986, Kobe et.al. 1990, Wordehoff et.al. 1987,
Santangelo et.al. 1988, Sauerbruch et.al. 1988, Piai et.al. 1988, Potzi et.al.
1989, Russo et.al. 1989, Triger et.al. 1991, VACVSG 1991, De Franchis
et.al. 1991, Saggioro et.al. 1986, Fleig et.al. 1987, Planas et.al.). These trials
include 1630 patients and these studies are significantly heterogeneous. Ten
of the trials included only patients with large varices; the other 9 include
patients with varices of any size. Various sclerosants were used at different
doses and injected intra or para variceally. The results of these trials are very
variable with 2 studies showing reduction in both bleeding and mortality
(Paquet et.al. 1982, Witzel et.al. 1985), 1 study showing a reduction in
mortality but no difference in rebleeding (Potzi et.al. 1989), I study showing a
significant increase in the risk of bleeding (Santangelo et.al. 1988) and
another significantly greater mortality (VACVSG 1991). Due to marked
heterogeneity between these studies a meta-analysis is clinically useless. At
the present time sclerotherapy cannot be recommended for prophylaxis of
variceal haemorrhage in patients with cirrhosis.
Variceal band ligation: Sarin et.al. (Sarin et.al. 1996) compared
variceal band ligation with no active treatment in a randomised study and
showed that there was a significant reduction in variceal bleeding in patients
treated with band ligation. No significant effect on mortality was found. This
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treatment needs to be compared with the present gold standard, i.e.
propranolol.
1.415. Prognosis of acute variceal haemorrhage
The average mortality of the first episode of variceal bleeding in most
studies is 50%. Mortality from variceal haemorrhage is related closely to the
severity of liver disease (Lebrec et.al. 1984, Burroughs et.al. 1983,
Villeneuve et.al. 1986, Colombo et.al. 1989, Garden et.al. 1990). Over a
mean follow up of 1 year, the average mortality for subsequent variceal
haemorrhage is 5% in Child class A patients, 25% in Child class B patients
and 50% in Child class C patients. Although serum creatinine has been
shown in some studies to predict overall survival (Garden et.al. 1985,
Christensen et.al. 1989), Child class is superior to any other predictive factor
in determining mortality within 6 weeks or 30 days of the initial haemorrhage.
Vinel et.al. (Vinel et.al. 1986) showed that HVPG was predictive of
survival when this was measured at 2 weeks after the acute bleed. However,
it is unclear whether this was independent of the severity of liver disease.
Whether active bleeding at the time of endoscopy predicts mortality is not
clear. Although Cardin et.al. (Cardin et.al. 1990) found that this was an
important factor, Balanzo et.al. (Balanzo et.al. 1991) could not confirm this
finding. Active bleeding at the time of endoscopy does however predict early
rebleeding (Siringo et.al. 1991). Risk of death decreases quickly after
admission such that the risk of death becomes virtually constant about 6
weeks after bleeding (Graham DY and Smith JL, 1981, Burroughs et.al.
1989).
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1.416. Management of acute variceal bleeding
The most important step in the management of acute variceal haemorrhage
is the initial resuscitation and the protection of the airway to prevent
aspiration. Early endoscopy allows examination of the upper gastrointestinal
tract enabling accurate diagnosis of the bleeding site and decision regarding
the management. The following measures of controlling the bleeding are
presently available.
Pharmacological Therapy
The two major classes of drugs that have been used in the control of acute
variceal bleeding are vasopressin or its analogues, either alone or in
combination with nitroglycerine, and somatostatin or its analogues.
Vasopressin reduces portal blood flow, portal systemic collateral blood
flow and variceal pressure (Reichen 1990). It does however have significant
systemic side effects such as increase in peripheral resistance, reduction in
cardiac output, heart rate and coronary blood flow. In comparison with no
active treatment, the pooled results of 4 randomised trials (Merigan et.al.
1962, Conn et.al. 1975, Mallory et.al. 1980, Fogel et.al. 1982) showed that it
reduced failure to control variceal bleeding although mortality was unaffected.
Five trials have compared sclerotherapy with vasopressin and although 1
study showed significant effect upon reduction in the failure to control the
variceal bleed, no significant differences between these groups were found in
the overall analysis. Flowever, rebleeding was significantly lower in patients
treated with sclerotherapy.
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The addition of nitroglycerin enhances its effects on the portal
pressure and reduces the cardiovascular side effects (Grosszman et al
1982). Three randomised trials compared vasopressin alone against
vasopressin and nitroglycerine (Tsai et.al. 1986, Gimson et.al. 1986, Bosch
et.al. 1989) and the pooled data from these showed that the combination was
associated with a significant reduction in the failure to control bleeding
although no survival benefit was demonstrated.
Glypressin which is a synthetic analogue of vasopressin has an
immediate vasoconstrictor action followed by haemodynamic effects due to
slow conversion to vasopressin. Its efficacy has been found in 3 placebo
controlled trials to significantly reduce the failure to control bleeding
significantly and also to improve survival (Freeman et al 1989 and Soderlund
et al 1990, Levacher et.al. 1994). Three randomised trials compared its
efficacy against vasopressin alone in 3 (Freeman et.al. 1989, Desaint et.al.
1987, Chiu et.al. 1990) and 2 compared it with vasopressin in combination
with nitroglycerine (Lee et.al. 1988, D'Amico et.al. 1994). Glypressin reduced
failure to control bleeding significantly when compared with vasopressin
alone and was as good as the combination of vasopressin and nitroglycerine.
It was however shown to be safer to use. Three trials compared it with
somatostatin and found it to be equally effective (Silvain et.al. 1993, Walker
et.al. 1992, VBSG 1993). Two trials compared its efficacy against balloon
tamponade and found it to be equally effective (Colin et.al. 1987, Fort et.al.
1990).
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Somatostatin causes selective splanchnic vasoconstriction and
reduces portal pressure and portal blood flow (Bosch et al 1981). It was
shown to significantly reduce the failure to control bleeding in one trial
(Burroughs et.al. 1990) and did not show any significant differences against
placebo in another (Valenzuela et.al. 1989). Seven trials (Kravetz et.al. 1984,
Jenkins et.al. 1985, Bagarani et.al. 1987, Cardona et.al. 1989, Hsia et.al.
1990, Saari et.al. 1990, Rodriguez-Moreno et.al. 1991) compared its efficacy
with vasopressin and showed that somatostatin reduced the failure to control
rebleeding and was associated with significantly fewer side effects.
Three trials compared somatostatin with balloon tamponade and
showed that these were equally effective in reducing the failure to control
variceal bleeding (McKee 1990, Jaramillo et.al. 1991, Avgerinos 1991). Five
trials have compared somatostatin or its analogue, octreotide with
sclerotherapy (DeFebo et.al. 1990, Jenkins et.al. 1992, Sheilds et.al. 1992,
Planas et.al. 1994, Sung et.al. 1993) and have shown no significant
differences in either the failure to control bleeding, rebleeding and mortality.
Data from a large randomised trial comparing octreotide with placebo
was presented at a recent meeting and showed conclusively that there was
no significant difference between the two groups either in terms of reduction
in the failure to control bleeding, amount of blood transfused and mortality at
42 days or at 90 days (Burroughs AK, 1996).
Endoscopic Therapy
Sclerotherapy: Endoscopic variceal sclerotherapy using a flexible endoscope
with sclerosants is based upon the concept that bleeding from varices is
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stopped by thrombosis of the bleeding varix secondary to either an
intravariceal or a paravariceal injection of a sclerosant which is an oily ester.
When assessing trials of sclerotherapy in acute bleeding there is enormous
variation in the type of sclerosant used, the experience of the operator,
whether intravariceal or paravariceal injections was used and what the
schedule of follow up was. Furthermore, the interpretation of the results of
trials comparing injection sclerotherapy with non invasive therapy is
complicated by the inclusion of patients who were not actively bleeding at the
time of randomisation (Soderlund et al 1985, Larson et al 1986). Four trials
have compared sclerotherapy with balloon tamponade (Barsoum et.al. 1982,
CEVSP 1984, Paquet KJ and Feusener F, 1985 and Moreto et al 1988) and
2 of these showed a significantly higher control of bleeding in patients treated
with sclerotherapy (Paquet KJ and Feusener F, 1985 and Moreto et al 1988).
The results of control of bleeding in the sclerotherapy patients are unrealistic
at 95% and 100% respectively.
Sclerotherapy has been compared with oesophageal transection in 4
randomised trials (Cello et.al. 1982, Huizinga et.al. 1985, Teres et.al. 1987b,
Burroughs et.al. 1989) and with the portacaval shunt in 1 (Cello et.al. 1987)
in patients who had variceal haemorrhage that was uncontrolled. Although all
the studies showed a reduction in failure to control bleeding in patients
treated with surgical therapy, this reached statistical significance in one
(Burroughs et.al. 1989). Rebleeding was also significantly higher in the
sclerotherapy group. Although there were no differences in mortality, the rate
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of development of encephalopathy was significantly higher in patients treated
with the surgical shunt.
Variceal Band Ligation
This technique is a modification of that used for the elastic band
ligation of internal haemorrhoids. Its use in humans was first described in
1988 (Stiegmann GV and Goff JS, 1988) and a subsequent randomised
clinical trial comparing banding with sclerotherapy showed a significant
reduction in the rate of complications and improvement in survival
(Stiegmann GV and Goff JS, 1992). Another trial compared these two forms
of treatment and confirmed that banding controls active variceal
haemorrhage and no significant differences were found in the control of
active bleeding in the 2 groups. This trial showed a reduction in the rates of
rebleeding in the band ligation group. There was however no survival benefit
(Gimson et al 1993).
Other Endoscopic Measures
Control of bleeding using tissue adhesives has been reported in about
90% of cases (Ramond et al 1986, Soehendra et al 1987). There were
however similar rates of re-bleeding as with sclerotherapy and there were
significant complications in the form of cerebrovascular accidents, related to
the injection of the tissue adhesives, and the risk of damage to the
instrument.
Uncontrolled studies have shown that thrombin is effective in
controlling acute haemorrhage, but its role would probably be in the
treatment of bleeding gastric varices for which the conventional sclerosants
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are inappropriate (Williams et.al. 1994). Larger studies are needed to
establish its role.
Balloon Tamponade
This form of treatment is highly effective and controls acute bleeding in
up to 90% patients, although about 50% of patients re-bleed when the
balloon Is deflated (Panes et al 1988). It is, however, associated with serious
complications such as oesophageal ulceration and aspiration pneumonia in
up to 15 - 20% patients. Despite this, it is a life saving treatment in cases of
massive uncontrolled variceal haemorrhage pending other forms of
treatment.
Liver Transplantation
This is probably only appropriate for the patients who bleed while awaiting
liver transplantation. Studies comparing variceal band ligation ortransjugular
intrahepatic portal-systemic shunt with liver transplantation is difficult to
compare because it is an exceedingly uncommon option for the vast majority
of patients, both because it is not commonly available and due to shortages
and delays in organ procurement. No controlled trials of liver transplantation
in uncontrolled/active bleeding are available.
1.417. Risk of recurrent bleeding
Rates of rebleeding vary from 60%-90% depending firstly, upon the number
of patients in these studies with Child class C disease and secondly, upon
the duration of follow up. Looking at the control groups of the propranolol
trials for the secondary prevention (Lebrec et.al. 1984, Burroughs et.al.
1983, Villeneuve et.al. 1986, Colombo et.al. 1989, Garden et.al. 1990) of
variceal rebleeding the highest risk of rebleeding was found by Garden et.al.
and Villeneuve et.al. who found rebleeding in 70% and 75% patients
respectively. They had included 46% and 30% patients with Child class C
liver disease respectively. In contrast, rebleeding was reported in only 51%
and 48% in studies by Quieniet et.al (Quieniet et.al. 1987) and Colombo
et.al. (Colombo et.al. 1989) who studied only patients with Child class A and
B disease or 96% were Child class A or B patients respectively.
1.418. Secondary prophylaxis of variceal haemorrhage
This form of treatment is aimed to prevent recurrence of variceal bleeding.
Surgery
Portacaval shunts may either be non-selective or selective Non¬
selective shunts (eg portacaval shunt, PCS) refer to virtually total diversion of
portal blood flow into the systemic circulation, thereby reducing liver blood
flow. Selective shunts (eg distal spleno renal shunt, DSRS) refer to drainage
of the varices into the systemic circulation without affecting the portal blood
flow.
Four trials have compared non-selective shunts with no active
treatment (Jackson et.al. 1968, Resnick et.al. 1974, Rueff et.al. 1976,
Reynolds et.al. 1981) and all of these have shown a significant reduction in
rebleeding, and mortality was reduced in 3 (Jackson et.al. 1968, Resnick
et.al. 1974, 1976, Reynolds et.al. 1981) and increased in 1 (Rueff et.al.
1976). This difference was thought to be related to the randomisation
procedure.
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Six trials compared non-selective shunts with the distal splenorenal
shunt (DSRS) (Reichle et.al. 1979, Fischer et.al. 1981, Langer et.al. 1985,
Millikan et.al. 1985, Harley et.al. 1986, Grace et.al. 1988) and included a total
of 336 patients. No difference in rebleeding or encephalopathy was observed
in any of the studies. Mortality was not significantly different in 5 of the trials,
although it was significantly reduced in 1 trial (Fischer et.al. 1981).
DSRS has been compared with sclerotherapy in 4 randomised trials
(Rikkers et.al. 1987, Teres et.al. 1987a, Henderson et.al. 1990, Spina et.al.
1990) and with PCS (Cello et.al. 1987, Korula et.al. 1988, Planas et.al. 1991)
in 3 trials. Shunt surgery was associated with a significantly lower rebleeding
in 5 of the trials (Rikkers et.al. 1987, Teres et.al. 1987a, Henderson et.al.
1990, Spina et.al. 1990, Planas et.al. 1991) and also in a meta-analysis (OR
0.18, 95% CI 0.12-0.28). Incidence of HE after shunt surgery was also
significantly greater than sclerotherapy in 4 studies (Rikkers et.al. 1987,
Teres et.al. 1987a, Henderson et.al. 1990, Planas et.al. 1991) and remained
unchanged in two (Cello et.al. 1987, Spina et.al. 1990). Mortality was
increased significantly in the PCS group in 1 study but overall there were no
significant differences.
P blockers
A total of 755 patients were randomised in 11 trials comparing
propranolol or nadolol (Gatta et.al. 1987) with no active treatment (Burroughs
et.al. 1983, Lebrec et.al. 1984, Villeneuve et.al. 1986, Queuniet et.al. 1987,
Gatta et.al. 1987, Colombo et.al. 1989, Sheen et.al. 1989, Garden et.al.
1990, Rossi et.al. 1991, Cerbelaud et.al. 1986, Colman et.al. 1990).
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Significant reduction in rebleeding was seen in 4 trials and a meta-analysis
showed significant overall reduction (OR 0.4 95%CI 0.3-0.54). Eight trials
showed significant reduction in mortality, as did the overall analysis.
Sclerotherapy
One thousand one hundred and eleven patients have been
randomised to either sclerotherapy or no active treatment in 8 trials (Rossi
et.al. 1991, Terblanche et.al. 1983, CEVSP 1984, Westaby et.al. 1984,
Soderlund et.al. 1985, Korula et.al. 1985, Burroughs et.al. 1989, Gregory
et.al. 1991). Rebleeding was significantly reduced in 2 studies (Westaby
et.al. 1984, Korula et.al. 1985). Overall there was also a significant reduction
in rebleeding (OR 0.63 95%CI 0.49-0.79). Mortality was significantly reduced
in 1 study (Westaby et.al. 1985). Overall there was a significant reduction in
mortality (OR 0.77 95%CI 0.61-0.98).
Sclerotherapy has been compared with p blockers in 9 trials which
have randomised a total of 787 patients (Rossi et.al. 1991, Alexandrino et.al.
1988, Dollet et.al. 1988, Westaby et.al. 1990, Martin et.al. 1991, Dasarathy
et.al. 1992, Fleig et.al. 1987, Liu et.al. 1990, Teres et.al. 1993). Significant
reduction in rebleeding was found in the sclerotherapy group in 2 studies
(Dasarathy et.al. Liu et.al. 1990) and increase was noted in 3 studies (Rossi
et.al. 1991, Dollet et.al. 1988, Martin et.al. 1991) which was not statistically
significant. The rest of the studies showed a reduction in rebleeding which
was not statistically significant. The overall results were significantly
heterogeneous and therefore a meta-analysis is not strictly valid which
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showed significantly reduced rebleeding with sclerotherapy. No significant
differences were detected in mortality.
No significant differences were detected in a meta-analysis of 10 trials
comparing sclerotherapy with sclerotherapy and p-blockers (D'Amico et.al.
1995). Two trials comparing sclerotherapy and p-blockers with p-blockers
showed that the combined therapy reduced rebleeding and mortality
significantly.
There are now 7 fully published trials in the literature comparing
sclerotherapy with variceal band ligation (VBL) which were combined in a
meta-analysis (Steigmann and Goff 1992, Gimson et.al. 1993, Laine et.al.
1993, Lo et al 1995, Hou et.al. 1995, Hashizume et.al. 1993, Laine et.al.
1996) This included 547 patients and concluded that variceal band ligation
carried a significantly lower rate of rebleeding (OR 0.52 95%CI 0.37-0.74),
mortality (OR 0.67 95%CI 0.46-,0.98) and complications such as
oesophageal stricture (OR 0.10 95%CI 0.03-0.29).
These studies comparing the two best available modalities of
treatment have shown that VBL reduces rebleeding, mortality and local
complications. VBL should now considered as the endoscopic treatment of
choice for patients with oesophageal variceal bleeding.
1.419. Pitfalls in the assessment of prognosis
There is inherent bias in assessing the natural history and the risk of
first variceal bleed when exploring the relationship between the time of
development of varices, the time of diagnosis and the time when the patient
is recruited into the study. It is therefore logical that any assessment must be
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fundamentally flawed because of inclusion into these studies of patients who
have been known to have varices for different lengths of time prior to
inclusion into the study. These patients may have different natural histories,
i.e. 'bleeders' or'not bleeders'.
Smith and Graham (1981) showed that the time interval between
admission to the hospital and the entry into clinical studies of variceal
bleeding could influence the results of the study quite dramatically. This
observation has been confirmed in a study by Burroughs et.al. (Burroughs
et.al. 1989) who showed that when assessing rebleeding, if the starting point
was moved from 0-5 days the proportion free of rebleeding at 25 days
changed dramatically (25-41%, p<0.001). Mortality is similarly affected. This
is significantly more marked when assessing 30 day or 6 week mortality than
when assessing 1 year mortality. Delaying the starting point of analysis tends
to select out patients who are poor-risk.
1.42. SODIUM RETENTION, ASCITES AND THE HEPATORENAL
FAILURE
Ascites in patients with cirrhosis is a major cause of morbidity and a serious
prognostic development. The kidney is central to the development of ascites
and the purpose of this section is to discuss the pathogenesis and the
principles of management of the renal dysfunction of cirrhosis. There is a
spectrum of renal abnormalities in cirrhosis. In its mildest form, there is
retention of sodium and the development of diuretic responsive ascites,
56
which may progress to diuretic refractory ascites. The most severe form is
manifested as the hepatorenal syndrome (HRS).
Refractory ascites is defined as ascites that cannot be mobilised or its early
recurrence (after therapeutic paracentesis) cannot be prevented by medical
therapy. The term includes diuretic-resistant ascites in which there is a lack
of response to dietary sodium restriction and intensive diuretic treatment, and
diuretic-intractable ascites where there is development of diuretic-induced
complications that precludes the use of an effective diuretic regimen (Arroyo
et.al. 1996). The HRS can be classified into type 1, which is characterised by
rapidly progressive reduction of renal function defined by a doubling of the
initial serum creatinine to a level greater than 2.5mg/dl (250pmol/l) or a 50%
reduction of the initial 24-hour creatinine clearance to a level lower than
20ml/min in less than 2 weeks, and type 2 in which the renal failure does not
have such a rapidly progressive course (Arroyo et.al. 1996). The kidneys are
histologically normal in HRS.
1.421. PATHOGENESIS
The pathogenesis of renal dysfunction in cirrhosis is controversial and
incompletely understood but can be thought of as having an afferent and an
efferent component (Figure 1.1). Patients with cirrhosis exhibit characteristic
circulatory abnormalities which are manifested by an increase in cardiac
output, arterial hypotension, reduced peripheral vascular resistance and
splanchnic vasodilatation. The pathogenesis of these circulatory
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abnormalities are not clear but seems to be due either to portosystemic
shunting and/or impaired clearance of vasodilators such as nitric oxide,
endotoxins, prostacyclin, glucagon and adenosine. These vasodilators
cause peripheral and splanchnic vasodilatation, which is perceived as a
reduction in 'effective' plasma volume. This leads to the activation of
neurohumoral factors which attempt to maintain the arterial pressure. These
changes in the neurohumoral systems and activation of intrarenal factors is
responsible for the renal dysfunction of cirrhosis (Schrier et.al. 1988). In
addition, there appears to be a direct relationship between the severity of
hepatic dysfunction and the onset of renal manifestations which argues for an
interaction between the liver and the kidneys which has been postulated to
be neural or biochemical in nature (Wong et.al. 1997, Jalan et.al. 1997).
Localisation of fluid to the abdomen is the result of the abnormal Starling's
forces in this area.
Patients with cirrhosis and portal hypertension manifest renal dysfunction
with sodium retention, water retention and HRS. These manifestations may
either present de novo or appear step wise. The following section deals with
the pathogenic mechanisms associated with these syndromes.
1.4211. Retention of Sodium
There is considerable evidence for increased activity of the renin-
angiotensin-aldosterone system (RAAS) (Bosch et.al. 1980, Hayes et.al.
1992). High levels of aldosterone, plasma renin activity and angiotensin II
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have been demonstrated in patients with cirrhosis which is probably due to
increased production rather than reduced metabolism of these substances by
the liver. Plasma renin activity is inversely related to sodium excretion and to
renal blood flow. Concentrations of angiotensin II are also significantly higher
in cirrhotics with ascites than those without (Tobe et.al. 1993). Atrial
natriuretic factor is a powerful vasodilator and its role in sodium retention
remains controversial. Concentrations of the hormone are raised in patients
with cirrhosis but its effects are not pronounced because of marked renal
refractoriness. This refractoriness may enhance the action of the
vasopressors (Gines et.al. 1988a). Several studies have shown that plasma
norepinephrine levels are elevated in patients with cirrhosis who have ascites
and this is because of increased production rather than reduced clearance
(Ring-Larsen 1982). Renal blood flow has been shown to be inversely
related to norepinephrine levels. These data suggest that the activity of the
sympathetic nervous system is enhanced and plays a significant role in
sodium retention in cirrhosis (Henriksen et.al. 1984). Urinary kallikrein
excretion in patients with cirrhosis and ascites deteriorates in parallel with the
glomerular filtration rate. Infusion of aprotinin (kallikrein inhibitor) produces
marked improvement in renal blood flow, glomerular filtration rate and sodium
excretion (MacGilchrist et.al. 1994). The role of prostaglandins in the renal
dysfunction of cirrhosis is not clear. Urinary excretion of its metabolites is
increased when ascites is present but reduced in some patients with HRS
(Moore et.al. 1990). Cyclo-oxygenase inhibitors such as non-steroidal
antinflammatory drugs increase renal vascular resistance and reduce
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glomerular filtration rate in patients without ascites. These agents can
produce oliguric renal failure in patients with ascites (Gines et.al. 1986).
Endothelin is the most potent naturally occurring vasoconstrictor substance
known. Elevated levels of endothelin-1 have been found in patients with
ascites. This does not change either with volume expansion or tilting, and no
correlation has been observed with endotoxaemia. The exact physiological
role of this elevation is still not clear (Gerbes et.al. 1995, Rockey D 1997).
1.4212. Retention of Water
Hyponatremia is the biochemical expression of reduced water excretion. In
patients with cirrhosis it may occur either due to diuretics or spontaneously.
The former is diagnosed by low central filling pressures. Patients with
cirrhosis exhibit an inverse relationship between the levels of antidiuretic
hormone (ADH) and glomerular filtration rate. The use of a Kappa opioid
receptor agonist, RU51599, which inhibits anti diuretic hormone (ADH)
secretion enhances free water clearance (Moreau et.al. 1996). Similarly,
demeclocycline, which is an ADH antagonist has been shown to improve free
water clearance (De Troyer et.al. 1976). Patients with ascites and cirrhosis
have diminished glomerular filtration rate which may reduce the delivery of
filtrate to the diluting segments thereby reducing water clearance (Schedl HP
and Bartter FC 1960). Increasing the distal delivery of filtrate using plasma
volume expansion improves free water generation. Renal prostaglandins
increase free water generation by numerous mechanisms. Although the data
do not clearly establish a role for the renal prostaglandins, the relative
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deficiency of renal prostaglandins may contribute to the pathogenesis of
water retention (Epstein M 1985a). Data regarding the role of the
sympathetic system in causing water retention is not entirely clear. Studies
have shown an inverse relationship between the plasma concentrations of
norepinephrine and free water clearance but maneuvers which reduce
sympathetic stimulation demonstrate no relationship between changes in free
water clearance and plasma norepinephrine (Epstein et.al. 1985b).
1.4213. Hepatorenal syndrome
The HRS is characterised by severe renal hypoperfusion due to an increase
in renal vascular resistance. It develops in the setting of decompensated
liver disease, poorly controlled ascites, and marked alterations in splanchnic
and systemic haemodynamics. In some patients, HRS may be precipitated
by gastrointestinal bleeding, sepsis, use of non-steroidal or nephrotoxic
agents, hypovolemia, progressive liver failure or excessive use of diuretics
(Epstein et.al. 1985b). The pathogenesis of the HRS is multifactorial. The
sympathetic nervous system is highly activated and this produces renal
vasoconstriction and reduction in renal plasma flow (Henriksen JH and Ring-
Larsen H, 1994). Poor liver function and altered splanchnic haemodynamics
further contribute to this renal vasoconstriction through the hepatorenal axis.
RAAS is stimulated in cirrhosis and produces afferent arteriolar
vasoconstriction (Jalan et.al. 1997, Lang et.al. 1991). Further renal
vasoconstriction is produced by increased endothelin-1, the concentration of
which correlates with the severity of renal dysfunction. Renal prostaglandins
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usually compensate for the vasoconstriction induced by the various
vasopressors (Moore et.al. 1991). In HRS, this compensatory mechanism
fails to maintain renal perfusion. Patients with HRS demonstrate a decrease
in the mean arterial pressure which is a risk factor for its development (Gines
et.al. 1993). In normal circumstances, the renal blood flow is autoregulated
but in patients with HRS who have an activated neurohumoral system the
autoregulatory curve (renal blood flow/renal perfusion pressure) is shifted to
the right (Persson et.al. 1990). This means that a small reduction in the
arterial pressure produces pronounced reduction in renal blood flow.
1.422. PRINCIPLES OF MANAGEMENT
Ascites is a frequent complication of cirrhosis and about 50% patients
develop this complication within 10 years of the diagnosis of cirrhosis. Of the
patients who have ascites, 18% develop HRS at 1 year and 39% at 5 years
(Gines et.al. 1993). A patient with ascites may present with moderate
ascites, tense ascites, refractory ascites, hyponatremia or with HRS.
The principles of management are summarised in Figure 1.2. Restriction of
dietary sodium (to 80 mmol/day) and use of diuretics are the most important
modalities of treating ascites. When ascites is diagnosed, it is important to
admit the patients to the hospital to establish the underlying diagnosis,
exclude spontaneous bacterial peritonitis and educate the patient regarding
their diet which will remain the corner stone of treatment. In patients with
moderate ascites, the use of a combination of spironolactone and frusemide
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and dietary sodium restriction is the most effective regimen for controlling
ascites, reducing hospitalisation and hypokalaemia. Patients should be
monitored using their body weight, and the dose of the diuretics adjusted to
produce a weight loss of 1 Kg per day in patients with ascites and peripheral
oedema and 500 gm in patients with ascites alone. Total paracentesis with
infusion of human albumin solution (8 gram per litre of ascites drained) is
recommended for patients who present with tense ascites. When they are
discharged from the hospital they should remain on dietary sodium restriction
and diuretic therapy as discussed above.
The options for the management of refractory ascites are total paracentesis,
peritoneovenous shunt, TIPSS and orthotopic liver transplantation. The most
important advance in the management of refractory ascites has been the re-
introduction of large volume paracentesis in the management of ascites. This
method of treatment is both safe and effective as long as adequate plasma
volume expansion with human albumin solution is provided (Gines et.al.
1988). A cheaper alternative is to use Dextran 70 and other synthetic
gelatins which is effective but may be followed by subtle circulatory
disturbances (Planas et.al. 1990). Insertion of TIPSS reduces portal
pressure and has been suggested as a treatment for refractory ascites.
Although some authorities suggest that this is useful in the treatment of
refractory ascites (Ochs et.al. 1995) a randomised trial comparing TIPSS with
paracentesis showed reduced survival in the patients treated with TIPSS
(Lebrec et.al. 1996). At present, TIPSS should be used for refractory ascites
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as a part of randomised trials only. Peritoneovenous shunts are based on
the principle of a pressure difference between the intraabdominal pressure
and the superior vena cava in the thorax. A randomised study comparing the
LeVeen shunt with paracentesis showed that paracentesis was as effective
as LeVeen shunt in relieving refractory ascites, but the shunts were
associated with better long-term control of ascites, shunt occlusion was
common (50%) and there were no significant differences in survival between
the groups (50%, at 1 year in both groups) (Gines et.al. 1991). Patients with
refractory ascites who are otherwise good candidates for transplantation
should undergo liver transplantation as this treatment improves survival
significantly.
The presence of hyponatremia in a patient with ascites denotes a dilutional
state and an impaired capacity to excrete water. Therefore, the most
important modality to treat this complication is adequate water restriction.
Although demeclocyline has been suggested by some investigators, this form
of treatment should be avoided in patients with cirrhosis for the fear of
precipitating renal failure (De Troyer et.al. 1976). Some patients may benefit
from plasma volume expansion which acts by increasing the delivery of fluid
to the diluting segments of the kidney (McCormick et.al. 1990). The effect of
over-diuresis must be considered when ascites and oedema is absent and
ruled out by the measurement of central venous filling pressure. The effect of
nephrotoxic drugs is excluded on the history.
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The mortality in patients with the HRS and end stage cirrhosis approaches
100% (Gines et.al. 1993). Management of HRS is largely supportive and care
must be taken to remove potential precipitating factors such as hypovolemia,
drugs and sepsis. Although TIPSS may improve renal function (Brensing
et.al. 1997) it has not been shown to reduce mortality and can at present be
regarded as no more than a bridge to orthotopic liver transplantation which is
the only form of treatment that reduces mortality in patients with refractory
ascites and HRS (Moore KP, 1997, Forrest et.al. 1996).
The first abnormality leading to sodium and water retention in cirrhosis is the
renal tubular defect that is related to the deteriorating liver function and
hyperaldosteronism. With progression of liver disease and portal
hypertension renal blood flow falls because of the hepatorenal reflex, and is
then maintained by the vasoactive hormonal systems. With increasing
peripheral vasodilatation, intrarenal factors that attempt to maintain renal
perfusion cause intense cortical vasoconstriction. The systemic vasoactive
factors are predominantly compensatory; any attempts to counteract their
action risk circulatory collapse. Future studies should be directed at intrarenal
factors. The ideal drug for the treatment of portal hypertension would reduce
portal pressure, increase renal blood flow and produce insignificant changes
in arterial pressure.
1.423. Natural History And Prognosis Of Patients With Ascites
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The appearance of ascites in cirrhosis carries a poor prognosis and the
probability of one and five years survival after the first episode of ascites has
been estimated at 15 and 20% respectively (Arroyo et al 1996). Arroyo also
showed that patients with cirrhosis and renal failure die within weeks or
months independent of the degree of hepatic insufficiency. Arroyo et al
(1996) and Genoud et al (1986), performed two large multivariate analyses
and assessed prognostic factors responsible for death in patients with
cirrhosis. Llach et al (1988) studied 38 variables in 139 patients suffering
from ascites in cirrhosis and showed that mean arterial pressure, plasma
noradrenaline concentration, glomerular filtration rate, urinary sodium
excretion, nutritional status, hepatomegaly and serum albumin concentration
independently predicted mortality. Tage-Jensen et al (1988) showed in a
multivariate analysis in 81 alcoholic cirrhotics that the presence of ascites,
plasma noradrenaline concentration, portal pressure and serum bilirubin
concentration independently predicted mortality. Both these studies indicate
that the parameters such as systemic and portal haemodynamics, and renal
function predicts survival better than the estimated hepatic function in
patients with cirrhosis and ascites.
1.43. HEPATIC ENCEPHALOPATHY
Hepatic Encephalopathy (HE) is a neuropsychiatric syndrome with potential
for full reversibility which occurs in patients with significant liver dysfunction
and cannot be attributable to other causes. Two distinct forms can be
identified in patients with cirrhosis. The 'overt' form which is easy to diagnose
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and the 'subclinical' form (SHE). The prevalence of SHE in cirrhosis varies
from 30-84%, and this wide variation is due to differences in definition,
diagnostic methods and patients studied. It is defined as abnormalities in
electrophysiological and psychometric tests and the most clinically useful
tests for its diagnosis are the number connection test, digit symbol test and
the digit copying test. The role of electroencephalography is diagnostically
limited. Because the level of consciousness is not disturbed, its clinical
impact is difficult to judge. Its presence has, however, been reported to be
linked with a reduced ability to drive and with poorer quality of life (Quero JC,
Schalm SW, 1996). Overt HE is associated with asterixis, hyper-reflexia, and
with an electroencephalography showing slowing of the dominant rhythm.
Lateralising neurological signs should not be attributed to HE without further
investigations such as CT scan of the brain. Various methods have been
described for estimating the severity of HE but the one that is clinically most
useful is the West-Haven criteria (Conn HO and Leiberthal MM, 1979).
However, this method has limitations because it is subjective, and has little
relationship with prognosis. A more objective system of classification is
being currently developed. This section will focus upon recent developments
in the pathogenesis and the principles of management of hepatic
encephalopathy that occurs in cirrhosis.
1.431. PATHOGENESIS
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The pathogenesis of HE remains unclear and many different mechanisms
have enjoyed periods of popularity. The most important factors are
summarised in Figure 3.3.
1.4311. The role of alterations In the blood brain barrier (BBB)
The BBB ensures protection of the biochemical environment of the brain.
Patients with HE exhibit a functional derangement in the BBB which results in
increased transport of neutral amino acids and reduced transport of basic
amino acids (Mans et.al. 1982). The mechanism of this functional
disturbance is not clear although increased levels of ammonia and
methanthiols have been implicated. Subtle indicators of disturbances in the
BBB stem from studies using in vivo 31-phosphorus magnetic resonance
spectroscopy (MRS, an in vivo method that can be used to quantify the
concentration of brain metabolites) which show a reduction in choline in the
brain in patients with HE. It is likely that this disturbance in the BBB provides
the mechanism whereby other factors in HE may operate (Kreis et.al. 1991).
1.4312. The role of changes in energy metabolism
Patients with HE have reduced cerebral blood flow and glucose and oxygen
consumption (Lockwood et.al. 1991). Using positron emission tomography
scanning, alterations in cerebral blood flow have been shown to correlate
with the severity of neuropsychological function (O'Carroll et.al. 1991). In
animal models, abnormalities in cerebral energy metabolism are delayed until
after the onset of coma (Hindfelt et.al. 1977). It is not easy to extrapolate this
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model to the human situation, but it is likely that changes in cerebral blood
flow and glucose metabolism are an epiphenomenon, secondary to the
global depression in CNS function, rather than the cause of HE. Longitudinal
studies are required for further clarification.
1.4313. The role of gut derived factors
Any putative toxin that may be of pathogenic importance in HE should
demonstrate the following characteristics. It should be (i) nitrogenous, (ii)
originate in the gut, (iii) be produced by the action of gut bacteria or be
present in the diet, (iv) be found in the portal circulation, (v) be metabolised in
the liver and (vi) be able to cross the blood brain barrier (Basile et.al. 1963).
Ammonia: Historically, ammonia has been considered the most important
factor in the genesis of HE. In HE, the concentrations of ammonia are
elevated both in the systemic circulation and the cerebrospinal fluid. The
proposed mechanisms of ammonia induced neurotoxicity are outlined in
Figure 1. Factors supporting the importance of ammonia include
hyperammonaemia caused by factors unassociated with cirrhosis or
portosystemic shunting such as urea cycle enzyme deficiencies, which
produce a syndrome resembling HE, reduction of circulating ammonia levels
by treatment with lactulose and antibiotics improving HE, and the feeding of
ammoniagenic substances precipitating encephalopathy in patients with
cirrhosis. Observations which are against ammonia being the sole factor in
the development of HE are the poor correlation between blood and
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cerebrospinal fluid ammonia concentration and the severity of HE, the
occurrence of HE despite normal levels of ammonia, and the seemingly
contradictory effect of ammonia upon the CNS function with low ammonia
concentrations producing CNS excitation rather than neurodepression (Basile
et.al. 1991, Stahl J 1963). Recent studies focus upon the role of ammonia in
the modulation of other neurotransmitter systems such as y-aminobutyric
acid, benzodiazepines and serotonin (Basile AS and Jones EA, 1997).
Other metabolites: Although derangements in mercaptans, phenols and
fatty-acids have been described in HE, there is no consistent evidence that
they are of major importance in HE and possibly exert synergistic effects with
ammonia. Proton (1H) MRS studies of the brain in patients with HE show a
reduction in the brain myo-inositol and an increase in brain glutamine
(Lauenberger et.al 1996). In patients with HE, there is a good correlation
between reduced myo-inositol and increased glutamine, with the severity of
HE. Derangements in plasma amino acid concentration in patients with HE
include typically a pattern of increased aromatic amino acids and decreased
or normal branched-chain amino acids (BCAA) (Basile et.al. 1991, Soeters
et.al. 1977).
Manganese. Patients with cirrhosis have a characteristic abnormality in the
Ti weighted magnetic resonance image (MRI) of brain which is manifested
by hyperintensity of the globus pallidus (Mans et.al. 1982, Pomier-Layrargeus
et.al. 1995). HE and manganese toxicity produce similar changes in MRI
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appearances of the basal ganglia. Increased manganese concentrations
have been found in the basal ganglia of patients with HE and good
correlation occurs between the MRI abnormalities and the blood manganese
levels. Manganese levels may be elevated in patients with cirrhosis because
of impaired excretion in bile but the significance of these findings are
uncertain (Spahr et.al.1996).
1.4314. Changes in cerebral neurotransmission
The normal state of wakefulness is determined by a fine balance between the
state of excitatory and inhibitory neurotransmission. Changes in cerebral
neurotransmission in HE are discussed below.
Glutamate is the most important cerebral excitatory neurotransmitter in the
brain and its concentration at the synaptic level is dependent upon the
glutamate-glutamine cycle whereby glutamate is released by the presynaptic
neurons, reacts with the postsynaptic neurons, and is inactivated to
glutamine in the astrocyte. In patients with HE, cerebral glutamate is reduced
(Butterworth RF 1994, Michalak et.al. 1996), reuptake mechanisms for
glutamate are impaired and there is down regulation of glutamate binding
sites on the post-synaptic neurons (Michalak et.al. 1996). All of these
contribute to reduced neuroexcitation. This change is specific and correlates
with the severity of HE.
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y aminobutyric acid (GABA), benzodiazepines and diazepam binding
inhibitors (DBI): GABA is an important neuroinhibitory neurotransmitter and
although it does not cross the BBB, GABAergic tone is increased in HE
(Basile et.al. 1991). Endogenous benzodiazepines are elevated in the
plasma and CSF of patients with HE (Jones et.al. 1988). They may be
present in the diet or may be metabolic products of the microbial flora of the
gut (Mullen KD and Jones EA, 1996). Recent PET studies suggest a diffuse
increase in the benzodiazepine receptor binding in the brain following
administration of 11C-Flumazenil (Jalan et.al. 1996). DBI modulates the
activity of GABAergic and glutamatergic tone by inducing the glial cells to
produce neurosteroids which have been implicated in the pathogenesis of HE
(Itzhak et.al. 1995). Its significance is unclear but all the above evidence
suggests that an increased GABAergic tone may contribute to the
neurodepression observed in HE (Lauenberger et.al. 1996, Pomier-
Layrargeus et.al. 1995).
Catecholamines, dopamine, serotonin, 'false neurotransmission' and
other metabolites Brain concentrations of catechecholamines are reduced
in animal models of hepatic encephalopathy but this has not been
substantiated in the humans. Dopamine2 receptors have been shown to be
downregulated in patients with severe HE and may be the cause of the
derangements in psychomotor function (Baraldi et.al. 1983). Serotonin
concentrations are increased in animal models of HE but there is controversy
regarding the concentration of cerebral serotonin receptors. The increased
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cerebral concentrations of aromatic amino acids inhibit tyrosine hydroxylase
thereby generating 'false neurotransmitters' such as octopamine, tyramine
and phenyl ethanolamine which are believed to compete with both
catecholamine and dopaminergic neurotransmission. Although their
concentration is increased in HE, direct injection of octopamine into the brain
of animals did not produce any significant abnormality (Fischer JE and
Baldessarini RJ, 1971). Reduced aspartate (neuroexcitatory) has been found
in comatose rats, levels of taurine (neuroinhibitory) are increased in animal
models and opiate (neuroinhibitory) receptor density is increased in dogs with
portacaval shunts (Basile et.al. 1991, Butterworth RF 1994).
HE appears to be a disorder of multiple neurotransmitter systems and
ammonia plays a central role in its pathogenesis.
1.432. PRINCIPLES OF MANAGEMENT
The question regarding treatment of subclinical encephalopathy is unclear
and this discussion will be limited to the principles of management of 'overt'
HE. Patients with HE fall into two groups. First, are those patients who have
episodes of encephalopathy and are relatively well between attacks. These
patients usually have a precipitating event such as dietary protein loading,
gastrointestinal bleeding, exacerbation of the underlying liver disease, sepsis,
dehydration, hypokalemia, hypoxia, use of sedatives, and constipation.
Second, are patients with spontaneous encephalopathy. Management of HE
therefore involves the detection and treatment of the precipitating events, the
73
treatment of HE itself and the treatment of the underlying liver disease. In
patients with spontaneous HE, measures should be introduced to prevent the
occurrence of encephalopathy. Treatment efficacy is difficult to judge as
about half of the patients with HE recover spontaneously. Therefore, large
numbers of patients are required to assess the beneficial effect of a new
treatment. Furthermore, many trials compare newer drugs against
'established treatments' which themselves have not been rigorously tested. A
summary of different modalities of treatment are described in Table 1.1.
Treatment aimed at reducing ammonia toxicity
Management of the precipitating event, dietary protein restriction, avoidance
of constipation and manipulation of the bowel flora remain the mainstays of
therapy (Conn HO and Leiberthal MM, 1979, Ferenci et.al. 1996, Simmons
et.al. 1970, Morgan MY and Hawkey KE 1987). Dietary protein restriction is
effective but should only be used short-term to avoid deleterious nutritional
consequences. Protein intake in individual patients requires careful titration.
In three studies, vegetable diet was shown to be better tolerated than diets
containing animal protein (Ferenci et.al. 1996). This was not confirmed in a
further study, although the fiber content of the diet seems to have a favorable
effect. In practice lactulose and lactitol are of greatest value in the short and
in the long-term and they probably act by ensuring bowel movement, by
affecting bacterial metabolism including ammonia production and absorption
of ammonia. Antibiotics are rarely used nowadays. Neomycin is effective in
modifying the bacterial flora but it has serious ototoxicity and renal toxicity,
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and should not be used long-term or where there is renal dysfunction.
Alternative antibiotics, such as tetracyclin, metronidazole and vancomycin
also have significant long term toxicity (Ferenci et.al. 1996). Newer agents
such as sodium benzoate (Sushma et.al. 1992) and L-ornithine L-aspartate
(Kircheis et.al. 1997) are aimed at metabolic removal of ammonia. Although
both these agents have been studied in controlled clinical trials and shown to
have significant beneficial effects in patients, they clearly require further
studies before their role in clinical practice becomes defined.
Treatment based on cerebral neurotransmission
Five controlled trials of Flumazenil have been performed in patients with
cirrhosis and varying severity of encephalopathy (Ferenci et.al 1996).
Flumazenil was shown to be superior to placebo in 3 of the studies. In two
studies, which included patients with mild HE or SHE, no significant
improvement was demonstrated with Flumazenil. Overall, the use of
Flumazenil in patients with HE cannot be routinely recommended apart from
patients who have been administered benzodiazepines, and as a part of
clinical studies.
Other approaches
Supplementation with BCAA was aimed at the 'false neurotransmitter
hypothesis'. Of the nine controlled trials performed, only 3 have shown a
beneficial effect of BCAA administration. This effect seems to be most
beneficial in patients with HE who are severely intolerant of protein and no
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beneficial effects were observed in patients who were protein tolerant
(Ferenci et.al. 1996, Fischer JE 1990). Orthotopic liver transplantation is the
only treatment which reverses the mental disorder permanently by correcting
both the poor liver function and the portacaval shunting. Other treatments
under current investigation include drugs aimed at serotonin, opiates,
melatonin and zinc metabolism.
HE is a complex metabolic disorder which may result from regional rather
than global effects in the brain. No single mediator has been found to
account for the syndrome of HE, and HE may result from the effect of several
interacting mediators. Further research should be directed at developing
newer radioligands for PET and increasing the sensitivity of the MR
spectroscopy which will provide a better understanding of the biochemical
and metabolic changes directly. Effective therapy will only emerge once the
pathogenesis of this syndrome is fully understood.
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Table 1.1
TREATMENT OF Hepatic Encephalopathy
Studies




































Modified from Ferenci et.al.(1996)+ significantly betterthan control Rx, = as good as control
Rx, - no effect, + unclear data, NA-data not available.
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1.44 HYPERSPLENISM
The cardinal features of hypersplenism are splenomegaly, reduction in
one or more cellular elements of the blood and the presence of normal
hypercellular bone marrow, and correction of blood cytopenias by
splenectomy. This is not usually recommended as treatment in patients with
cirrhosis. The incidence of hypersplenism in patients with cirrhosis varies
between 36-90% in different series (Mutchnik et.al. 1980). The mechanism
of splenomegaly in patients with cirrhosis which produces the congestive
form of splenomegaly, is partly due to hyperplasia of the white pulp and
fibrosis superimposed upon congestion of the red pulp (Michael et.al. 1934).
There is a poor correlation between the splenic size and the portal pressure
which suggests that passive congestion is not the sole mechanism involved
in its development (Witte et.al. 1971). Another factor which may be important
in its causation is lymphoid hyperplasia due to persistent stimulation induced
by gut derived antigens which bypass the hepatic Kupffer cells (Rozga et.al.
1985). Nishida et.al. (Nishida et.al. 1990) have suggested that there may be
a relationship between splenic and intestinal circulation with reciprocal
changes in flow occurring in the two circulations to maintain portal venous
pressure and flow. This suggests that the splenic circulation may play an
important role in the maintenance of portal hypertension.
1.5 HISTORICAL ASPECTS OF TRANSJUGULAR INTRAHEPATIC
PORTOSYSTEMIC STENT-SHUNT (TIPSS)
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The idea of TIPSS emerged in 1969 when Rosch and Hanafee (1969)
used the inadvertant punctures of the portal vein during transjugular
cholangiography to develop the technique of transjugular portography.
Following successful use of this technique for portography in experimental
animals the next obvious logical step was to develop transjugular intrahepatic
portosystemic shunt. Using a modified Ross needle they created a
communication between the right hepatic vein and the right portal vein,
dilated it with coaxial catheters and kept it open with non-expandable plastic
or coilspring tubing of 4-6 mm in diameter (Rosch J and Hanfee WN, 1969,
Rosch J and Hanafee WN, 1971). These shunts functioned for about 2
weeks before clotting. They concluded from these studies that TIPSS was a
feasible technique but the technology available at the time prevented its
application in humans.
In the 1970's further experiments were performed in animals using
various methods for the creation an intrahepatic shunt. Various techniques,
such as cutting, drilling and freezing using cryoprobes were used, each of
which created a successful shunt but patency of the shunt was limited (Koch
et.al. 1973, Reich et.al. 1977, Dotter et.al. 1981). The introduction of
angioplasty balloons were instrumental in developing this technique further.
Burgener and Gutierrez (Burgener FA and Gutierrez OH, 1979, Burgener FA
and Gutierrez OH, 1988) used balloon angioplasty in animals and
demonstrated that they could keep the shunts patent for over a year with
repeat balloon angioplasty.
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This was the impetus for the first clinical application of TIPSS which
was performed by Colapinto (Colapinto et.al. 1982). The shunt was created
using a 9 mm balloon which was kept inflated in the intraparenchymal tract
for 12 hours. This resulted in a reduction in the portal pressure by 20 mmHg
and stopped variceal bleeding. They then expanded their experience and
reported the use of TIPSS in 15 patients with cirrhosis and uncontrolled
variceal haemorrhage. The mean reduction in the portal pressure following a
successful TIPSS was 5.9 mmHg. This was also associated with immediate
arrest of variceal haemorrhage (Gordon et.al. 1987).
Palmaz was instrumental in the introduction of the expandable metal
stent to 'cover" the intraparenchymal track (Palmaz et.al. 1985, Palmaz et.al.
1986). Their detailed experimental work on dogs showed clearly that a 10
mm diameter shunt normalised the portal pressure. Shunt function in dogs
with portal hypertension remained normal for the full duration of the study
which was 48 weeks. At autopsy they demonstrated that the shunt was
endothelialised. Rosch et.al. (Rosch et.al. 1987) demonstrated the suitability
of modified Gianturco stents for TIPSS in portal hypertensive pigs.
These experiments were the basis for the movement of TIPSS from
the bench to clinical practice. The first clinical TIPSS, as we understand it
today, i.e., using a metal stent was performed by Richter. He demonstrated
that the portal pressure was reduced by 20 mmHg and the patient improved
clinically. This patient died 12 days after TIPSS due to adult respiratory
distress syndrome and disseminated intravascular coagulation. The shunt
was patent at autopsy. Since then numerous groups have reported their
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experience with the use of this technique in large numbers of patients. The
groups which have provided the largest initial experience have been the
Freiburg groups (Rossle et. al. 1994) in Europe and University of California,
San Francisco in the United states (LaBerge et.al. 1993).
Although these studied have confirmed that TIPSS can be performed
in large numbers of patients with high degree of success, numerous
questions remain unanswered. The 'aims of this thesis' outline some of the
current controversies and devises various experiments to try to answer them.
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AIMS OF THE THESIS
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The advent of TIPSS has provided a unique opportunity to access the portal
venous system repeatedly, in patients with cirrhosis. This allows firstly, to
study the role of portal pressure in the manifestations of portal hypertension
in cirrhosis and provides an exciting opportunity to treat portal hypertension.
Data about long-term follow up, its effects upon haemodynamics, liver
function, neuropsychological function, haematology and its place in the
management of complications of cirrhosis are still unknown. The purpose of
this thesis was to answer four basic questions.
1. What does TIPSS do to alter the natural history of cirrhosis?
• Long term follow up
• Assess prognostic variables to predict mortality, rebleeding,
encephalopathy and shunt insufficiency after TIPSS
• Study changes in Liver function after TIPSS
• Study changes in neuropsychological function after TIPSS
• Study haematological changes after TIPSS
2. What happens to shunt function after insertion and why does it
occlude?
• Compare Doppler ultrasonography with portography in the assessment of
shunt function after TIPSS
• Clinical, radiological and pathological study to define the pathogenic
mechanisms in the development of shunt insufficiency
3. What is the place of TIPSS in the management of portal hypertension
of cirrhosis?
• A retrospective study comparing TIPSS with oesophageal transection in
the management of uncontrolled variceal haemorrhage
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• A randomised and controlled study comparing TIPSS with Variceal band
ligation in the secondary prophylaxis of variceal bleeding
4. Can patients who have TIPSS be studied to understand the
pathophysiology of portal hypertension better?
• Mechanism of changes in renal function after TIPSS
• Use of TIPSS in the evaluation of the 'hepatorenal reflex'
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CHAPTER 2
The Natural History, Manifestations
and Prognosis Of TIPSS
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2.1 AIMS
This section was designed to answer the following questions
1. Prospectively evaluate the long term effects of insertion of Transjugular
intrahepatic stent-shunt (TIPSS) to assess the natural history of the patient
after TIPSS insertion and the effect upon shunt function during follow up.
2. To determine the prognostic indicators for mortality, variceal rebleeding
shunt insufficiency and encephalopathy following TIPSS.
3. To prospectively assess changes in the neuropsychological state,
measures of memory, quality of life and scores for anxiety and depression in
patients without prior encephalopathy and their relationship with the change
in portal pressure gradient.
4. To prospectively assess changes in biochemical tests of liver function and
also in ICG clearance and their relationship with the changes in the portal
pressure gradient.
5. To assess the changes in the red cell profile following the insertion of
TIPSS with particular reference to haemolysis and secondly, to study
changes in the spleen size and platelet counts and their relationship with
changes in the portal pressure gradient.
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2.2 METHODS
2.21 TIPSS insertion, assessment of shunt function
TIPSS Insertion
All the TIPSS procedures were performed by a single interventional
radiologist together with a hepatologist.
Operating environment and the operator TIPSS was performed in an
angiography laboratory with facilities for high resolution C arm fluoroscopy,
digital subtraction angiography and Doppler ultrasonography.
Electrocardiogram, pulse rate, blood pressure and oxygen saturation were
continuously monitored throughout the procedure. Access to resuscitative
equipment was available throughout. The technique is essentially
interventional radiological but close cooperation between a hepatologist and
radiologist appears ideal. Other assistants who were available for the TIPSS
procedure included a trained nurse and a radiographer.
Preparation for TIPSS Informed consent was obtained from all patients prior
to TIPSS which when electively performed was usually the morning after an
overnight fast. Prothrombin time was corrected to within 6 seconds of the
normal range and platelet count maintained above 50,000/litre. We
administered cefotaxime and augmentin routinely starting 1 hour prior to the
procedure and continuing up to 48 hours afterwards because of the risk of
sepsis. Midazolam and pethidine were used for sedation and analgesia
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during TIPSS. General anaesthetic was reserved for the severely agitated,
actively bleeding patients (to protect the airway from the risk of aspiration)
and those who could not tolerate sedation. No anticoagulants were used as a
prophylactic measure against shunt thrombosis.
Pre procedure imaging Over the years our practice evolved from the routine
transhepatic placement of a catheter into the portal vein to serve as a guide,
to a superior mesenteric and coeliac angiogram (venous phase) to visualise
the portal venous anatomy (first 32 patients), and to the use of duplex
Doppler ultrasonography to mark the site of portal vein bifurcation (next 27
patients). In the rest of the patients, Doppler ultrasonography was performed
prior to TIPSS only to rule out the possibility of portal vein thrombosis.
Type of stent There are a number of stents available but the two in common
usage are the Palmaz (Johnson and Johnson, Interventional systems co.,
New Jersey, USA) and the Wallstents (Schneider, Ackerstrasse, Bulach,
Switzerland). Both of these stents have theoretical advantages and
disadvantages. Palmaz stents are short, rigid and more than one stent may
be required for adequate shunt coverage. They do have the advantage of
allowing graduated expansion to attain the portal pressure desired. The
Wallstent is longer, more flexible, easier to deploy and more than 1 stent is
seldom required. However, the stent diameter is fixed. The first 24 patients
had Palmaz stents and all the rest have had Wallstents.
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TIPSS procedure The method of TIPSS insertion used was based upon the
method described by Richter (1988) and modified by Rossle et.al. (1994).
The right internal jugular vein was the common site of entry although the left
internal jugular vein was used in about 10% patients. After sterile draping and
dressing, the site of entry was infiltrated with 5-10 mis. of lignocaine. The
internal jugular vein was punctured and, a 41 cm (10F) sheath (William-Cook,
Sandet 6, Bjaeverskov, Denmark) was introduced over a guide wire into the
inferior vena cava. The right or the middle hepatic vein was selected using a
stiff hydrophilic guide wire (Terumo Corp. Hatagaya, Tokyo, Japan) and a 16
gauge, curved transjugular needle (William-Cook, Sandet 6, Bjaeverskov,
Denmark) was introduced over the guide wire into the hepatic vein and used
to guide a fine stylet anteriorly towards a branch of the portal vein. Several
attempts were needed to puncture the portal vein and this was generally the
most time consuming part of the procedure. Entry into the portal vein was
associated with a marked resistance followed by a characteristic "give".
Aspiration of blood followed by delineation of the portal system by injection of
contrast medium indicated satisfactory entry. The hydrophilic guide wire was
exchanged for an Amplatz wire (Medi-Tech, Boston scientific corporation,
Watertown, Massachusetts, USA) and an angioplasty balloon catheter was
used to dilate the parenchymal tract to an appropriate size to accommodate
the stent to be used. This was determined by the age of the patient, the
severity of portal hypertension, the indication for TIPSS and the presence or
absence of encephalopathy. The aim was to reduce the portal pressure
gradient to below 12 mm Hg below which variceal bleeding. The dilatation of
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the tract was associated with appearance of 2 characteristic waists
representing the hepatic and the portal veins respectively. This was usually
the most painful part of the procedure and we used extra analgesia at this
point. The balloon was then removed and either 1 or 2 Wallstents or 2-4
Palmaz stents inserted to support the tract open. This is depicted pictorially
in Figure 2.1.
Pressure measurements and portography were performed at the time
of portal vein catheterisation and after shunt creation to ensure adequate
shunting. In occasional patients with uncontrolled variceal haemorrhage the
varices were embolised using either steel coils or particulate matter such as
spongostan.
Evaluation Of Shunt Function During Follow Up
Definition of shunt insufficiency The aim of TIPSS is to control variceal
bleeding or prevent rebleeding by reducing the portal pressure gradient (PPG
= portal pressure - inferior vena cava pressure) to <12 mmHg. This is
considered by most authorities to be the critical figure below which variceal
haemorrhage does not occur (Garcia-Tsao et.al. 1985). We therefore defined
shunt insufficiency as an increase in the PPG to >12mmHg in patients in
whom the PPG was greater then 12mmHg at the time of insertion of TIPSS.
Timing and methods of evaluation of shunt function The timing of
assessment of shunt function has varied some what during the study period.
Initially, shunt function was assessed using Doppler ultrasonography prior to
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discharge from the hospital and using portography 3 months after TIPSS
had been inserted. After the first fifteen patients schedule of follow up was
regularised with shunt function being assessed using Doppler the day after
TIPSS and using portography at between 6 and 12 weeks and then at 6 and
12 months and then yearly thereafter.
Doppler ultrasound has been used for the assessment of shunt function and
a flow in the shunt of less than 1000 mls./min and a portal flow velocity of
less than 10 cm/sec has been suggested as indicating shunt insufficiency
(Rossle et.al. 1994). The use of this technique as the principal means of
follow up has however, been unsatisfactory in our hands. Portography with
direct pressure measurements was considered the gold standard for
assessing shunt function. The preparation was exactly the same as the
original TIPSS procedure although antibiotics were not routinely prescribed.
Following cannulation of the right internal jugular vein the shunt was
catherised using the Terumo wire as described above. Portal pressure and
inferior vena caval pressures were determined directly. Following this a
portography was performed.
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2.22 Patient details, Follow up and evaluation
Patients
The population of patients included into this evaluation were consecutive
patients who underwent the TIPSS procedure between mid 1991 and end
1993. Details of the patients included in this study are summarised in Table
2.1. Seventy six cirrhotic patients were referred for TIPSS for variceal
haemorrhage. Sixty eight patients (89.5%) who had TIPSS inserted
successfully were the subjects of this study. Mean age was 54.8 yr (± 10.4);
41 were males and 27 females. TIPSS was performed for variceal
haemorrhage; from oesophageal varices in 51 and oesophagogastric varices
in 17. Forty one patients had associated ascites and 14 had clinically
detectable hepatic encephalopathy (Parson-Smith et.al. 1957) prior to TIPSS.
Ten patients were ventilated mechanically (6 for hypoxia from aspiration
pneumonia and 4 for severe hepatic encephalopathy), 10 had active infection
and 15 patients were haemodynamically unstable (pulse > 110/min. or
systolic blood pressure < 90 mmHg) at the time of TIPSS.
Mean haemoglobin was 9.4 g/dl (± 1.2), prothrombin time was 19.4
sec (±2.4) (control 12 sec), bilirubin was 96.4 umol/l (±4.3) and serum
albumin was 29.8 g/l (±3.4). Seventeen patients were Child Class A, 30 were
Class B and 21 were Class C. Cirrhosis was due to alcohol in 47, primary
biliary cirrhosis in 7, cryptogenic cirrhosis in 7, hepatitis B or C virus infection




Age (years) 56.3 (±10.4)
Sex (M/F) 41/27
Aetiology of Liver Disease
Alcoholic cirrhosis 47










Variceal bleeding (uncontrolled) 18
Variceal bleeding (recurrent) 34
Refractory ascites 06









Haemoglobin (g/l) 9.4 (±1.2)
Prothrombin time (s) 19.6 (±)
Bilirubin (pmol/l) 96.4 (±5.4)
Albumin (g/l) 26.8 (±3.4)
Results expressed as mean and SD
2 patients were not cirrhotics (amyloidosis and non-cirrhotic portal fibrosis)
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Follow Up And Evaluation
The patients were discharged 1 week after the procedure if there were no
complications and followed up clinically, biochemically and radiologically as
described. Patients were followed up for a mean of 10.8 months (±3.1) with a
range of 0.1 to 40 months.
In the absence of clinical encephalopathy the patients were allowed a
normal diet and lactulose was not used prophylactically. At every visit they
had complete neurological examination and encephalopathy was diagnosed
according to Parson-Smith et.al. (1957). Psychometric tests were not
routinely used. Episodes of encephalopathy were managed with protein
restriction and lactulose, reduction in the size of the shunt was required in 2
patients.
Definitions
Rebleeding Subsequent upper gastrointestinal bleeding manifested by
haematemesis and/or malena, with a reduction in haemoglobin by 20 g/l and
requiring an unscheduled endoscopy. It was classified as originating from
oesophageal varices if the patient was bleeding from varices at the time of
endoscopy had large oesophageal varices with blood in the stomach and no
other recognisable cause of bleeding. Alternatively, the site of rebleeding was
noted.
Uncontrolled variceal bleeding Continued bleeding despite 2 separate
sessions of banding/sclerotherapy within five days of the first treatment.
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Early mortality Death within 6 weeks of the initial episode of bleeding.
Hepatic encephalopathy Detection of, or deterioration in the grade of
encephalopathy (Parson-Smith et.al. 1957).
2.23. Statistical methods in the assessment of outcome and prognosis.
Thirty variables related to clinical or biological data or to the importance of
haemorrhage were collected on the day of the TIPSS procedure. Sixteen
were quantitative: age (yr), Child Class, haemoglobin (g/dl), leucocyte count
(/I), platelet count (/I) prothrombin time (sec, control 12), serum alanine
aminotransaminase (IU/I), bilirubin (umol/l), alkaline phosphatase (IU/I),
albumin (g/l), sodium (mmol/l), urea (mmol/l) and creatinine (umol/l), size of
the shunt used (mm) and the initial and final portal pressure gradients
(mmHg). These were expressed as means and standard deviations. The
qualitative variables studied were, sex, aetiology of underlying liver disease,
indication for TIPSS, active alcoholism, emergency or elective TIPSS, need
for mechanical ventilation, haemodynamic stability (systolic blood pressure
<90 mmHg, or resting pulse rate >110 beats/min), active infection, ascites
(none, mild-moderate or severe), clinically detectable encephalopathy
(Parson-Smith criteria), nutritional status, presence of associated diseases
and the type of stent used.
The univariate association between individual prognostic factors and
post treatment encephalopathy was tested by Chi squared or Wilcoxon rank
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sum tests as appropriate and multiple logistic regression was used to test the
significance of factors adjusted for one another. Cox's proportional hazard
regression was used to test the univariate and multivariate significance of
prognostic factors in relation to the other 3 outcomes. All 3 survival outcomes
were censored when the patients underwent liver transplantation; shunt
failure and rebleeding were also censored at death.
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2.24. Mental state and neuropsychological tests
Study population
The population studied comprised of 3 groups.
Group I Patients undergoing TIPSS for recurrent variceal haemorrhage
that was difficult to control with variceal band ligation.
Group II Patients presenting with variceal haemorrhage and enrolled into
a programme of band ligation and
Group III Age and sex matched healthy volunteers acted as controls.
Characteristics of patients in the TIPSS and band ligation groups are
summarised in Table 2.2.
Patients treated with TIPSS
Twenty nine patients undergoing TIPSS for prevention of recurrent variceal
haemorrhage were included in this study. The mean number of sclerotherapy
sessions they had was 2.1 (±1.2). Patient characteristics are summarised on
Table 2.2. Patients were only included in the study if they showed no
evidence of clinically detectable encephalopathy (Parson-Smith et.al. 1957).
All patients at the time of assessment were haemodynamically stable, had
not bled during the week leading up to TIPSS, were on no neurotropic or
vasoactive medications, had no renal failure and had not had any sedation of
any kind within 3 days of the TIPSS. They were enrolled between 4 and 26
days after the last variceal bleed (mean 8.6 (±2.7)days). Prophylactic
lactulose or protein restriction was not used. Fifteen patients were recruited
into the study prior to TIPSS, 14 others were assessed at 1 month, 26 of
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Sixteen healthy volunteers with a mean age of 46 (±3.1) on no medications
acted as controls.
Cirrhotic controls
Twelve patients with cirrhosis and variceal haemorrhage being treated with
variceal band ligation for prevention of recurrent variceal haemorrhage were
recruited as controls. Mean number of sclerotherapy sessions they had prior
to entry into the study was 1.6 (±2.2). They were enrolled into a programme
of variceal band ligation following the index haemorrhage. Mean time from
their last bleed to the time of entry into the study was 5.1 days (±2.7). These
patients had no clinically detectable encephalopathy (Parson-Smith et.al.
1957), were on no vasoactive or neurotropic medications, were
haemodynamically stable and had no evidence of renal failure.
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Methods Of Treatment
TIPSS
TIPSS was performed according to the method outlined in section 3.21.
Shunt function was assessed at 1, 3 and 9 months and yearly thereafter.
Variceal band ligation
Variceal band ligation was performed using the Bard ligator at 1-2 week
intervals until variceal eradication and then at 3 months and 6 monthly
thereafter.
Assessment Of Neuropsychological Function
The following battery of tests was used in the assessment of
neuropsychological function and quality of life. They were performed at the
time of enrollment of the patients into the study and then at 1,3 9 and 15
months.
Cambridge Automated Neuropsychological Assessment Battery (CANTAB)
This is a sensitive instrument for carrying out detailed neuropsychological
assessment. It incorporates measures, amongst others, of delayed matching
to sample memory test, and simple and complex reaction times. A touch
sensitive VDU screen is used for accurate recording of responses and
reaction times. It has been shown to be a valid, reliable and sensitive
measure of neuropsychological function (Owen et.al. 1991). It has the
advantage of having 4 parallel forms which allows repetitive measurements
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and has been shown to be useful in a large study assessing the efficacy of
cognitive enhancers in Alzheimer's disease.
Rivermead Behavioral Memory Test (RBMT)
This 'ecologically valid' measure assesses the memory problems
encountered by patients in their everyday lives and consists of a number of
sub-tests each of which provides a measure of everyday problems such as
remembering an appointment, remembering a short route, remembering to
deliver a message, etc. This also has 4 parallel forms which serves to
eliminate the effects of learning (Wilson et.al. 1989).
Hospital Anxiety and Depression Scale (HAD)
This is a well validated measure of anxiety and depression which was
designed for use in medically ill patients. Despite the use of the word
'hospital' in the title, it is valid even for community work. It assesses anxiety
and depression separately and consists of 7 depression items and 7 anxiety
items (Zigmond et. al. 1983). Care has been taken to eliminate symptoms
which can be present in both anxiety and in depression. The validity of this
test has been corroborated by other workers (Moorey et.al. 1991).
Quality of Life (QOL)
This was measured using a modified version of Rotterdam Symptom
Checklist (Trew M and Maguire P, 1984) which assesses physical and
psychological symptoms separately. It was developed to assess symptoms in
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cancer patients and was constructed on the basis of analysis of data from 3
different studies done with 3 different checklists (Pruyn JFA 1980, Linssen
et.al 1979, McCorkle R and Young K 1978). Its validity and stability in the
assessment of both psychological and physical dimensions has been
confirmed in an independent study (de Haes et.al. 1990).
Assessment Of Liver Function
Routine tests of liver function and hepatocellular injury
Changes in serum albumin, prothrombin time, alanine transaminase (ALT)
and bilirubin were measured at enrollment, after 7 days, 1 and 3 months and
6 monthly thereafter in patients in both the banding and the TIPSS groups.
Measurement of Indocyanine green (ICG) clearance
ICG clearance was measured using the method described previously (Jalan
et.al. 1994) prior to TIPSS, 1 week and 3 months after TIPSS in the 15
patients who were recruited into the study prior to TIPSS. Briefly, a bolus
injection of 0.5 mg per kg was used for measuring clearance. Venous blood
samples were collected from an indwelling cannula inserted into a peripheral
vein at 5 minute intervals for 20 minutes, concentration was measured
spectrophotometrically and transformed logarithmically. Volume of
distribution (VD) was calculated as the ratio of the dose to the concentration
at time 0 (extrapolated from the graph). The elimination rate constant (K) was
derived from the half life time and the slope of the curve. Clearance was
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measured as the product of the volume of distribution and the elimination rate
(clearance = VD x K).
Follow Up And Analysis
All the patients enrolled into the study were assessed routinely by a
designated team. The patients have been followed up with regular
portography to assess shunt patency, assessment of neuropsychological
function and quality of life and measure of liver function tests. Results were
expressed as mean and standard error. Differences within groups were
calculated using Wilcoxon signed-ranks comparing values at baseline with
the values at subsequent time points and between groups using unpaired t-
tests. Correlation between changes in different parameters was calculated
using linear regression. Subclinical encephalopathy was operationally
defined in a patient if the value for the subtests of CANTAB (delayed
matching to sample memory test, and simple or complex reaction times)




Twenty three patients with TIPSS with a minimum duration of follow up of 3
months were included in this study; 13 of the 23 were males, mean age was
53.6 (se 1.7). Eight were Child grade A, 7 were grade B and 8 were grade C.
Eighteen patients had alcoholic cirrhosis, cryptogenic cirrhosis (3), Hepatitis
B (1) and Hepatitis C (1). Indications for TIPSS were prevention of recurrent
variceal haemorrhage in 18, refractory ascites in 2, hypersplenism in 1 and
portal hypertensive gastropathy in 2. All the patients were stable without any
evidence of continued haemorrhage at the time of the procedure, had no
clinically apparent infection or renal failure and were on no drugs known to
cause haemolysis. No patients required transfusion of blood or blood
products for at least 48 hours prior to or for seven days following TIPSS.
TIPSS
TIPSS was performed according to the method outlined in section 3.21.
Shunt function was assessed at 1, 3 and 6 months and yearly thereafter.
Haematological Assessment
Complete haematological assessment was made prior to, at 3, 7 and 30 days
following TIPSS and 3 monthly thereafter.
Full blood count Red and white cell counts, platelet count, mean cell volume,
mean corpuscular haemoglobin and erythrocyte count were measured using
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routine methods. Red cell morphology was assessed to look for evidence of
haemolysis.
Assessment of haemolysis Reticulocyte count (measured automatically),
serum haptoglobin (measured electrophoretically), urinary haemosiderin
(early morning sample), red cell morphology and Coombs test were used to
assess haemolysis.
Spleen size was measured using ultrasonography and the maximum length
was taken as the representative value.
Follow Up And Analysis
The patients were routinely followed up clinically at 1, 3 and 6 months and 3
monthly thereafter. Complete clinical, haematological and biochemical
examination was performed at this stage. Doppler ultrasonography and
routine portogram with the measurement of portal pressure gradient was
performed at 3 and 6 months and 6 monthly thereafter. Results were
expressed as means and standard error. Differences between groups were
tested using ANOVA and correlations sought using linear regression. A p




These are summarised in Table 2.3. The TIPSS procedure was unsuccessful
in 8 patients because of failure to puncture the portal vein branch
satisfactorily. At the time of TIPSS 8 patients were still haemodynamically
unstable (Palmaz stent (PS)-3, Wallstent (WS) -5, p=NS) and 5 required
mechanical ventilation (PS-2, WS-3, P=NS). Twelve of the 16 patients in
whom the shunt was successfully inserted as an emergency procedure had
WS (P<0.01).
The mean portal pressure gradient before TIPSS was similar in both
groups (PS-22 and WS-19, p=NS).The mean size of the stents required to
produce adequate reduction in the portal pressure gradients in the 2 groups
were similar. With similar sized shunts the reduction in the portal pressure
gradient in the WS group was significantly greater than in the PS group
(p<0.01). The mean number of stents required for shunt coverage was
significantly lower in the WS group (p<0.001) (Table 2.3).
Two patients died of procedure related complications from
intraperitoneal bleeding. One in the PS group was related to bleeding from
extrahepatic puncture of the portal vein bifurcation. The other in the WS group
was related to bleeding from the liver after breach of the liver capsule.
Clinically significant complications either in the form of variceal
rebleeding or reaccumulation of ascites were significantly higher in the PS
group (p<0.01) (Figure 2.2). Similarly, asymptomatic complications were also
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significantly greater (p<0.01). Frequent problems were encountered with the
PS at the time of shunt deployment or shortly thereafter with significantly
higher rates of portal vein thrombosis, dislocated stent (Fig 2.3) and stent
migration (Fig 2.4).The overall incidence of hepatic vein stenosis (Fig 2.5)
was similar in both groups but the rate of shunt stenosis due to intimal
hyperplasia (Fig 2.6) was significantly higher in the PS group (p<0.001).
Problems in the management of stent complications occurred primarily
in the PS group. This was manifested by frequent rupture of the angioplasty
balloons by the frayed ends of the wire mesh. On 2 occasions the angioplasty
balloon ruptured and was caught on the wire mesh. This resulted in major
problems; in 1 case insertion of a large caliber sheath over the balloon
allowed withdrawal, in the other manipulation of the balloon caused it to
break. Most but not all of the catheter was recovered with the use of a goose
neck snare and WS inserted through the shunt to trap the remaining
fragment (Fig 2.7).
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Kaplan Meier Analysis Of Variceal Rebleeding Following TIPSS
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Fig 2.4 A Palmaz stent that has migrated from the parenchymal track into the trunk
of the portal vein.
Fig 2.5 Hepatic vein stenosis producing recurrence of varices.
Fig 2.6 Intimal hyperplasia within a Wallstent.
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Successful TIPSS 24/28 (85.7%) 32/36 (88%) NS
Initial PPG (mmHg) 22 (±6) 19 (±5.4) NS
Final PPG(mmHg) 12.4 (±2.9) 8.6 (±3.6) <0.01
Size of stents (mm) 12 (±1.5) 12.5 (±1.1) NS
Number of stents 2.8 (±0.6) 1.3 (±0.4) <0.001
Procedure related death 1 1 NS
Clinically significant
complications
10 (41.6%) 5 (15.6%) <0.01
Diagnosed on surveillance
(shunt events) 16 (66.6%) 5 (15.6%) <0.01




















- two sample t-test, results expressed as mean and SD
PPG - Portal pressure gradient
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2.32. Results of patient follow up and evaluation and 2.33 Results of
analysis of prognostic variables in the prediction of variceal rebleeding,
mortality, encephalopathy and shunt insufficiency following TIPSS
Mortality
During the period of follow up 22 patients with TIPSS died (14 within 30 days)
and 8 underwent orthotopic liver transplantation. Early mortality was related
to the procedure in 1 (intraperitoneal bleeding from injury to the portal vein at
its bifurcation), acute-on-chronic liver failure in 3, hepatorenal failure in 2,
end-stage liver disease in 6 and sepsis in 2. Deaths during follow-up were
related to end stage liver disease in 5, variceal haemorrhage in 1,
bronchopneumonia in 1 and cerebrovascular accident in 1. Kaplan Meier
analysis of mortality is depicted in Figure 2.8.
Prognostic variables predicting early death in the univariate analysis
were the severity of liver disease (Child Class), hyponatremia, presence of
encephalopathy, bilirubin concentration and serum alanine
aminotransaminase (Table 2.4). Only 2 variables retained independent
predictive value at multivariate analysis and these were the Child Class and
hyponatremia. The risk of early mortality in a Child C cirrhotic who is
hyponatremic is about 80%.
Mortality in the long term was predicted in the univariate analysis by
Child Class and hyponatremia. Hyponatremia and the presence of
encephalopathy prior to TIPSS retained independent predictive value for
death in the long term.
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Rebleeding was of variceal origin in 14 of the 19 patients who rebled. The 5
episodes of non variceal haemorrhage were from post sclerotherapy
oesophageal ulcers in 3 and duodenal ulcers in 2. Variceal rebleeding
occurred within the first week of TIPSS in 5 patients, in 9 within 30 days, in
12 within 3 months and in all 14 within 1 year. No variable significantly
predicted subsequent variceal haemorrhage. Rebleeding rate was higher in
patients with the Palmaz compared with the patients with the Wallstents,
although the difference failed to reach statistical significance (p = 0.052). All
the episodes of variceal haemorrhage were however, associated with
portographic and manometric (PPG >12mmHg) evidence of shunt
insufficiency.
Encephalopathy
Twenty one patients (30.9%) were encephalopathic following TIPSS. In 7
patients (12.8%) this was shunt induced (these patients did not have any
evidence of hepatic encephalopathy before TIPSS insertion). Statistical
significance for encephalopathy following TIPSS on univariate analyses was
found with Child Class, the presence of encephalopathy prior to TIPSS,
serum albumin, active infection and serum creatinine. When adjustment was
made for the pretreatment status, only the presence of encephalopathy prior
to TIPSS remained significant (Table 2.6).
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2.34. Relationship between PPG and variceal haemorrhage
It is an accepted notion that a portal pressure gradient (PPG) of > 12 mmHg
is necessary for the development of and bleeding from oesophagogastric
varices although no linear correlation exists between the severity of portal
hypertension and the risk of variceal haemorrhage (Garcia-Tsao et.al. 1985,
Lebrec et.al. 1980). In a prospective study comparing propranolol with
placebo for prevention of first variceal haemorrhage Groszmann et.al. (1990)
showed that bleeding from varices did not occur if the hepatic venous
pressure gradient (HVPG) could be reduced to less than 12 mmHg. He
concluded that reducing the portal pressure gradient to <12 mmHg protects
from variceal bleeding, prolongs survival and should be the aim of
pharmacological therapy of portal hypertension.
The introduction of transjugular intrahepatic portosystemic stent -
shunts (TIPSS) in the treatment of variceal haemorrhage allows direct
measurement of the portal pressure while performing this technique (Jalan
et.al. 1994). The aim of this study was to assess the frequency of variceal
haemorrhage in patients with a baseline PPG of < 12 mmHg.
Between June 1991 and June 1994, 48 patients who underwent
TIPSS for recurrent variceal haemorrhage which was poorly controlled by
injection sclerotherapy and/or band ligation were studied. Mean number of
sessions of sclerotherapy / band ligation was 3.2 (range 2-5) and the mean
duration from the last bleed to the time of TIPSS was 3.9 (range 2-9) days.
The method of insertion of TIPSS has been described in detail
elsewhere (Section 3.21). The portal vein was punctured using a thin needle
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(5 Fr.) passed through a transjugular needle and the pressure was measured
from the main portal vein following placement of a 5Fr. pigtail catheter into
the portal vein. Right atrial, inferior vena caval and portal pressure were
recorded and the gradient calculated (portal pressure - inferior vena caval
pressure).
PPG was reduced from a mean of 21.4 (±6.4) prior to TIPSS to 10.6
(±3.1) mm Hg following the procedure. Seven patients had a baseline portal
pressure gradient of < 12 mm Hg (Table 2.7). At the time of the TIPSS all 7
patients were haemodynamically stable (systolic blood pressure >100 mmHg
and heart rate <100/min) and had normal right atrial pressures ( >4 mmHg).
None of them was receiving any vasoactive medications.
This study clearly demonstrates that in 14.7 % patients variceal
haemorrhage from oesophagogastric varices occurred despite a PPG of < 12
mmHg. It is unlikely that this was due to hypovolemia because of the
haemodynamic stability and normal central filling pressures.
In the earlier studies the HVPG was used to define the threshold for
variceal haemorrhage. We used direct pressure measurements in this study
which has been shown to closely reflect the HVPG in alcoholic cirrhosis
(Valla et.al. 1984, Boyer et.al. 1977). In patients with cirrhosis and portal
hypertension with a significant pre-sinusoidal component the directly
measured PPG tends to be higher than the HVPG (Boyer et.al. 1977) and
would therefore not explain the present observation.
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2.35. Increase in intracranial pressure after TIPSS
Acute liver failure (ALF) is defined by a rapidly developing hepatic
encephalopathy in the presence of acute liver injury of less than 8 weeks
duration. This is often progressive over a period of days or even hours and is
characterised neuropathologically by cerebral oedema. There is a high
associated mortality if left untreated, with up to 40% of deaths in patients with
ALF, resulting from the effects of increased intracranial pressure and reduced
cerebral perfusion pressure (Jones EA and Schafer DF, 1990). Chronic
hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome,
typified by global depression of the central nervous system (CNS) with
varying degrees of severity. However, it is a reversible metabolic abnormality,
the manifestations of which are widely variable and involve a spectrum from
mild subclinical disturbance to deep coma.
About 15 -20% patients become encephalopathic after TIPSS.
Although numerous studies have shown a transient deterioration in liver
function after TIPSS, features of ALF are not a well recognised complication
following TIPSS placement. Four patients developed features of 'acute liver
failure' with hypoglycemia and elevation in the intracranial pressure. Patient
characteristics are summarised in Table 2.8.
Case 1
This 55 year old man with alcoholic cirrhosis and Child class C (Pugh 12)
disease presented with severe ascites, grade II HE and oesophageal variceal
haemorrhage which was controlled after two sessions of sclerotherapy. He
required mechanical ventilation for aspiration pneumonia. Five days later he
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rebled and TIPSS was performed as an emergency. He developed epileptic
seizures after TIPSS and became hypoglycaemic. A CT scan showed
cerebral oedema. Mannitol infusion was started and an intracranial pressure
(ICP) monitor inserted. This showed an initial ICP of 13 mmHg which rapidly
increased to 26 mmHg and then to 37 mmHg. Thiopental infusion was
started with some initial improvement but neurological deterioration continued
and the patient died 3 days later with cerebral oedema. Changes in liver
function tests are illustrated in Table 2.9.
Case 2
This 69 year old lady with primary biliary cirrhosis and Child class C (Pugh
10) disease presented with grade 1 HE, mild ascites and variceal bleeding.
After resuscitation she was endoscoped which showed bleeding from gastric
varices. Bleeding was controlled using a Sengstaken tube and TIPSS was
performed as an emergency. The following day she became profoundly
encephalopathic and had epileptic seizures. She was mechanically ventilated
and CT scan of brain showed diffuse brain oedema. Mannitol was infused
and an intracranial pressure monitor inserted which showed an initial ICP of
16 mmHg which rose to 22 mmHg and finally to 34 mmHg. The jugular bulb
oxygen saturation was measured at 65%. ICP was controlled initially using
mannitol and thiopentone infusion but she died of progressive liver failure
and cerebral oedema 3 days after insertion of TIPSS. Changes in her liver
function tests are illustrated in Table 2.9.
Case 3
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This 74 year old lady had cryptogenic cirrhosis and Child class B (Pugh 8)
presented with mild ascites, grade 1 HE and bleeding oesophageal varices.
Bleeding was controlled with endoscopic variceal sclerotherapy. The
following day she rebled and became profoundly hypotensive from which she
was resuscitated successfully. She was mechanically ventilated and an
endoscopy showed bleeding varices which continued despite sclerotherapy.
Bleeding was controlled with Sengstaken tube and TIPSS was performed as
an emergency. The following day the pupils were poorly reactive and an ICP
monitor was inserted which showed an ICP of 24 mmHg. This was poorly
controlled despite mannitol and thiopentone infusion. Subsequently, she
developed hypoglycaemia, epileptic seizures and acidosis. Her ICP rose to
34 mmHg and then to 41 mmHg. She died the day after the TIPSS
procedure. Changes in her liver function tests are illustrated in Table 2.9.
Case 4
This 42 year old man with alcoholic cirrhosis and Child class C (Pugh 10)
disease presented with mild ascites, grade 1 HE and variceal haemorrhage.
Following resuscitation, an endoscopy confirmed bleeding from oesophageal
varices which was not controlled with sclerotherapy. A Sengstaken tube was
inserted and TIPSS performed. Two hours after insertion of TIPSS the
patient developed seizures and was electively ventilated. Mannitol infusion
was started and an ICP monitored inserted. ICP was 27 mmHg which rose to
30. The ICP was successfully controlled with Mannitol and thiopentone
infusion. Despite an ICP of 3 mmHg the patient developed fixed and dilated
pupils and died. Changes in his liver function tests are illustrated in Table 2.9.
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The mechanism of development of cerebral oedema in these patients
can be explained on the basis of some innovative studies by Cordoba et.al.
(1995). They showed in a rat model that there was a significant and
progressive reduction in brain myoinositol when they were subjected to
portacaval anastomosis. When ammonia was infused in large doses there
was a significant increase in brain water even when accompanied by reduced
myoinositol. The introduction of TIPSS is like producing a side-to-side
portacaval shunt which may provide a large dose of ammonia particularly if
the patients were actually bleeding at the time of TIPSS. Furthermore, in a
recent study, they also showed that the reduction in myoinositol does not
offer protection against a new osmotic stimulus, i.e ammonia or
hyponatremia. All 4 of these patients exhibited hyponatremia at the time of
insertion of TIPSS and this may have sensitised them to the development of
increased ICP. Hyponatremia is an independent marker of poor outcome in
patients undergoing TIPSS for variceal haemorrhage (Jalan et al. 1995).
These cases suggest that cerebral oedema and an increase in ICP
may occur in patients with cirrhosis having TIPSS for uncontrolled variceal
haemorrhage.
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2.36. Changes in Neuropsychological and Liver function
Clinical
No significant complications of the procedure were encountered during or
immediately after TIPSS. During follow up, 4 patients developed significant
shunt dysfunction (PPG > 12mmHg or an increase in the PPG by more than
20% over the value attained following TIPSS). Two presented with variceal
haemorrhage within 7 days of TIPSS and one with re accumulation of ascites
about 3 weeks after TIPSS. The other patient was diagnosed on routine
screening at 1 month. They were all managed successfully with balloon
angioplasty or insertion of a parallel shunt. Overall, the PPG (Figure 2.11) did
not change significantly during follow up.
Overt encephalopathy was precipitated immediately following TIPSS
in one patient. This failed to respond to medical therapy and was only poorly
controlled following reduction in the diameter of the shunt. This patient
underwent orthotopic liver transplantation (OLT). Four other patients died
during follow up from complications of end stage liver failure and an
additional patient underwent liver transplantation.
Neuropsychological function, HAD and QOL
Patients with cirrhosis both in the TIPSS and the banding groups performed
significantly worse on all three of the subtests of CANTAB and RBMT. Ten of
the 15 patients in the TIPSS group who were recruited into the study prior to
TIPSS (67.6%) had values of simple and complex reaction times that fell
outside 2 standard deviations of the normal. Delayed matching to sample
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Patients in both the TIPSS and banding groups had significantly
higher HAD scores (p<0.05 and p<0.01 respectively) compared with the
control group. There were no significant differences in the HAD score
between the TIPSS and banding groups. Levels of anxiety following TIPSS
improved significantly at 1 month but deteriorated subsequently. Levels of
anxiety were significantly lower in the normal volunteers at 1 month. No
significant change was seen in the patients in the banding group (Table
2.13).
Patients in the TIPSS group had significantly worse quality of life on
both physical (p<0.001) and psychological (p<0.01) measures when
compared with normal volunteers. Similarly, patients in the banding group
had significantly poorer scores for QOL (p<0.01 and p<0.05 respectively for
physical and psychological components). There was no significant difference
in the quality of life between patients in the TIPSS and the banding groups.
Psychological component of the quality of life deteriorated significantly in the
patients in the TIPSS group. No significant change was noted in the patients
in the banding group or normal controls (Table 2.14).
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Liver function tests
Serum alanine transaminase and bilirubin deteriorated significantly following
TIPSS (Figure 2.12, 2.13) but both returned to the pre-TIPSS value during
follow up. There was no significant change in serum albumin or prothrombin
time following TIPSS. No significant change was noted in the above
parameters during follow up in the patients in the banding group. There was
dramatic reduction in ICG clearance following TIPSS which returned to pre
TIPSS values during follow up (Fig. 2.14).
Good correlation was observed between the changes in ICG
clearance and the change in serum bilirubin and ALT (p<0.01 r = 0.71, and
p<0.01, r = .68 respectively) when measured 7 days following TIPSS.
Although, the changes in ICG clearance seemed to parallel the changes in
PPG no significant correlation was observed between these parameters (r =
0.3).
Relationship between changes in the neuropsychological tests and liver
function tests and PPG
Changes in the neuropsychological tests were completely independent of
changes in the conventional liver function tests. There was however, good
correlation between changes in both the complex and simple reaction times
(sub tests of CANTAB) and the changes in the ICG clearance (r=0.6, p,0.05,
and r=0.66, p<0.05, respectively) measured at 3 months. No correlation was
observed between changes in the PPG and the changes in
neuropsychological function.
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2.37. Results of Haematological assessment
Clinical
TIPSS was performed successfully with an immediate reduction in the portal
pressure gradient from a mean of 21.9 (±1.6) to 9.5 (±1.0) (p<0.01). There
was no significant change in the pressure thereafter. Three patients did
however, develop significant shunt insufficiency which was manifested by
variceal rebleeding in 2 and reaccumulation of ascites in 1. Three patients
died during follow up from their underlying, end stage chronic liver disease
and 1 underwent successful orthotopic liver transplantation after 4 months.
The patients have been followed up for a mean of 8.0 months (±1.2) (longest
19 months).
Haematology
Haemoglobin concentration improved significantly from 89.9 (se 1.6) g/l to
119 (1.9) g/l after TIPSS (p<0.05) (Fig 2.16). No evidence of haemolysis was
detected prior to TIPSS with negative or normal Coombs test, reticulocyte
counts, serum haptoglobin , undetectable urinary haemosiderin and absence
of fragmented red cells in the peripheral blood. There was no significant
change in the mean reticulocyte count, mean cell volume or serum
haptoglobin level (Table 2.15). During the first week following TIPSS 3
patients (13%) showed evidence of haemolysis manifested by increase in the
reticulocyte count to 7, 8. and 10% respectively with a simultaneous
reduction in the haemoglobin concentration requiring at least 2 units of blood
transfusion, without any signs of bleeding (Fig 2.17). This was also
associated with reduction in serum haptoglobin to undetectable levels and
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the appearance of haemosiderin in the urine. Fragmented red cells
suggestive of traumatic haemolysis were also present on the peripheral blood
film. These features of haemolysis disappeared within 2 weeks of the TIPSS
and there was no evidence of haemolysis at 3 months. Four other patients
developed transient haemolysis, which was not accompanied by a change in
the haemoglobin concentration and associated with the appearance of
fragmented red cells and the disappearance of measurable haptoglobin from
the serum.
There was a significant reduction in the size of the spleen from a
mean of 16.9 (±1.1) to 13.7 (±2.4) cm (p<0.01) (Figure 2.18) at 3 months. No
significant change occurred thereafter. There was neither any significant
correlation between changes in the portal pressure gradient and the change
in spleen size (r = 0.3) nor was there a correlation between these parameters
prior to TIPSS (r =0.12).
The platelet count changed significantly following TIPSS ( p<0.01)
(Figure 2.19) but no significant correlation was observed between changes in
the portal pressure gradient and platelet count (r = 0.38). No significant
correlation existed between them prior to TIPSS (r = 0.15). There was no
correlation between the change in the size of the spleen and change in the
platelet count (r = 0.29). White cell count did not change significantly (3.6 to
4.1 x 10 9/I).
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1. TIPSS is relatively safe and can be performed on very ill patients with a
high degree of success in the management of bleeding varices. Numerous
questions remain unanswered such as which patients should be offered this
treatment, what is the complication rate and how best to monitor these
patients. It is, however, clear that complications are frequent and usually
associated with shunt insufficiency and regular and detailed follow up is
required to identify and address these at an early stage.
2. We have found that severe liver disease and hyponatremia indicate a poor
outlook after TIPSS and a high portal pressure predicts shunt failure. The
precipitation of encephalopathy following TIPSS was predicted independently
only by its presence prior to TIPSS. These predictors should lead to
consideration of the value of the procedure, the need for anticipation of shunt
failure and rebleeding and perhaps the use of prophylactic measures such as
lactulose and smaller shunts in patients likely to develop encephalopathy.
3. The commonly accepted dictum that a PPG of > 12 mmHg is required for
variceal haemorrhage requires revision. The relationship between variceal
rupture, its relationship to portal pressure and splanchnic blood flow clearly
require further study.
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4. The development of cerebral oedema and an increase in ICP after TIPSS
for uncontrolled variceal haemorrhage is of importance both from the point of
view of clinical practice and from the point of view of understanding the
pathogenesis of cerebral oedema in patients with liver disease. All 4 of our
patients exhibited hyponatremia at the time of insertion of TIPSS and this
may have sensitised them to the development of increased ICP.
5. (a) Clinical encephalopathy in this selected group of patients with
moderately severe liver disease occurred in 3% patients following TIPSS.
Neuropsychological tests were significantly worse in cirrhotic patients
compared with controls, 67% showing evidence of subclinical
encephalopathy. In this group of patients without previous encephalopathy
there was a temporary deterioration in the neuropsychological function both
in patients having TIPSS and the cirrhotic controls.
(b) Although temporary deterioration occurred in the levels of anxiety and the
psychological component of the quality of life in patients with TIPSS,
measures of memory improved. Significant deterioration occurred in ALT,
bilirubin and ICG clearance.
(c) Changes in ICG clearance following TIPSS correlated significantly with
the changes in the neuropsychological tests. Further studies should address
the mechanism of these changes and the effect of different prophylactic
measures on their prevention.
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6. Clinically significant haemolysis occurs in a minority of patients and is mild
and transient. TIPSS is associated with reduction in splenomegaly and
improves red cell and platelet counts and may therefore be useful for
troublesome hypersplenism. Further studies should address specific changes





• Methods Of Follow Up
• Mechanisms Of Shunt Stenosis and Occlusion
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3.1. Comparison of Doppler ultrasonography and portography in the
assessment of shunt dysfunction
3.11 BACKGROUND AND AIMS
The aim of follow-up is to identify the TIPSS patients with shunt insufficiency
and re-intervene before variceal bleeding recurs. The "gold standard" is venous
portography via the shunt with measurement of the PPG. This is invasive and
costly compared with clinical assessment or ultrasound examination. Clinical
assessment and endoscopic findings are poor predictors of shunt dysfunction.
Ideally non-invasive ultrasound screening for shunt dysfunction would allow
regular follow-up. Portography and re-intervention would then only be required
when shunt stenosis or occlusion was suspected or identified.
The aims of this prospective study was to assess Duplex and Colour Doppler
ultrasonography in the assessment of shunt function and compare the results





Shunt function was assessed routinely 3 months after insertion. None of the
patients showed clinical evidence of shunt dysfunction such as acute or chronic
gastro-intestinal blood loss or ascites at the time of follow-up. Shunt function
was assessed using Duplex and Colour flow Doppler within 24 hours of
portography and measurement of PPG. The investigators performing the
portographic examination and the ultrasonography were blinded to one
another's results and also to the clinical details.
Patients
Twenty three patients (15 male, 8 female) with a mean age of 53 years were
assessed with both Duplex and Colour Doppler and portography in the follow-
up of TIPSS. The indication for TIPSS was variceal haemorrhage in all patients.
Fifteen patients had alcoholic cirrhosis, 4 patients had cryptogenic cirrhosis, 2
patients had Hepatitis B associated cirrhosis and 1 patient each had
autoimmune chronic active hepatitis and Hepatitis C virus infection each. Ten
patients were Child-Pugh class A, 8 class B, and 7 class C at presentation.
TIPSS were created using the Wallstent (Schneider (Europe) AG, Switzerland)
in a similar manner to that previously reported (Jalan et.al. 1994).
3.122. Portography And Measurement Of Portal Pressure
Details of the method used for portography are described in section 3.21.
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3.123. Doppler Ultrasonography
Duplex and colour Doppler sonography were carried out by a single
experienced operator (Dr PL Allan) using an Acuson 128/XP (Acuson Corp.,
Mountain View, Calif., U.S.A.) with a 3.5 MHz OR 4 MHz phased-array
transducers. Values in triplicate were obtained for peak velocity, time averaged
velocity, cross-sectional area and from this blood flow and congestive index
were calculated (Moriyasu et.al. 1986) for both the main portal vein and the
shunt.
Analysis
Adequate Doppler examination was not possible in 6 patients due to their large
body habitus. Mean Doppler values for the previously defined variables were
calculated on each of the remaining 17 patients and correlated with the PPG
using linear regression. To demonstrate the range of results these have been




Shunt peak velocity (cm/sec) 90.6 (±12)
Shunt time averaged velocity (cm/sec) 40.6 (±7)
Shunt cross sectional area (cm2) 1.0 (±0.1)
Portal vein peak velocity (cm/sec) 68.4 (±7)
Portal vein time averaged mean velocity (cm/sec) 21.4 (±3)




Shunt function was assessed routinely 3 months after insertion. None of the
patients showed clinical evidence of shunt dysfunction such as acute or chronic
gastro-intestinal blood loss or ascites at the time of follow-up. Patients were
also assessed clinically for signs of hepatic encephalopathy both prior to and
following TIPSS. Two patients without prior encephalopathy became clinically
encephalopathic.
4.132. Portography. DopplerAnd Correlation
There was no significant correlation between portal vein peak velocity (PVPV),
portal vein blood flow (PVBF), portal vein congestive index (PVCI), shunt blood
flow (SBF), shunt congestive index (SCI) and the PPG. All 7 patients (41%)
with a shunt peak velocity (SPV) > 90 cm/sec had normal shunt function at
portography (PPG <12 mm Hg). However, a SPV < 90 cm/sec was not
predictive of the measured PPG (Figure 3.1). Shunt insufficiency at portography
(PPG > 12) was diagnosed in 8 patients (47%), due to intimal hyperplasia in 6
and hepatic vein stenosis in 2.
In the two patients who developed hepatic encephalopathy following





























This study assessing Doppler ultrasound in the assessment of shunt function
shows that a peak velocity in the shunt > 90 cm/sec indicates that the PPG is <
12 mm Hg. SPV may be high at about 200 cm/sec in a functioning shunt
(Foshager et.al 1994) but localised values >200 cm/sec may be due to a focal
stenosis associated with a raised PPG. The lack of correlation of blood flow and
PPG is probably related to the difficulties of accurate measurement of area
within the shunt. The shunt often lies deep within the abdomen and
visualisation of the whole shunt and the hepatic vein is difficult. Furthermore,
stenoses are often poorly visualised and the cross-sectional area if measured
between the metal stent struts will not reflect the true luminal area when intimal
hyperplasia is present.
An interesting observation was the association in 2 patients of significant
hepatic encephalopathy with a measurable ratio of SBF to PVBF of >1.0 .
Larger studies would be required to confirm the validity of this observation. The
presumed reason for this high ratio is that shunt blood is derived from not only
the main portal vein but the hepatic artery via shunting through the hepatic
portal vein branches which flow retrogradely to the shunt. These patients have
too large a shunt and some form of shunt reduction may need to be undertaken
such as inserting a stent with a smaller diameter within the existing shunt.
Our results therefore show sonographic evaluation of TIPSS follow-up is
of only limited value. The finding of an SPV > 90 cm/sec but <200 cm/sec,
particularly with maintenance of reversed portal vein branch flow, indicates a
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functioning shunt and satisfactory PPG. However, the finding of a SPV of <90
cm/sec may not indicate shunt malfunction and portography is required for
further evaluation. This probably reflects inaccurate angle correction when the
shunt is difficult to visualise clearly at a favorable Doppler angle which has
been noted by others authors (Longo et.al. 1993).
It is concluded that portography remains the "gold standard" for accurate
TIPSS follow-up assessment and is still required in the majority of patients.
However, if the Doppler criteria of SPV >90 cm/sec without a focal increase in
SPV >200 cm/sec is met, then portography may not be required.
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3.2 INVESTIGATION INTO THE PATHOGENESIS OF SHUNT
INSUFFICIENCY AFTER TIPSS
3.21 INTRODUCTION AND AIMS
The pathology and pathogenesis of shunt stenosis or occlusion is unclear
and differs according to when this occurs and whether it is due to narrowing
at the venous end or within the shunt. Radiologically, shunt insufficiency may
be due to narrowing of the hepatic vein (hepatic vein stenosis) or due to
stenosis or occlusion within the shunt itself. Narrowing of the portal vein is
not commonly seen (Darcy et.al. 1992). Early shunt occlusion is invariably
associated with thrombosis of the shunt, whilst late dysfunction is due to
hepatic vein stenosis or stenosis within the shunt due to "pseudo intimal
hyperplasia" (Ring et.al. 1992, LaBerge et.al. 1993).
The pathogenesis of hepatic vein stenosis is not clear although intimal
hyperplasia due to exaggerated proliferative response from local trauma and
stent motion, and retraction of the Wallstent following full expansion have
been blamed (Haskal et.al. 1994, Lind et.al. 1994).
The aim of this study was to assess the pathology and pathogenic
mechanisms of stenosis and occlusion within the shunt.
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3.22. METHODS
3.221. Patients and clinical follow up
The study population comprised 34 patients who had TIPSS inserted for
variceal haemorrhage (29), ascites (3) and portal gastropathy (2), and had at
least 2 separate portographic assessments of shunt function. Mean follow up
was 8.3 months (±1.2) (range 1-32 months). Patient characteristics are




Age (mean ±se) 56 (±1.6)
Sex (M/F) 20/14
Aetiology of Liver disease
Alcoholic cirrhosis 27
Cryptogenic cirrhosis 04










Duration of follow up
Results expressed as mean ± se
TIPSS Procedure
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TIPSS was performed by the standard procedure and has been described in
detail in section 2.21.
Follow Up
These patients were followed up clinically, biochemically and with Doppler
ultrasonography at 3 month intervals. In all patients, portography for
assessment of shunt function was carried out routinely at 3 and 6 months
and 6 monthly thereafter or earlier if they developed complications . Shunt
insufficiency was defined as either an increase in the porta-caval gradient to
greater than 12mmHg or portographic evidence of shunt insufficiency
(>70%). Balloon dilatation was performed when shunt insufficiency was
diagnosed either portographically or manometrically. Parallel stents were
inserted in 3 patients with recurrent intraparenchymal shunt insufficiency.
3.222. Pathology
Shunt Biopsy
In cases of shunt stenosis diagnosed at portography, endoscopic biopsy
forceps (Olympus, FB24K) were introduced through the sheath into the stent
and 4 biopsies of the occluding material taken from within the shunt (Figure
3.2). These were fixed in 4% formaldehyde and processed routinely.
Sections were cut at 4 microns and stained with haematoxylin/eosin,
PAS, PAS-diastase, Prussian blue reaction and Van Gieson for elastic tissue.
Immunohistochemistry was performed using PKK1/CAM 5.2 for epithelial
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Fig 3.2 Radiograph showing endocopy biopsy forceps introduced into the shunt
through the sheath for obtaining biopsies of the occluding material.
cells, factor V111 for endothelial cells (Dako ltd., U.K.) using standard avidin -
biotin - peroxidase detection with diaminobenzidine as substrate.
3.223. Explant Livers
Livers were obtained from the 10 patients who either died (8) or underwent
orthotopic liver transplantation (2). Only 1 of these patients had
instrumentation to the TIPSS within 30 days. The mean duration from
insertion of the TIPSS to obtaining the liver was 5.6 months (range 1-13
months). They were processed for radiological and pathological examination
as described below.
Pathology: The liver was perfused and fixed in buffered formalin immediately
afterwards and dissected to remove the stent with approximately 2 cm of the
surrounding liver. Several sections (at 5 mm intervals) were taken from the
surrounding liver. The stent was then opened with wire cutters. The contents
were examined macroscopically, the lining tissue was stripped off with
forceps and the contents taken separately. The tissues were processed as
described previously.
Radiology: All these explanted livers were placed on ice and the common bile
duct cannulated using a 10 Fr. Foley's catheter. Under radiological
screening, contrast was injected to fill the right and left biliary ductal systems.
Radiographs were taken at various angles to outline the ductal anatomy




Successful control of bleeding and ascites was achieved in all the patients in
whom the TIPSS was inserted successfully. Requirements for blood
transfusion were significantly reduced in patients who had TIPSS inserted for
portal gastropathy. During the study 8 patients have died and 2 have been
transplanted.
Depending upon the results of the first portographic assessment and
subsequent follow up the patients could be clearly divided into 3 groups.
There was no significant difference in the post-TIPSS porta-caval gradient in
the three groups. Group A (19 patients) comprised the patients in whom no
shunt insufficiency was noted. Group B (6 patients) comprised the patients
with mild shunt stenosis (<30% and a porta-caval gradient <12mmHg) and
Group C (8 patients) was composed of patients with severe shunt stenosis
(>70% and a porta-caval gradient of >12mmHg). Three patients in Group C
presented with variceal rebleeding whilst the remainder were discovered on
routine screening. None of these patients had any evidence of hepatic vein
stenosis.
During follow up there was no significant change in the porta-caval
gradient in the patients in Group A and B (Figures 3.3 and 3.4). Shunt
dysfunction in patients in Group C was initially managed by balloon dilatation
and this normalised the haemodynamic abnormality at the time but re -
stenosis occurred by the time of the second assessment in all. Shunt
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occlusion in this group was manifested by variceal rebleeding in 2 patients
and re-accumulation of ascites in 2. The other 4 patients with severe shunt
stenosis were symptomless and identified only on routine portography. Three
of the 4 patients with complications were managed by insertion of parallel
stents through another hepatic vein (Figure 3.5) and remained free of shunt
dysfunction on subsequent assessment (Figure 3.6). The other 5 patients
who were treated by dilatation had significant shunt stenosis at subsequent
portography (Figure 3.7).
3.232. Radiology
Direct portography in 1 patient prior to the biopsy showed a persistent biliary
venous fistula in association with shunt stenosis when contrast was injected
forcefully into the shunt (Figure 3.8). Cholangiography in the post mortem
livers showed marked distortion of the biliary tree around the shunt indicating
fibrous cicatrization (Fig 3.9). Although, 3 of these patients had severe shunt
stenosis and macroscopic evidence of transection of a major bile duct,
persistence of a patent fistulous connection could not be demonstrated due
possibly to thrombosis of the transected bile duct.
3.233. Pathology:
4.2331. Shunt biopsy Adequate biopsy specimens were obtained in all with
severe stenosis. In patients with minor stenosis (<30%) the biopsies were too
poor to be adequately examined. This was due to paucity of tissue and the
degree of fibrosis of the underlying pseudo intima. Organised thrombus
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containing fibrous tissue was seen in all 8 patients with bile in the thrombus
in 5. In addition, 2 of these patients had biliary epithelium in the biopsy
specimens (Figure 3.10).
Explanted livers Four of the 10 explanted livers showed shunt stenosis.
Three were severe (>70%) and the other was mild (30%). No stenosis was
seen in the other 6.
Composition of the lining : The shunt was lined with a white fibrous structure
which extended from the point of insertion of the shunt in the hepatic vein to
the lower limit of the shunt extending beyond the portal vein bifurcation.
Microscopically, it was composed of organising thrombus and fibrous tissue
with evidence of endothelialisation (Figure 3.11 and 3.12).
Occluding "thrombus": Macroscopic examination of the contents of the shunt
in 3 patients with severe stenosis showed bile stained contents. In all 3 there
was a primary thrombus which was adherent to a transected bile duct and
was composed of organised thrombus containing bile and occasional biliary
epithelium. Associated with the bile there was a granulomatous inflammatory
response containing numerous foreign body type giant cells. The underlying
bile duct was occlude by thrombus. The propagated thrombus was adherent
to the primary thrombus and was histologically similar to the primary
thrombus but lacked bile. Exuberant fibrous tissue was responsible for the
mild stenosis seen in 1 patient. Bile was not identified in the fibrous tissue,
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nor was there any evidence of transection of a major bile duct. The degree of
shunt stenosis was related closely to the size of the duct transected being
greater when the size of the duct transected was greater (Figure 3.13, 3.14,
3.15, 3.16). No evidence of bile was seen either in the pseudo intima or in the
shunt in the 5 patients with no stenosis.
In 2 cases there was marked accumulation of stainable iron in the
hepatocytes adjacent to the shunt compared with the distant liver tissue and
this may be due to local haemorrhage during TIPSS insertion or to shunt
related haemolysis.
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Fig 3.10 Photomicrograph of the histopathological appearance of a biopsy specimen obtained from an occluded
shunt demonstrating biliary epithelium (positive staining for cytokeratin).
Fig 3.15 and Fig 3.16 Photomicrograph of the histopathological appearance of the thrombus which overlies
the transected bile duct demonstrating granulomatous inflammation and bile impregnation.
Fig 3.11 An endoscope view of the shunt obtained from an explanted liver
showing the continuous pseudo-intima.
Fig 3.12 Photomicrograph of the lining of the shunt showing the pseudointima.
Fig 3.13 Photograph of a shunt that has been dissected out of the liver showing that a
major bile duct has been transected.
Fig 3.14 Photograph of a shunt which has been dissected out and opened to demonstrate
the occluding material.The arrow represents the primary thrombus that overlies
the transected bile duct
3.24. SUMMARY
In conclusion, severe stenosis or occlusion within the TIPSS is most common
in the intrahepatic portion, has a primary or bile related and a propagated
component and is probably related to the transient formation of biliary venous
fistulae caused by introduction of the shunt and made possible by the
incomplete interface of the mesh. This may be avoided by altering shunt
design such that the parenchymal portion of the shunt may be covered. In
view of these findings it may be advisable to establish a new shunt in a
patient who has evidence of severe shunt stenosis or shunt occlusion since
the persistence of the bile in the shunt will make re-stenosis likely.
Alternatively, in the event of a covered stent becoming available, this may be
used within the old stent to eliminate the detrimental effect of bile entrapped
within the thrombus. Further studies estimating markers of bile leak or
thrombogenesis at the time of TIPSS insertion may be able to identify
patients likely to develop subsequent shunt dysfunction.
151
CHAPTER 4
Evaluation of TIPSS for variceal
haemorrhage in patients with
Cirrhosis
• Uncontrolled Variceal haemorrhage
• Secondary prophylaxis
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4.1 COMPARISON OF TIPSS WITH OESOPHAGEAL TRANSECTION IN
THE MANAGEMENT OF UNCONTROLLED VARICEAL HAEMORRHAGE
IN CIRRHOSIS
4.11. INTRODUCTION AND AIMS
Surgical intervention has been the treatment of choice for patients whose
variceal bleeding continues or recurs after 2 sclerotherapy treatments.
Oesophageal transection and gastric devascularisation (OT) is the most
commonly performed operation for uncontrolled variceal haemorrhage but
has high rates of perioperative mortality and late rebleeding (McCormick
et.al. 1995).
The aim of this retrospective study was to compare TIPSS with
surgery in the treatment of patients with uncontrolled variceal bleeding in a




Criteria for entry into the study were defined prior the start of the study.
Patients would be included for analysis if they had underlying cirrhosis,
uncontrolled variceal haemorrhage, defined as variceal bleeding despite 2
separate sessions of sclerotherapy within 5 days of the first episode of
variceal haemorrhage and had been assessed for either OT or TIPSS.
Patients would be excluded from the analysis if they exsanguinated before
they could be reviewed either for OT or TIPSS. To eliminate any element of
bias the data were collected independently by two independent observers.
4.122. Patient Population
Two hundred and sixty patients with biopsy proven cirrhosis were referred to
the Royal Infirmary of Edinburgh with variceal haemorrhage over a 7 year
period (1988-1991 - 124, 1991-1994 - 136). The senior medical and surgical
teams who have an interest in variceal bleeding looking after these patients
have been constant over this period with the exception of the availability of
TIPSS as a therapeutic alternative since July 1991.
Routine management of patients with variceal haemorrhage involved
resuscitation followed by urgent intravariceal endoscopic sclerotherapy with
5% ethanolamine oleate or 2% sodium tetradecyl sulphate. In the event of
continued or recurrent bleeding; balloon tamponade, pharmacological
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therapy and repeat sclerotherapy were used individually or in various
combination.
During this period 41 patients (15.8%) were diagnosed as having
uncontrolled variceal haemorrhage of which 38 form the basis of this study.
Similar percentages of patients in both study periods were defined as having
uncontrolled variceal haemorrhage (1988-1991 - 15.3%, 1991-1994 -13.1%).
Three patients were excluded because of rapid exsanguinating bleeding
before surgical review was possible. Between 1988 and July 1991 all patients
with uncontrolled bleeding were treated by transection and since then TIPSS
has been used for all the patients with uncontrolled bleeding.
Four other patients had uncontrolled variceal haemorrhage as a result
of extrahepatic portal vein obstruction in 3 and non cirrhotic portal fibrosis in
1. These patients were managed successfully by creation of surgical
portasystemic shunts.
Of the 38 patients there were 19 each in the TIPSS and the OT
groups. The patients in the 2 groups were well matched for age, sex,
aetiology of underlying liver disease, its severity and its complications
(Tables 4.1). Severity of liver disease was defined at the time of the initial
bleed. Five patients with uncontrolled variceal bleeding were in hepatorenal
failure, defined as raised plasma creatinine, oliguria and intense sodium
retention in spite of a normal central venous pressure. Of the 8 patients with
active infection, 1 had fungal septicemia prior to TIPSS. Four patients were
diet controlled diabetics (TIPSS 3, surgery 1), 1 had underlying ischemic
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heart disease (surgery) and 1 was receiving propranolol for the treatment of
systemic hypertension.
The majority of the patients in both groups were bleeding from
oesophageal varices but 11 were bleeding from oesophagogastric varices.
None of these patients had isolated gastric varices. Nine of these 11 patients
were in the TIPSS group. There was no significant difference in the number
of sessions of sclerotherapy, nor the requirement for blood transfusion. A
similar number in the 2 groups were haemodynamically unstable (blood
pressure of less than 100 mmHg or persistent tachycardia of greater than
100 per minute) at the time of the respective procedures despite greater
number of patients in the TIPSS group requiring mechanical ventilation
(Table 4.1). The mean duration of time from first bleed to referral was 2.6
days (range 1-6 ) in the TIPSS group and 3.2 days (range 0.25-7 days)




Patients (n=38) TIPSS (N=19) Surgery (n=19) p-value
Age 57.1 (±2.3) 54.9 (±4.2) NS
Sex (M/F) 8/11 11/8 NS
Aetiology
Alcoholic cirrhosis 15 14 NS
Cryptogenic cirrhosis 4 3
Others 0 2
Child class
Class A 3 3 NS
Class B 3 5
Class C 13 11
Ascites 14 12 NS
Hepatorenal failure 3 4 NS
Encephalopathy 3 3 NS
Sepsis 5 3 NS
Bleeding site
Oesophageal varices 10 17 NS
Oesophagogastric varices 09 02
Sclerotherapy sessions 2.3 (±0.6) 3.1 (±0.3) NS
Balloon tamponade 14 13 NS
Blood transfusion (units) 10.2 (±1.3) 13.1 (±0.9) NS
Mechanical ventilation 05 02 NS
Haemodynamic instability 13 11 NS
Results expressed as mean and standard error
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4.123. TIPSS Procedure
TIPSS was performed by the standard procedure and has been described in
detail in section 3.21.
4.124. Oesophageal Transection And Devascularisation
Oesophageal transection and devascularisation was performed by the well
described method using a stapling gun (Burroughs et.al. 1989, McCormick
et.al. 1992) by either a consultant surgeon or by a senior registrar under the
supervision of a consultant surgeon. Splenectomy was not routinely
performed. Gastrografin swallow was performed in all patients following
surgery, and a Doppler ultrasonography to ensure adequate shunt function
was carried out after TIPSS.
4.125. Definitions and analysis
The definitions used were the same as described in section 3.221.
Follow up arid Analysis
Patients in the TIPSS group were assessed clinically, using Doppler
ultrasonography and portography at 3 and 6 months and 6 monthly
thereafter. Earlier clinical and portographic assessment was made in the
patients developing complications. Patients treated with OT were assessed
routinely at 3 month intervals and earlier in case of complications. The
patients with TIPSS have been followed for 7 patient years (longest 20
months) and those in the OT group for 6 patient years (longest 23 months).
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All results were expressed as mean and standard error of the mean and the
difference in the 2 groups tested using unpaired t - test. Survival and




Overall outcome of the patients in the 2 groups is summarised in Figure 4.1.
Control of bleeding was achieved in all patients in the TIPSS group in whom
a shunt could be constructed (17 patients). Failure to insert a shunt in 2
patients was due to an inability to puncture the portal vein. The mean portal
pressure gradient was reduced from 22.2 (±1.2) to 9.7 (+0.7) mm Hg. Initial
control of bleeding was achieved in all patients having successful surgery.
Figure 4.1, The outcome of patients with uncontrolled variceal haemorrhage
in the TIPSS and oesophageal transection groups. Numbers within brackets













































Early mortality was significantly higher in the OT group as compared with the
TIPSS group (OT 78.9%, TIPSS 42.1%) (p < 0.05) (Figure 4.2). Long term
survival in the patients who left the hospital was similar.
Eight of the 9 deaths in patients with TIPSS occurred within 30 days of
the procedure. Two patients died after failure to insert a TIPSS, one from
massive variceal haemorrhage and the other following subsequent
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oesophageal transection. One death was procedure-related and due to
rupture of the extrahepatic part of the portal vein, and 3 patients died from a
fulminant liver failure syndrome with characteristic haemodynamic
disturbances, hypoglycemia, renal failure, acidosis and intracranial
hypertension (2 patients). The patient with Candida septicemia prior to TIPSS
died from uncontrolled sepsis and 1 patient died from hepatorenal failure.
One patient died 6 months after TIPSS from end stage liver disease and 1
underwent orthotopic liver transplantation for intractable encephalopathy.
In the OT group 7 patients were considered too ill for the operation.
Six of the 7 patients considered too ill for surgery died within 30 days of the
referral, 5 from the effects of uncontrolled bleeding and the sixth from
hepatorenal failure. The seventh patient required 2 further sclerotherapy
treatments and recovered to leave the hospital but she died 18 months later
from end stage liver failure. Nine of the 12 patients undergoing OT died
within 30 days of the variceal bleed. Three deaths were related to
complications of the procedure (anastomotic leak - 1, cardio respiratory
arrest - 2), 3 from sepsis and 3 patients from early rebleeding. One further
patient who left the hospital rebled and died 5 months later from end stage
liver disease.
4.132. Rebleedinq
Three of the 19 patients in the TIPSS group rebled from varices (15.7%)
during the index admission; related to an inadequate shunt in 1 and shunt
thrombosis in 2. No further episodes of rebleeding occurred in the TIPSS
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group during follow up. These were managed successfully by shunt
extension and balloon dilatation respectively. One patient bled from
sclerotherapy ulcers and responded to treatment with sucralfate. Following
OT 5 of the 12 patients rebled (41.6%) from varices; 3 during the same
hospital admission and 2 during follow up. The outcome of variceal
rebleeding in the OT group was much worse with 4 of the patients dying from
the effects of the bleed. Bleeding was controlled in the fifth patient following
an emergency TIPSS. Overall, there was no statistically significant difference
in the rates of rebleeding.
4.133. Encephalopathy
Two patients with TIPSS developed encephalopathy that was absent prior to
the procedure. One patient required reduction in shunt size and was
subsequently transplanted. The other was managed satisfactorily with protein
restriction and lactulose. In the OT group 1 patient developed
encephalopathy which was successfully treated conservatively. Overall,
clinically detectable encephalopathy was evident in 22 and 25% of patients in
the OT and TIPSS groups respectively.
4.134. OTHERS
Ascites And Hepatorenal Failure
Ascites improved in all patients with TIPSS. All patients with hepatorenal
failure died in both groups, although transient improvement in renal function
was noted in 1 patient with TIPSS. Reaccumulation of ascites occurred in 3
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patients with TIPSS (spontaneous bacterial peritonitis 2, hepatic vein
stenosis 1) which were managed successfully conservatively.
Sepsis
Following TIPSS 3 patients developed infection (staphylococcal septicemia 2
and chest infection 1) which responded readily to antibiotics. One patient with
prior Candida associated septicemia died following TIPSS. In the surgical
group 6 patients developed sepsis which was fatal in 2.
Shunt Function
Shunt insufficiency (defined as an increase in the portal pressure gradient to
>12 mmHg or a rise in the gradient to >20% over the base line value)
occurred in 5 patients. Three patients rebled from varices and 1 presented
with reaccumulation of ascites. One patient was diagnosed to have shunt
insufficiency at routine screening. All episodes of shunt insufficiency were
successfully treated by balloon angioplasty, extension of the shunt or
insertion of a new shunt. Overall, there was no significant change in the
mean portal pressure gradient with it increasing to 10.4 (se 1.1) mmHg at 3




The results of this study indicate that TIPSS can be performed successfully in
very ill patients who are not fit to undergo OT and is associated with
significantly lower rates of early mortality. In this group of very ill patients, it
prolongs life and we believe, should be regarded as the preferred mode of
treatment as compared with OT for uncontrolled variceal haemorrhage. A
randomised prospective study comparing these treatments is needed to
answer this question definitively.
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4.2 TIPSS VS VBL IN THE SECONDARY PROPHYLAXIS OF VARICEAL
BLEEDING IN PATIENTS WITH CIRRHOSIS. A RANDOMISED AND
CONTROLLED STUDY
4.21. INTRODUCTION AND AIMS
Acute variceal haemorrhage can be controlled in about 90% patients using
endoscopic approaches such as variceal band ligation (VBL) or
sclerotherapy, pharmacological agents, or balloon tamponade. When
compared with placebo endoscopic variceal sclerotherapy has been shown
to reduce the rates of variceal rebleeding and mortality (Westaby et.al. 1985).
There are now 7 fully published trials in the literature comparing
sclerotherapy with VBL which were combined in a meta-analysis (Laine et.al.
1993). This included 547 patients and concluded that VBL carried a
significantly lower rate of rebleeding, mortality, complications such as
oesophageal stricture, and the number of treatments required for variceal
eradication. VBL is now considered by most as the endoscopic treatment of
choice for patients with oesophageal variceal bleeding (Laine et.al. 1995).
TIPSS reduces the portal pressure thereby controlling variceal
haemorrhage. It has been shown in numerous uncontrolled studies to reduce
rebleeding in patients with recurrent variceal hemorrhage and is now
considered the preferred modality of treatment for uncontrolled variceal
hemorrhage (LaBerge et.al. 1993, Rossle et.al. 1994, Jalan et.al. 1994).
However, there have been some concerns in the literature about
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deterioration in liver function and an increase in the incidence of chronic
hepatic encephalopathy after TIPSS (LaBerge et.al. 1993, Rossle et.al. 1994,
Jalan et.al. 1994).
The aim of this randomised and controlled study was to compare
TIPSS with VBL in the secondary prophylaxis of variceal haemorrhage in





Between May 1993 and December 1995 a total of 105 patients were referred
with endoscopically proven variceal haemorrhage. Of these, 58 patients were
enrolled into the trial. Patients were included if they were between 18 and 75
years of age, had underlying cirrhosis, and presented with the first episode of
oesophageal variceal haemorrhage. Patients were excluded from the study
for the following reasons; less than 18 years of age (n=2), patients who
rebled from varices within 24 hours of the initial endoscopy (n=12), bleeding
from ectopic varices such as gastric, duodenal or rectal varices (n=14),
previous endoscopic treatment for variceal bleeding (n=18), hepatorenal
failure (n=3), hepatic or extra-hepatic malignancy (n=2), thrombosed portal
vein (Colour flow Doppler ultrasonography) (n=3), or failed to give informed
consent (n=3).
4.222. Informed Consent, Ethical Approval, Randomisation and Study
Design
The study design was approved by the Lothian Regional Ethics Committee
and informed consent was obtained from all the patients or their next of kin.
Patients with active bleeding were resuscitated and underwent an upper
gastrointestinal endoscopy within 6 hours of admission. If the patients were
bleeding actively from varices, endoscopic variceal sclerotherapy was
performed using 5% ethanolamine oleate, otherwise they underwent VBL.
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Treatment assignment was achieved using the closed envelope method in
batches of 25 patients. Patients were randomised 24 hours after their first
endoscopic treatment if no further haemorrhage occurred. Randomisation
was performed if patients fulfilled the criteria for inclusion into the study, had
no exclusion criteria and had endoscopically confirmed variceal haemorrhage
which was defined as bleeding from an oesophageal varix at the time of
endoscopy or the presence of large oesophageal varices with blood in the
stomach and no other recognisable cause of bleeding. The assigned
treatment (VBL or TIPSS) was performed as soon as possible after
randomisation.
4.223. Transjugular Intrahepatic Portosystemic Stent-Shunt
Details of the TIPSS procedure are described in section 3.21.
4.224. Variceal Band Ligation
All the endoscopic procedures and VBL were performed or closely
supervised by one of the three experienced endoscopists as described by
Steigmann et.al (1992). Each of the varices were ligated with a single band
using an end-viewing endoscope and an outer adapter (Bard Intervention
Products, Tewkesbury, Massachusetts, USA). The ligation was started as
near the oesophago-gastric junction as possible and extended in a spiral
upwards to 4-5 cm above the oesophago-gastric junction. At each session
each variceal cord was ligated using a single band. Eradication was
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confirmed when the proposed column had either disappeared or could not be
'sucked' into the ligator.
4.225. Follow Up Treatment
Care of the patients in both the groups was identical and involved complete
clinical and biochemical assessment at 1 and 3 months, and 6 monthly
thereafter. The presence or absence of encephalopathy was assessed using
Parson-Smith criteria (Parson Smith et.al. 1957).
TIPSS group. Shunt function was assessed using Doppler ultrasonography 1
week after insertion of the shunt. Routine portography was performed at 1
month after TIPSS and then at 6 monthly intervals.
VBL group: Repeat endoscopy and band ligation was performed at weekly
intervals until variceal eradication, and then at 3 and 6 months and 6 monthly
thereafter.
4.226. Definitions and Management of Complications
All the definitions used were from a consensus meeting (De Franchis et.al.
1992)
Rebleeding: This was defined as subsequent upper gastrointestinal bleeding
manifested by hematemesis and/or malena, and a reduction in haemoglobin
by 20 g/l and requiring an unscheduled endoscopy. It was classified as
originating from oesophageal varices if it fulfilled the criteria outlined above.
Alternatively, the site of rebleeding was noted.
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Patients with variceal rebleeding were resuscitated and managed as follows.
TIPSS group - Banding/Sclerotherapy at endoscopy followed by urgent
portography and measurement of PPG. Shunt complications were dealt with
as explained below.
VBL group - Banding/Sclerotherapy at endoscopy followed by continuation
on the banding programme.
Uncontrolled variceal bleeding: This was defined as continued bleeding
despite 2 separate sessions of endoscopic treatment within five days of the
first treatment.
In both groups the patients were resuscitated and the bleeding was
temporarily controlled using a Sengstaken tube.
TIPSS group - Urgent portography and treatment of shunt dysfunction.
VBL group - An urgent TIPSS procedure would be performed if the patients
had uncontrolled variceal haemorrhage as defined above or at the time of the
rebleed they were thought to be bleeding from isolated gastric varices.
Early mortality Death within 6 weeks of the initial episode of bleeding.
Hepatic encephalopathy: This was defined as detection of encephalopathy,
or deterioration in the grade of encephalopathy using the Parsons-Smith
criteria (Parson-Smith et.al. 1957).
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TIPSS group - Hepatic encephalopathy was treated with protein restriction
and lactulose and reduction in the size of the shunt (Angiomed) (Hauenstein
et.al. 1995) if this failed.
VBL group - Hepatic encephalopathy was treated with protein restriction to
40 grams per day and lactulose to ensure at least 2 soft bowel motions per
day.
Shunt insufficiency: This was defined as an increase in the PPG to greater
than 12 mm Hg or an increase in the PPG by 20% over the post TIPSS
value.
Management: Shunt insufficiency was treated with balloon angioplasty, shunt
extension or insertion of a parallel stent.
4.227 Estimation Of The Cost Of The Procedures
The cumulative duration of time spent by each patient during the period of
follow up was estimated. This was subdivided into the amount of time that
each patient required in the intensive care unit, in the high dependency unit
and on the ordinary wards. Patients were admitted to the intensive care unit if
they required mechanical ventilation, to the high dependency unit if they
required intensive cardiovascular monitoring and were managed on the
ordinary wards if they required hospital treatment. The costs of treatment in
the different groups were estimated as they were costed for the National
Health Service in the UK. These do not include cost for personnel. Blood
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products are available free at the point of use within the National Health
Service.
Cost of TIPSS related procedures
The costs for the TIPSS procedure were divided into consumable cost for
TIPSS (£2239), consumable cost for routine portography (£228), consumable
cost for angioplasty (£405), consumable cost for shunt extension (£1194),
consumable cost for parallel shunt (£2245) and consumable cost for reducing
stent (£1000).
Cost of variceal band ligation
The standing charge for variceal band ligation and endoscopy is £150.
Cost of in patient and out-patient care was taken from the Scottish Office
Registry for health expenditure and normalised for the date they were
treated.
4.228. End Points, Determination Of Sample Size, Study Termination
And Statistical Analysis
The primary end point in this study was variceal rebleeding, and the
secondary end points were death and complications such as
encephalopathy, sepsis, shunt dysfunction in the TIPSS group and
oesophageal complications in the VBL group during follow up. Other
secondary end point were estimation of the amount of time patients spent in
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the hospital, total number of procedures they underwent and an estimation of
the cost in the two groups.
Assuming a reduction in the rate of rebleeding of 25% in studying
patients with the first episode of variceal bleeding (predicted rebleeding; VBL
- 35%, TIPSS - 10%) (Laine et.al. 1995, Jalan et.al. 1994), the estimated
sample size to detect a difference with a and p values of 0.05 and 0.20,
would be 27 patients in each group using a one tailed test. Patient
recruitment was stopped when the above number was reached and the study
was terminated 3 months after the last patient had been recruited. An interim
analysis was built into the protocol which was performed by an independent
statistician to ascertain whether there was any adverse effects of the new
treatment and, if necessary, recalculate the sample size.
All the data were expressed as mean and standard deviation. All the
results were analysed on an intention to treat basis. Mortality, rebleeding and
shunt insufficiency were analysed using the Kaplan-Meier method. Difference
between groups was tested using the Chi square test for qualitative data,





Of the 58 patients who were enrolled into the study, 27 were randomised to
VBL and 31 to TIPSS. Mean follow up in the TIPSS group was 15.7 (+10.2)
months and in the VBL group was 16.8 (±10.9) months. Patient
characteristics and duration of follow up in both the groups were similar
(Table 4.2). At initial endoscopy 4 patients in the TIPSS group and 3 in the
VBL group were bleeding actively from oesophageal varices. Bleeding in
these patients was controlled using endoscopic variceal sclerotherapy with
5% ethanolamine oleate. The rest of the patients in both groups underwent
VBL. None of the patients in either group showed any evidence of continued
bleeding at the time of randomisation. Mean time from the first evidence of
bleeding to initial endoscopy was 8.5 (±0.4) hr in patients in the TIPSS group
and 7.4 (±0.5) hr in patients in the VBL group. Mean time from the initial
endoscopy to randomisation was 1.2 (±0.3) days in the TIPSS group and 1.4




CHARACTERISTICS TIPSS (n=31) VBL (n=27)
Age 55.17 (±9.5) 59.9 (±8.6)
































Encephalopathy 7 (25.8%) 9 (33.3%)
Haemodynamic instability 3 (9.7%) 2 (7.4%)
Mechanical Ventilation 1 (3.2%) 2 (7.4%)
Blood Transfusion at randomisation (Units) 5.8 (±1.2) 6.3 (±3.7)






Continued alcohol abuse 72% 76%
Duration of Follow up (months) 15.7 (±10.2) 16.8 (±10.9)
Results expressed as mean and standard deviation. ALD - Alcoholic Liver
Disease
CAH - Chronic active hepatitis, PBC -
Hepatitis B virus,
HCV - Hepatitis C virus *Assessed 1
alcoholic cirrhosis
primary biliary cirrhosis, HBV -
week after discharge in patients with
4.232. Procedures
TIPSS was performed successfully in 28 of the 31 (90.3%) patients
randomised. Failure in the 2 patients was due to an inability to puncture the
portal vein. These patients were managed successfully by VBL. The third
patient was found to have a thrombosed portal vein at the time of insertion of
TIPSS and this patient was managed successfully with oesophageal
transection. Mean time to the performance of TIPSS from the time of
randomisation was 2.2 (±0.2) days. Successful TIPSS was followed by a
reduction in the PPG to less than 12 mmHg in all patients undergoing
successful procedures. Perforation of the capsule of the liver occurred in 1
patient and respiratory depression due to the sedation in another. The former
patient died and the latter responded quickly to the reversal of sedation using
the benzodiazepine antagonist, flumazenil.
VBL was successfully performed in all patients. Mean time from
randomisation to VBL was 2.4 (±0.2) days. Varices were successfully
eradicated in 18 patients (3 patients died before eradication, 6 patients had
TIPSS for uncontrolled variceal rebleeding before variceal eradication). Mean
number of sessions for eradication of varices was 3.1 (±0.4). Complications
related directly to endoscopic therapy were oesophageal ulceration in 12
patients and aspiration pneumonia in 2. A total of 83 endoscopic sessions
were performed in patients in the VBL group during the period of the study.
Eight endoscopic sessions were required for variceal eradication in the 2
patients in whom the insertion of TIPSS was unsuccessful.
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4.233 Rebleedinq
Four episodes of rebleeding from oesophageal varices occurred in 3 patients
(9.8%) in the TIPSS group. Variceal rebleeding was associated in all patients
with significant shunt insufficiency due to shunt thrombosis in 2 (days 2 and 3
after TIPSS). PPG in both these patients increased from 9 and 10 mmHg
immediately after TIPSS to 14 and 21 mmHg. The shunts were balloon
angioplastied with successful reduction in the PPG to less than 12mmHg in
both patients. Both these patients had Child class C disease. The third
patient rebled before TIPSS was inserted (2 days after randomisation). One
further patient rebled from a duodenal ulcer. No deaths occurred within 6
weeks of the rebleed.
Twenty two episodes of variceal rebleeding occurred in 14 of the 27
patients in the VBL group (51.9%). One further patient rebled from a
sclerotherapy ulcer. Rebleeding in 12 patients occurred before variceal
eradication. One patient rebled from recurrence of oesophageal varices and
1 from gastric varices. Seven rebled in the first week of VBL, 3 in the second
week, 2 in the third week and 1 after 7 months and 1 after 14 months.
Frequency of variceal rebleeding was significantly higher in patients with
Child class C disease compared with those having Child class A and B
disease (p-0.02). Rebleeding in the VBL group was uncontrolled in 8 patients
(oesophageal varices-7, gastric varices-1). These patients required
emergency TIPSS treatment. Four of the 14 patients who rebled from varices
died within 6 weeks of the episode of rebleeding. Two of these patients died
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despite adequate control of bleeding with TIPSS. The other six patients who
were treated with TIPSS have had no further rebleeding.
Variceal rebleeding was significantly lower in patients in the TIPSS
group (p<0.0006) (Figure 4.3). The frequency of rebleeding remained
significantly elevated in patients in the VBL group when sub-group analysis
was performed to compare the Child class A and B patients (<0.004), and
Child class C patients (p<0.004) separately between the two groups.
Overall, the absolute reduction in risk of rebleeding with TIPSS was
0.4 and the relative reduction in the risk of rebleeding was 0.8. This implies
that if 2.4 patients with variceal haemorrhage are treated with TIPSS instead
of VBL, 1 episode of variceal rebleed would be prevented.
4.234. Mortality
Thirteen patients (42.2%) died in the TIPSS group. Six of these patients died
early (19.7%). The deaths were related liver failure in 3, to the procedure in 1
(intraperitoneal bleeding from puncture of the liver capsule), cerebrovascular
accident in 1, aspiration pneumonia and sepsis in 1. Seven patients (22.6%)
died during follow up, and these deaths were due to end-stage liver failure in
4, cerebrovascular accident in 1, cardiomyopathy in 1 and pancreatic
neoplasm in 1. Patients with Child class C disease were at a significantly
higher risk of dying during the period of follow up compared with patients with
Child class A or B disease (p=0.01).
Ten patients (36.9%) died in the VBL group. Three patients died early
(11.1%). These deaths were related to aspiration pneumonia and sepsis in 1,
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and variceal rebleeding in 2. Seven other patients (25.8%) died during follow
up. Deaths were due to end-stage liver disease in 3, variceal rebleeding in 2,
pneumonia and respiratory failure in 1 and myocardial infarction in 1. Within
group analysis showed that patients with Child class C disease were at a
significantly higher risk of dying compared with patients with Child A or B
disease (p=0.005).
Mortality was not significantly different between the two groups (Fig
4.4). Sub-group analysis comparing mortality between Child class A & B, and
Child class C patients, between the two groups showed no significant
differences (p=0.23 and 0.68 respectively).
4.235. Encephalopathy
Seven patients (25.8%) were encephalopathic before TIPSS. Three had
grade II and four had grade III encephalopathy. Variceal bleeding was the
first presentation to the hospital in 2 patients with grade II encephalopathy
and 1 patients with grade III encephalopathy who were well upto the time of
presentation. Following insertion of TIPSS and control of bleeding there was
a transient improvement in encephalopathy in 2 of these patients. The third
patient improved with medical measures but has had episodes of
spontaneous encephalopathy during follow up. The other 4 patients were
known to suffer from chronic liver disease and had been diagnosed in the
past to have chronic relapsing encephalopathy. Worsening in the severity of
encephalopathy occurred in 1 patient. Development of the first episode of
encephalopathy that was previously absent occurred in 4 patients (total,
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16.1%). A total of 11 (35.5%) patients were encephalopathic after TIPSS.
Encephalopathy in 3 of these 4 patients was most marked immediately after
TIPSS. Encephalopathy became clinically evident 5 months after TIPSS in
the other patient. All episodes of encephalopathy responded to conservative
treatment with lactulose and protein restriction. One patient with recurrent,
spontaneous encephalopathy did however, require reduction in the shunt
size with the reducing stent (Angiomed, UK). This increased the PPG from 1
mmHg to 9 mmHg and this together with conservative measures allowed the
patient to be discharged home.
Nine patients (33.3%) in the VBL group were encephalopathic at
randomisation. Four had grade II and 5 had grade III encephalopathy.
Variceal bleeding was the first presentation to the hospital in 3 patients with
grade II encephalopathy and 2 patients with grade III encephalopathy who
were well upto the time of presentation. Following control of bleeding and
medical measures, significant improvement was noted in 3 of these 5
patients. The other four patients with encephalopathy were known to suffer
from chronic decompensated liver disease with recurrent encephalopathy.
Three other patients (11.1%) became encephalopathic during follow up. One
of these three patients had TIPSS inserted for uncontrolled variceal
haemorrhage. All episodes of encephalopathy were managed successfully
with conservative measures. Encephalopathy in these 3 patients occurred
after 3 weeks, 6 weeks and 8 months of randomisation. There was no
significant difference in frequency of development of encephalopathy
between the two groups.
180
4.236. Shunt Insufficiency
Nine patients (31.1%) in the TIPSS group developed shunt insufficiency
(Figure 4.5). Shunt thrombosis occurred in 6 patients and was manifested by
variceal rebleeding in 2. The other 3 patients had pseudo-intimal hyperplasia
which was diagnosed at routine portography. Portography was performed as
an emergency for variceal rebleeding on two occasions when balloon
angioplasty of the shunt was undertaken. Routine portography for shunt
surveillance was performed on 49 occasions, with balloon angioplasty being
performed for shunt insufficiency on 17 occasions in 9 patients. One patient
required insertion of a parallel stent for recurrent shunt insufficiency. Two of
the 8 patients in the VBL group who had TIPSS as 'rescue treatment'
developed shunt insufficiency. One had shunt thrombosis and the other had
intimal hyperplasia. Both were diagnosed at routine portography which was
performed on 21 occasions in these 8 patients during the period of follow up.
4.237. Sepsis
Three patients (9.7%) became septic during the first week of randomisation
in the TIPSS group. One patient acquired an aspiration pneumonia and died,
and 2 had staphylococcal septicaemia which responded to medical therapy.
Four patients (14.7%) in the VBL group became septic within the first week of
randomisation. Two patients acquired an aspiration pneumonia, 1 patient
developed spontaneous bacterial peritonitis and 1 developed a central-line-
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related sepsis. One of the patients with aspiration pneumonia died, and
others responded to medical treatment.
4.238. Duration of Hospital Stay And Cost Of Treatment
Patients in the TIPSS group spent a mean of 23.2 (±15) days per patient in
the hospital during the period of follow up compared with a mean of 31.2
(±19) days per patient by the VBL group (<0.05). Patients in the TIPSS group
spent a mean of 0.2 (±0.8) days per patient in the intensive care unit
compared with 1.15 (±2.3) days per patient in the VBL group (p=0.03). Days
per patient spent in the high dependency unit was 0.7 (±1.3) and 3.1 (±3.5) in
the TIPSS and VBL groups respectively (p<0.001). Patients in the VBL group
who rebled required significantly greater time in the intensive care unit than
the patients who did not rebleed (p=0.02).
Details of the costs incurred in the two groups are summarised in
Table 4.3. The total cost for procedures in the patients in the TIPSS group
were £2749 per patient compared with £1422 per patient in the VBL group.
The direct costs incurred from in hospital treatment was £4020 per patient in
the TIPSS group compared with £5782 in the VBL group. Overall, it was
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4.24. SUMMARY
In conclusion, if we take the primary end point as rebleeding, this study has
shown that TIPSS is superior to variceal band ligation for the secondary
prophylaxis of variceal haemorrhage in patients with cirrhosis. On the other
hand, if mortality is taken as the revised end point then, the results of this
study can also be interpreted to show the TIPSS is as effective as variceal
band ligation plus TIPSS rescue'. It is important to remember that our trial
compares TIPSS with variceal band ligation which has been shown to be
superior to sclerotherapy for prevention of rebleeding. However, this study
was designed to look at differences in rebleeding and not at mortality. This
study has also shown significant reduction in the total cost of treating a
patient with a variceal bleed in patients treated with TIPSS compared with
VBL. However, this is the first study to show such a marked difference in









5.1 MECHANISM OF CHANGES IN RENAL FUNCTION AFTER TIPSS
5.11. INTRODUCTION AND AIMS
The spectrum of renal abnormalities in cirrhosis range from mild degrees of
sodium retention to functional renal failure (hepatorenal syndrome). The
factors leading to changes in renal circulation are intrarenal, neural and
humoral. TIPSS reduces portal hypertension and has been reported to
reduce ascites. Patients undergoing TIPSS for recurrent variceal
haemorrhage or refractory ascites are haemodynamically stable and provide
an opportunity to study the relationship between changes in portal pressure,
renal handling of sodium and neurohumoral factors.
The aim of this study was to assess changes in the renal handling of sodium
in patients with ascites following TIPSS and its relationship to changes in the
neurohumoral profile (PRA, All ANP and cGMP), renal tubular function (LiC!)




Eighteen consecutive cirrhotic patients with ascites having TIPSS either for
recurrent variceal haemorrhage (16 patients) (recurrent variceal
haemorrhage was defined as bleeding requiring 3 or more admissions to the
hospital whilst being treated using endoscopic means) or refractory ascites (2
patients) were studied. Patients were excluded from the study if they were
haemodynamically unstable, had underlying malignancy, portal vein
thrombosis, severe co-morbid diseases, biochemical evidence of renal
dysfunction (serum creatinine of >150 pmol/l) or uncontrolled variceal
haemorrhage (bleeding from varices despite 2 separate sessions of
endoscopic treatment within five days). Patients were also excluded if they
exhibited shunt insufficiency when portography and pressure measurements
were performed at three months following insertion of TIPSS. Mean age was
52.5 years (±10.3) and 12 were males. Diagnosis of cirrhosis in all patients
was made histologically. The cause of liver disease was alcohol related in
14, due to Hepatitis C in 1, primary biliary cirrhosis in 1 and cryptogenic in 2.
Nine were Child class B and 9 were class C. All had ascites and their sodium
intake was limited to 80 mmol/day. All patients were on diuretics prior to




Details of TIPSS procedure are described in section 3.21.
5.123. Measurement Of Renal Function
Plasma and urine were collected for 24 hr before and after assessment of
shunt function for the measurement of urinary volume, serum and urinary
sodium and, serum and urinary creatinine. Creatinine clearance (Urinary
creatinine x volume of urine x 24/ plasma creatinine x 60) (ml/min) and
sodium excretion (mmol/day) was calculated from the above data.
5.124. Blood Sampling And Hormonal Assays
About 40 ml of blood was collected from a peripherally sited cannula into pre-
cooled tubes prior to TIPSS and 3 months afterwards when the patients
attended for portography. Blood was collected before the patients arose in
the morning and were in the fasted state. All patients were
haemodynamically stable at the time of collection of the blood at not
receiving concurrent infusions or transfusions. Plasma was separated and
the samples stored at -70°C for analysis at a later date.
5.1241. Measurement of Plasma renin activity (PRA): 5 ml blood was
collected into tubes containing 100 pi of 5% aqueous di-sodium salt of
ethylene diamine tetra acetic acid. Plasma stored at -70 degrees C were
thawed at room temperature. The assay is based on the principle that
Angiotensin I is generated by the action of renin on its substrate
angiotensinogen. This is carried out at 37 degrees C for 1 hour following
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which the reaction is arrested by sudden cooling. The protease inhibitors
prevent further degradation of Angiotensin I to Angiotensin II and III. The
assay for Angiotensin I is based upon competition of radio-iodinated
Angiotensin I or plasma Angiotensin I for binding the limited amount of
antibody added. Intra-assay coefficient of variation was about 5.2% and the
interassay coefficient of variation was 8.6%. Normal range for PRA was 1.6
ng/ml/hr (1.5 SD) for patients on 80 - 100 mmol/l (no added salt diet) sodium
intake per day and 3.2 ng/ml/hr (1.1 SD) for patients on unrestricted intake.
5.1242. Measurement of Angiotensin II (All): 2 ml sample of blood was
obtained in Angiotensin II inhibitor. Angiotensin II was extracted from 1 ml
plasma using an ethanol precipitation procedure. After centrifugation the
supernatant was dried down under air at 37 degrees C and the dried crystals
resuspended in 0.5 ml assay buffer. This was stored at -20 degrees C until
assayed. Angiotensin II values were then measured by radio-immunoassay
with an in house rabbit antibody R6B4. Intra-assay coefficient of variation
was 4.2% and the interassay coefficient of variation was 2.6%. Reference
range for All was 0.032 (+0.01).
5.1243. Measurement of Atrial natriuretic peptide (ANP): 5 ml of blood was
collected in tubes containing 100 pi of 5% aqueous di-sodium salt of
ethylene diamine tetra acetic acid and 50 ul of Trasylol (4000 Ill/ml). Plasma
ANP was extracted in the Millipore 8 sample extraction unit and the radio¬
immunoassay performed using an antibody to human ANP that has been
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raised in the rabbit following immunization with human ANP coupled to
bovine thyroglobulin by carbodi-imide. Intra-assay coefficient of variation was
6.9% and the interassay coefficient of variation was 9.8%. Reference range
for ANP was 62.1 ((±7.1) pg/ml.
5.1244. Measurement of cyclic Guanosine monophosphate (cGMP): 2.5 ml
sample of blood was collected in tubes containing 50 pi of 5% aqueous di-
sodium salt of ethylene diamine tetra acetic acid. 0.5 ml of the thawed
sample was extracted for cGMP using an ethanol precipitation procedure.
After centrifugation the supernatant was dried down under air at 37 degrees
C and the dried crystals resuspended in 0.5 ml assay buffer. This was stored
at -20 degrees C until assayed. The samples were then acetylated and the
plasma cGMP values measured with an in - house antibody (ED2-3).
Coefficient of variation for the assay was 3.6%. Reference range of cGMP
was 1.18 nmol/l (±0.34).
5.125 Measurement Of Lithium Clearance (Li CI)
Li CI was measured prior to and following insertion of TIPSS. LiCI was
calculated over a 6 hour period. Following ingestion of 300 mg of Lithium
carbonate 12 hr before, plasma and urine were collected at hourly intervals
for 6 hours. Patients drank about 1.5 L of fluids prior to and during the study.
Urine volume was measured and recorded hourly. Concentration of Lithium
were measured in the plasma and urine using flame photometry. Clearance
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was calculated for every hour as described for creatinine above and
averaged over 6 hours.
5.126. Analysis
Results were expressed as mean and standard deviation unless otherwise
specified. Difference within the group was calculated using paired t-test and
the relationship between variables calculated using linear regression. Data
for changes in the various parameters in individual patients are shown with




Bleeding was successfully controlled in the patients who had TIPSS for
variceal haemorrhage. Mean PPG prior to TIPSS was 19 (±6) mmHg and 8.8
(±3.4) mmHg after shunt insertion. No clinically detectable ascites was
present in any of the patients included in the study, although 4 still required
diuretics. Mean dose of diuretics required for control of ascites in these 4
patients was 62.5 mg (±13) of spironolactone and 30 mg (±8.1) of Frusemide
per day. Variceal rebleeding occurred in two patients due to shunt thrombosis
within 1 week of the TIPSS and these were managed successfully by
insertion of parallel stents. Two other patients had significant shunt
dysfunction (pseudo-intimal hyperplasia) when routine portography was
performed at 3 months and the mean PPG was 10.2 (±3.2) mmHg. Both
patients having TIPSS for refractory ascites died during follow up from
progressive liver failure 3.5 and 5.2 months after TIPSS and one other
patient underwent orthotopic liver transplantation for intractable
encephalopathy.
5.132. Changes In Renal Function
Urinary sodium concentration improved significantly from a mean of 39.3
(±6.3) to 69.6 (±7.9) mmol/l (p<0.001) (Figure 5.1) following TIPSS. Of the 2
patients having TIPSS for refractory ascites, sodium excretion improved from
less than 5 mmol/l in both to 10 and 25 mmol/l respectively. There was also a
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significant improvement in the control of ascites in these patients, although
they still required large amounts of diuretics. Creatinine clearance improved
significantly from 46.6 (±9.7) ml/min to 93.5 (±11.6) ml/min following TIPSS
(p<0.0001) (Figure 5.2). Creatinine clearance in the 2 patients having TIPSS
for refractory ascites improved from less than 5 ml/min before TIPSS to 12
and 15 ml/min after TIPSS.
5.133. Change In The Neurohumoral Profile
PRA decreased significantly from 13.4 (±3.8) to 4.5 (±1.5) ng/ml/hr (p<0.007)
(Figure 5.3). The levels were significantly higher than normal controls prior to
TIPSS (p<0.0001) and remained high after TIPSS (P<0.01). All was
significantly higher than controls before TIPSS (p<0.0001) and remained high
afterwards (p<0.01). There was however, a significant reduction in its
concentrations following TIPSS (pre TIPSS - 0.19 (±0.03) ng/ml, post TIPSS
- 0.07 (±0.01) ng/ml, p<0.002) (Figure 5.4). Concentration of cGMP was
significantly higher than controls prior to TIPSS (p<0.001) and increased
further from 2.7 (±0.3) nmol/l to 4 (0.4) nmol/l (p<0.001) (Fig 5.5) following
TIPSS. Concentration of ANP was not significantly different from the control
population prior to TIPSS (control -62.1 (±7.1) pg/ml, patients - 83.7 (±17.2)
pg/ml) and did not change significantly afterwards (90 (±18.7) (p=ns) (Fig
5.6).
5.134. Changes In Lithium Clearance
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Lithium clearance was measured in 8 of the patients with ascites who had
TIPSS for recurrent variceal haemorrhage. There was a significant
improvement in Lithium clearance following TIPSS from a mean of 19.4
ml/min to 25.3 ml/min (p<0.01) (Fig 5.7). The percentage change in Lithium
clearance correlated with the percentage change in UNa (r=0.52, p<0.05)
and with the percent change in ANP (r=0.54, p<0.05). There was no
significant correlation between the change in LiCI and the change in CrCI.
5.135. Relationship Between Changes In Renal Function And The Severity
Of Liver Disease And The Change In PPG
Although there was a significant improvement in the UNa and creatinine
clearance following TIPSS which caused significant reduction in the PPG, no
direct correlation was found between the change in PPG and the change in
UNa and the change in creatinine clearance. Furthermore, the degree of
change in UNa and CrCI was independent of the severity of underlying liver
disease as assessed by the Pugh score.
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The mechanism whereby sodium handling improves after TIPSS is
multifactorial. This study has shown that although there is a significant
reduction in PRA, All and PPG, none of these correlate with the changes in
UNa and CrCI. LiCI was used as a measure of sodium reabsorption proximal
to the inner medullary collecting duct. cGMP measurements in this study
probably reflects the activity of other unmeasured natriuretic factors and
probably nitric oxide activity because the change in ANP which is the other
major determinant of cGMP levels were both not significantly different prior to
TIPSS and did not change significantly thereafter.
In conclusion, we have demonstrated that significant changes in UNa and
CrCI after TIPSS is due both to changes in the renal proximal tubular function
and a reduction in the neurohumoral factors that are involved in sodium
retention. The degree of improvement in UNa and CrCI were independent of
the severity of underlying liver disease and the change in PPG.
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5.2 USE OF TIPSS IN THE EVALUATION OF THE 'HEPATORENAL
REFLEX'
5.21. INTRODUCTION AND AIMS
The characteristic circulatoryfinding in the renal dysfunction of cirrhosis is a
reduction in renal blood flow (RBF) and an increase in renal resistance
(Baldus et.al. 1970, Sacerdoti et.al. 1993). There is considerable evidence of
enhanced sympathetic nervous activity in patients with cirrhosis and sodium
retention. Concentrations of noradrenaline are inversely related to sodium
excretion (Ring-Larsen et.al. 1982). Lang et.al. (1991), in an animal model,
demonstrated an acute reduction in RBF following infusion of glutamine into
the portal vein. The effect of the infusion was to induce acute hepatocyte
swelling and portal hypertension. This reduction of RBF was abolished
following section of the hepatic vagal fibres and renal denervation. He
proposed the existence of a hepatorenal axis controlled by a reflex arc, the
afferent limb of which was the hepatic vagal innervation and the efferent limb
was the renal sympathetic system.
After insertion of TIPSS, portography is performed routinely to ensure
adequate shunt function and this involves direct cannulation of the shunt. The
shunt can be occluded using an angioplasty balloon producing significant
increase in the portal PPG. The aim of this study was to investigate the
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relationship between changes in portal haemodynamics and renal blood flow
in patients with cirrhosis.
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5.22. METHODS
The study was approved by the local ethics committee and the patients
studied gave their informed consent. They were divided into 2 groups which
were studied consecutively. Changes following shunt occlusion were
measured either in RBF (group I) or in cardiovascular haemodynamics
(group II).
5.221. Patients
Patients in the 2 groups were well matched for age, sex, aetiology and
severity of liver disease. All patients had undergone TIPSS for recurrent
variceal haemorrhage, 1-4 months previously. They were recruited into the
study when they were attending for portography for the assessment of shunt
function. None of them had ascites and were on no diuretics for at least 7
days prior to the study. They had no biochemical evidence of renal failure
and their sodium intake was limited to 100 mmol/day. They were included in
the study only if they had no signs of shunt insufficiency at the time of
portography which was defined as a Portal pressure gradient (portal pressure
- inferior vena caval pressure) of less than 12 mmHg. Patient details are
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5.222. PORTOGRAPHY
Assessment of shunt function involved the catheterisation of the shunt via the
internal jugular route using midazolam for sedation. Following portography to
outline the portal system and the shunt, pressure was recorded (Hewlett-
Packard, USA) from the portal vein, the inferior vena cava and the right
atrium, and the portal pressure and porto-atrial gradient (PAG) were
calculated. Unilateral RBF, renal vein pressure, portal vein flow and blood
was sampled from patients in group I. Cardiac haemodynamics were studied
in patients in group II. Measurement of other parameters as outlined in Table
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5.223. Measurement Of Portal Vein Flow
Following pressure measurements, the sheath was introduced through the
shunt and a double thermistor catheter (Webster Laboratories, California)
positioned in the portal vein. The distal end of this catheter was placed under
fluoroscopic control in the portal vein just distal to the junction of the superior
mesenteric and splenic veins. The protocol that was used for the
measurement of changes in the portal and renal blood flow has been well
validated by our group both in vitro and in vivo (Hayes et.al. 1992). Briefly,
the injectate used was 5% Dextrose (at room temperature, about 22°C). This
was infused at 50 ml/min using a syringe pump (Harvard model 22, modified
to meet BS 5724 standard). The signals from the internal (injectate) and
external (mixed blood) thermistors (distance-2.4 cm) were transferred
through a custom built interface (isolated to BS 5724 type CF) and processed
in an IBM compatible PS2-286 microcomputer system (Figure 5.8). This
provided a real time graphic display of blood flow. Collection of data was
started and stopped as required at the different stages of the test. Mean
blood flow was measured over 20 seconds. Specific events were designated
using on screen markers. Data was stored on floppy discs for analysis at a
later time.
5.224. Measurement Of Changes In Renal Blood Flow
Changes in unilateral RBF were measured in patients in group I. The
catheter was replaced by an angioplasty balloon which was positioned in the
intrahepatic portion (Figure 5.9) of the shunt. The sheath was positioned in
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the right atrium and the side arm used to measure the right atrial pressure.
Electrocardiogram and pulse rate were monitored continuously. Mean arterial
pressure was recorded non-invasively every 2 minutes. A double thermistor
catheter was introduced through a sheath in the right femoral vein into the
right renal vein and the changes in RBF and renal vein pressure continuously
recorded as described for measurement of portal vein flow above. The right
renal vein was chosen firstly, because the left renal vein also drains the
suprarenal glands which would complicate both sampling of blood and
measurement of blood flow and secondly, because cannulation of the right
renal vein was a lot easier from the femoral vein as it follows the natural
curvature of the catheter. Changes in the portal pressure were recorded
through the central lumen of the angioplasty balloon. The coefficient of
variation in RBF using this catheter was less than 10%.
Following measurements at base-line the angioplasty balloon was
inflated and the changes in RBF and other variables as outlined above
recorded at 2 minute intervals for 12 minutes. The balloon was then deflated
and the above parameters measured for 4 minutes at 2 minute intervals.
Renal vein resistance was calculated as the ratio of the RBF and renal vein
pressure.
5.225. Measurement Of Cardiac Haemodynamics
Changes in cardiac haemodynamics were measured in patients in group II.
The outline of the procedure was similar to that used for the measurement of
RBF. A Swan-Ganz catheter was introduced through a sheath in the femoral
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vein into the pulmonary artery and changes in cardiac output, systemic
vascular resistance and pulmonary capillary wedge pressure recorded prior
to, 6 and 12 minutes after shunt occlusion and, following balloon deflation.
Three separate recordings were made and the average of these were
recorded.
6.226. Blood Sampling And Hormonal Assays
Plasma was collected from the right atrium and the renal vein respectively,
prior to and 12 min after shunt occlusion and stored at -70°C for analysis at a
later date. Although, the pulmonary artery would have been ideal for
sampling to prevent the effects of streaming and inadequate mixing of blood,
the right atrium was chosen because it was thought unethical to introduce
another catheter into the pulmonary artery.
Plasma was also collected from a peripherally sited cannula from 12
healthy volunteers with a mean age of 51.3 (±4.2), male/female - 8/4 who
were maintained on 80-100 mmol Na diet for 1 week.
Measurement of Plasma renin activity (PRA): See section 6.1241
Measurement of Angiotensin II (All): See section 6.1242
Measurement of Atrial natriuretic peptide (ANP): See section 6.1243
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Measurement of cyclic Guanosine monophosphate (cGMP): See section
6.1244
Measurement of Adrenaline and Noradrenaline: Extracted samples were
assayed using high performance liquid chromatography and electrochemical
detection (Goldstein et.al 1981). Coefficients of variation was 8.2% and the
normal values for adrenaline and noradrenaline were less than 0.4 and 5
nmol/l respectively.
6.227. Statistical Analysis
Results were expressed as mean and standard deviation unless otherwise
specified. Difference between groups was calculated using unpaired t-test.
The relationship between variables were calculated using linear regression.
The method of summary measures as described by Matthews et.al. (1990)
was used to analyse the data. Briefly, a summary of the response (i.e. the
rate of change in renal blood flow, cardiac output (Figures 5.10 and 5.11),
arterial blood pressure, right atrial pressure) was calculated for every patient.
The second stage was to analyse the summary measure using simple
statistical technique such the paired t-test comparing the base-line value with
the value at 12 minutes which was the point of maximal change.
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Fig 5.8 The computer set-up and the thermodilution system that was used to measure
renal and portal blood flow.
Fig 5.9 X-ray showing an inflated angioplasty balloon in the shunt inserted through the
internal jugular vein and a reverse thermodilution catheter in the right renal vein
inserted through the femoral vein.
6.23. RESULTS
6.231. PPG And Portal Vein Blood Flow
The mean internal diameter of the shunt was 9.4 mm (±1.3) and the mean
PAG was 8.3 (±0.7) mmHg representing an adequate shunt. Following shunt
occlusion the PAG increased to 50 (±3.3). Following deflation of the balloon
the PAG was 8.1 (±0.6) mmPlg. Portal vein blood flow at rest was 482
(±201.6) ml/min. No significant correlation was found between portal vein
flow and the portal pressure gradient (r=0.3, p=0.4). Resting RBF was 289
(±102.6) ml/min and this correlated inversely with portal vein blood flow (r=-
0.73, p<0.02) (Figure 5.12).
6.232. Changes in RBF
Following shunt occlusion there was a progressive reduction in RBF
(P<0.001) which was most marked at 12 min (Figure 5.10) (Table 5.3). Mean
change was -133.8 (±89) ml/min (-43.5% (±25.3). Following balloon deflation
the RBF returned to base-line values over a period of 4 minutes. Shunt
occlusion was associated with a significant increase in the PAG from a mean
of 8.3 (±2.1) to 50.6 (±10.5) mmHg (P<0.0001). The change in RBF
correlated significantly with the change in PAG (r=-0.85, p<0.001) (Figure
5.13).
Renal vein pressure decreased significantly following shunt occlusion
(-26% (±17.2)) (p<0.01). Although there was a mild reduction in heart rate (-
6.3 (±7.4)/min, -7.8% (±9.5)), mean arterial pressure (-10.3 (±9.4) mmHg, -
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9.7% (±8.6)), and right atrial pressure (-0.3 (±1.7) mmHg, -21.3% (±74.2)),
these changes were not statistically significant (Table 5.4). Significant
correlation was observed between changes in renal blood flow and the
change in renal vascular resistance(r=-0.88, p<0.0005).
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6.233. Changes In Cardiac Haemodynamics
Cardiac output was reduced from a mean of 7.4 (±1.3) l/min prior to shunt
occlusion to 6.5 (±1) l/min 12 min after shunt occlusion (p=0.02). This
returned to pre-occlusion values following balloon deflation (Figure 5.12)
(Table 5.4). Mean change was -0.85 (±0.55) l/min (-10.9% (±6.9)). Shunt
occlusion was associated with a significant increase in the PAG (p<0.0001).
This was not associated with any significant change in the heart rate, mean
arterial pressure and the right atrial pressure. Shunt occlusion was
associated with insignificant reduction in the pulmonary capillary wedge
pressure (p=0.06). Systemic vascular resistance increased significantly from
1128 (±270.6) to 1347 (±356.4) dyne sec/cm5 (p=0.02). There was however,
no significant correlation between the changes in the SVR and the changes
in the cardiac output (r=0.4, p=0.24). The change in cardiac output was also
independent of the changes in the PAG (r=0.5, p=0.09).
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6.234. Changes In The Neurohumoral Profile
Blood for the measurement of neurohumoral factors was obtained from
patients in group I. Concentrations of the different factors in the renal and
systemic circulation prior to and following shunt occlusion are summarised in
Table 5.5. Systemic concentrations of PRA, All, and cGMP were significantly
higher in the patients compared to normal controls (p<0.04, p<0.02 and
p<0.01 respectively). There was no significant difference in the adrenaline,
noradrenaline, and ANP concentrations in the patients compared with age
and sex matched healthy volunteers.
Concentrations of cGMP and noradrenaline were significantly higher in
the renal compared with the systemic circulation (p<0.01 and p<0.02
respectively). PRA was significantly lower (p<0.04) and there was no
significant difference in the concentrations of All, ANP and adrenaline in the
systemic and the renal circulations. Following shunt occlusion there was no
significant change in the concentration of any of these variables in the
systemic or the renal circulations.
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6.24. SUMMARY
The contribution of the reduction in cardiac output following shunt occlusion
to the reduction in RBF cannot be disregarded. Occlusion of TIPSS appears
to induce a decrease in venous return and therefore, possibly re-distribution
of blood flow. However, the change in cardiac output did not produce any
significant haemodynamic disturbance. The transient increase in RBF
between 2 and 4 minutes in 3 patients following inflation of the balloon is
difficult to explain but further argues against a significant role of reduction in
CO being important in the change in RBF. Unfortunately, in this study we
have not measured changes in CO at the same time points as measuring
RBF. The statistical insignificance of the change in mean arterial pressure is
unlikely to be due to the number of patients studied in each group because
the difference remained inconsequential even when changes in both groups
were considered together. Finally, as pointed out above, the degree of
reduction in CO cannot fully explain the changes in RBF.
In conclusion, we have demonstrated a dramatic reduction in RBF with acute
increase in PAG which is compatible with the existence of hepatorenal reflex
in man, although other mechanisms may also be contributory. This is a
reproducible model which can be used to study this phenomenon further,
enhance our understanding of the changes in renal circulation in liver disease






Transjugular intrahepatic portosystemic stent-shunt (TIPSS) has
revolutionised the management of cirrhotic patients with variceal
haemorrhage. This section deals with the discussion of the results of the
various studies presented in this thesis in light of the available literature. The
following discussion will highlight some of the important areas that require
further evaluation
1. TIPSS procedure and shunt insufficiency
2. Prognosis of patients with TIPSS and predictive models
3. Hepatic encephalopathy
4. Variceal bleeding
5. Sodium handling after TIPSS
6. Hepatorenal reflex
6.1 TIPSS PROCEDURE AND SHUNT INSUFFICIENCY
Transjugular intrahepatic portosystemic stent-shunt (TIPSS) has
revolutionised the management of cirrhotic patients with variceal
haemorrhage (Rossle et.al. 1994). The occurrence of shunt insufficiency has
led to considerable speculation about the long-term benefit of TIPSS but
what is surprising is that this entity of shunt insufficiency remains poorly
defined. Detection and treatment of shunt insufficiency is important to prevent
variceal rebleeding. Numerous studies have addressed the rates of variceal
rebleeding and there is remarkable consistency in the data which place the
rate between 10 and 25% (LaBerge et.al. 1993, Rossle et.al. 1994, Jalan
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et.al. 1994, Martin et.al. 1993, Peramau et.al. 1993, Lind et.al. 1994, Stanley
et.al. 1996). This could be prevented if shunt insufficiency could be identified
and corrected before the rebleed. However, in order to estimate the
prevalence and devise strategies to prevent and correct shunt insufficiency, it
is important to define what is meant by shunt insufficiency.
The incidence of shunt insufficiency in published series varies
between 25% and 80% (LaBerge et.al. 1993, Rossle et.al. 1994, Jalan et.al.
1994, Martin et.al. 1993, Peramau et.al. 1993, Lind et.al. 1994, Stanley et.al.
1996) and is dependent upon the frequency of assessment of shunt function,
the duration of follow up and the method of surveillance used. This
remarkable variation in the rate of shunt insufficiency in the face of virtually
constant reported incidence of variceal rebleeding is noteworthy and
deserving of closer attention.
6.11 Definition of shunt insufficiency
The aim of TIPSS is to control variceal bleeding or prevent rebleeding by
reducing the portal pressure gradient (PPG = portal pressure - inferior vena
cava pressure) to <12 mmHg. This is considered by most authorities to be
the critical figure below which variceal haemorrhage does not occur (Garcia-
Tsao et.al. 1985). It is therefore reasonable to suggest that shunt
insufficiency should be defined as an increase in the PPG to >12mmHg in
patients in whom the PPG was greater then 12mmHg at the time of insertion
of TIPSS.
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However, about 15% of patients bleed from oesophageal varices with
a PPG of less than 12mmHg (Jalan 1995). Furthermore, TIPSS is often
inserted for the treatment of ascites (Ochs et.al. 1995) where the PPG at the
time of insertion may be less than 12mmHg. These issues complicate the
definition of shunt insufficiency. The definition of shunt insufficiency must
therefore take into account the PPG at the time of insertion of TIPSS. Any
degree of shunt narrowing that is not associated with significant
haemodynamic phenomenon should not be considered significant. The
precise definition of shunt insufficiency in these patients in whom the PPG is
<12 mmHg at the time of insertion of TIPSS is currently being debated. In
this population of patients we define shunt insufficiency as an increase in
PPG of 20% or more above the value obtained immediately after TIPSS
(Jalan et.al. 1994, Stanley et.al. 1996).
Similarly, in patients with variceal haemorrhage and a PPG of
>12mmHg, if the placement of TIPSS does not reduce the PPG below
12mmHg or, in patients with a PPG of <12mmHg at the time of insertion of
TIPSS the pressure is not reduced by 20% or more, then it should be
considered inadequate.
6.12. Pathogenesis of shunt insufficiency
What is apparent from the literature is that shunt insufficiency occurs in two
distinct forms (LaBerge et.al. 1993, Jalan et.al. 1994). The first is shunt
thrombosis which is associated with dramatic increases in the PPG and
occurs very early after the insertion of the shunt. Its true incidence is
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impossible to ascertain because routine portography is not often performed
early enough after the insertion of TIPSS but studies which have performed
routine portogram at 1 month suggest that its incidence is about 15%. The
second type is pseudo-intimal hyperplasia, which occurs in the
intraparenchymal portion of the shunt or in the hepatic vein above the stent.
This is noticeable about 1 month or more following insertion of TIPSS, is
slowly progressive and probably affects all the shunts to a variable extent.
The reported incidence of this type of insufficiency is widely variable and
depends almost entirely upon the duration of follow up and the frequency of
the surveillance.
Why shunt insufficiency occurs is unclear and the pathogenesis of the
two types are probably different. Unlike an intravascular shunt, TIPSS
encounters the liver parenchyma and its secretions. More than one group
have independently suggested that seepage of bile due to transection of a
major bile duct plays an important role in the development of shunt
thrombosis (LaBerge et.al. 1993, Jalan et.al. 1994). The later shunt
dysfunction is associated with pseudo-intimal hyperplasia and it appears that
its pathogenesis is multifactorial and includes contributions from bile, the
effect of turbulence, factors related to the radiological technique, stent
characteristics, patient selection and some hitherto undefined factors related
to the repair process (LaBerge et.al. 1993, Jalan et.al. 1994).
6.13 Shunt surveillance
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The most important questions that relate to everyday practice and need
answering are:
(i) what is the effect of shunt insufficiency and is shunt surveillance
necessary?
(ii) If necessary, when and how shunt surveillance should be performed and
(iii) if shunt insufficiency is detected what should be done?
It appears that the introduction of TIPSS alters the natural history of
variceal haemorrhage such that rebleeding is not the consequence in every
patient with an insufficient shunt but tends to occur in about 30-50%
(LaBerge et.al. 1993, Rossle et.al. 1994, Jalan et.al. 1994, Martin et.al. 1993,
Peramau et.al. 1993, Lind et.al. 1994, Stanley et.al. 1996) patients in whom
the shunt function is compromised. However, variceal rebleeding after
insertion of TIPSS occurs almost exclusively in patients with shunt
insufficiency (LaBerge et.al. 1993, Rossle et.al. 1994, Jalan et.al. 1994,
Martin et.al. 1993, Perarnau et.al. 1993, Lind et.al. 1994, Stanley et.al. 1996)
and therefore surveillance is necessary to prevent rebleeding.
A pointer as to when shunt function should be assessed is provided by
the observation that the rate of rebleeding is split almost equally between a
few days of the TIPSS and the remainder of follow up (LaBerge et.al. 1993,
Rossle et.al. 1994, Jalan et.al. 1994, Martin et.al. 1993, Perarnau et.al. 1993,
Lind et.al. 1994, Stanley et.al. 1996) (Figure 6.1). It would therefore seem
logical that the rates of rebleeding could be halved if the episodes of shunt
insufficiency that result from thrombosis can be identified early and corrected.
Shunt function should therefore be assessed early, i.e. within a week of
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TtPSS to detect early shunt thrombosis and then follow up should probably
be performed at 3 months and then 6 month intervals to identify shunt
insufficiency secondary to pseudo-intimal hyperplasia.
How they should be identified has been the subject of a number of
investigations. The two methods in current usage are Doppler
ultrasonography and portography with measurement of portal
haemodynamics. Although some investigators have found Doppler
ultrasonography with measurement of flow velocity in the portal vein to have
a close correlation with shunt function (Jalan et.al. 1994, Dabos et.al. 1996),
our prospective comparison of Doppler ultrasonography with portography and
measurement of portal pressure was disappointing and suggested that
portography should still be considered the 'gold standard' (Jalan et.al. 1994).
These differences may stem from operator characteristics or may be related
to the fact that assessments of shunt function in our studies were performed
on a routine ultrasonography list. A reasonable compromise may be to
combine the two procedures judiciously considering the invasive nature of
portography. One approach may be to use Doppler ultrasonography as a
screening method, maintaining a low threshold to proceed to portographic
assessment. Another approach may be to use changes in flow characteristics
of the portal vein haemodynamics following TIPSS to act as a guide to detect
shunt insufficiency.
Finally, once shunt insufficiency is identified what should we do about
it? The approach to this problem is based upon the proposed pathogenic
mechanisms of shunt insufficiency and long term follow up of patients with
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TIPSS. Early shunt insufficiency is almost entirely due to shunt thrombosis
which occurs in association with transection of major bile ducts. Balloon
angioplasty is invariably followed by re-occlusion. These patients should
have parallel shunts. Patients with pseudo-intimal hyperplasia either in the
hepatic vein or in the intraparenchymal portion of the shunt usually respond
and maintain shunt patency with balloon angioplasty alone (Jalan et.al. 1995,
Dabos et.al. 1996). The problem that is beginning to emerge with increasing
experience and longer follow up is that of the occlusion of the second shunt.
Whether a third shunt should be considered, whether they should undergo
repeated balloon angioplasty, whether they should have shunt surgery or
whether we should revert to endoscopic treatment of varices remains
unanswered.
The available data would suggest that a single early assessment of
shunt function and correction of the underlying insufficiency would halve the
rebleeding rate after TIPSS. The final impact of TIPSS in the management of
variceal haemorrhage will become apparent only when the problem of shunt
insufficiency has been solved. Future research should be directed at non¬
invasive methods of prediction of shunt insufficiency and the development of
stents with intraparenchymal covering.
6.2. MORTALITY
When TIPSS is inserted for variceal haemorrhage, there is transient
worsening of liver function in approximately one third of the patients and this
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may precipitate liver failure the severely ill patients (Jalan et.al. 1997, Sanyal
et.al. 1996). Thirty day mortality after TIPSS is about 20% and one year
survival rates vary from 50-85 (LaBerge et.al. 1993, Rossle et.al. 1994, Jalan
et.al. 1994, Martin et.al. 1993, Perarnau et.al. 1993, Lind et.al. 1994, Stanley
et.al. 1996). Mortality after TIPSS seems to be related to the severity of the
underlying liver disease (Jalan et.al. 1995, Somberg et.al. 1992). Accurate
identification of patients likely to die early after TIPSS would help in the
selection of patients for the procedure and plan on early orthotopic liver
transplantation.
Prognosis is conventionally assessed using Cox's proportional hazard
regression analyses (Cox DR, 1972). In patients with active variceal
haemorrhage treated with sclerotherapy, prothrombin time, encephalopathy,
severity of liver disease (LeMoine et.al 1992) and the amount of blood
transfusion in the first 72 hours have all been suggested as independent
predictors of early mortality (Jacob et.al. 1989). Similar observation of high
rates of early mortality for patients with worse Child class is evident in
surgical series (Planas et.al. 1992).
Although the Cox models have been assumed to have sufficient
precision to estimate outcome there are some problems with its usage in
predicting individual prognosis. First, the prognostic index reflects only
average prognosis with wide variation in individual prognosis. Previous
studies assessing outcome in patients with primary biliary cirrhosis
(Christensen et.al. 1985) have confirmed a marked difference between
observed and predicted survival. This imprecision may occur due to their
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inability to evaluate variables with sufficient prognostic information. Second,
these statistical methods are limited by their inability to assess non-linear
relationships between variables. Third, the Cox models have very limited
capacity for learning. This limits its ability to deal with factors that change
suddenly, especially in patients with variceal bleeding such as sepsis and
rebleeding.
The present predictive models of early mortality after TIPSS are based
upon retrospective data and suffer from poor specificity. Severity of liver
disease as judged by Child class (Rubin et.al. 1995), APACHE II (Rubin et.al.
1995), a combination of Child class and haemodynamic instability (Helton
et.al. 1993), a combination of creatinine, bilirubin, prothrombin time and
aetiology of liver disease (Malinchoc et.al. 1996), a combination of Child
class and hyponatraemia (Jalan et.al. 1995) have all been suggested as
predictors of early mortality after the insertion of TIPSS. However, these
data have not been tested prospectively and have poor sensitivity and
specificity. The reason for this poor specificity may relate to heterogeneity of
the data used to develop the regression models, or may reflect the limitation
of linear models as described above. Somberg et.al. (1992) have suggested
that aspartate aminotransferase, bilirubin and Child class were independent
predictors of mortality. Gordon et.al. developed a prognostic model using
bilirubin and creatinine to divide patients into a high and low risk categories.
The lack of prospective, blinded evaluation of the models makes these
difficult to use in a clinical situation. The large number of variables identified
in the different studies as predicting early mortality suggests that it is unlikely
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that one or two variables will determine final outcome accurately. This is the
major attraction of a model based upon neural networks because it has the
ability to simultaneously look at all the variables together.
We have recently used a 'feed forward' kind of neural network which
implies that signals flow only in one direction, i.e. from input to output
thereby, resembling the regression procedure. The learning of a 'feed
forward' network is associative where, the network learns to associate one
type of data with another. In an on-going study, an artificial neural network
has been trained to predict early mortality using data from a hundred patients
from two centres. Early results (presented to AASLD, 1997, Jalan et.al. 1997)
showed that the network predicted the outcome correctly in 186 patients
(93.5%). The sensitivity of accurate prediction of early mortality was 67% and
the specificity was 94% with a positive predictive value of 91%. The five
most weighted variables that predicted early mortality were the prothrombin
time, serum creatinine, need for mechanical ventilation, bleeding from gastric
varices and urgent TIPSS for uncontrolled variceal bleed. The development
and training of a neural network does not differ from any other data derived
decision making aid or from statistical analysis but it appears that a
significantly smaller sample size is required for determining outcome
accurately. Further datasets would be needed to develop this model further.
6.3 ENCEPHALOPATHY AND LIVER FUNCTION
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The controlled evaluation of neuropsychological function confirms that
subclinical encephalopathy occurs in about 67% patients with cirrhosis. The
major criticism that has been levied against the use of the computerised
neuropsychological assessment is that although they are scientifically valid
and reliable, these assessments do not accurately reflect the "real life"
functioning capability of the patient. The addition of Rivermead Behavioural
Memory Test, which is a measure of everyday memory difficulty serves to
address this criticism. Furthermore, with one exception, subclinical
encephalopathy did not progress to clinical encephalopathy in this study. It is
interesting that one patient did however, become profoundly encephalopathic
which was refractory to all forms of medical and radiological intervention. We
would like to re-emphasise that the group of patients we were studying were
relatively well and had no evidence of clinical encephalopathy prior to the
study.
There was significant deterioration in both the simple and complex
reaction time sub-tests of CANTAB following TIPSS at 3 and 9 months
suggesting a worsening in neuropsychological function following TIPSS.
Similar deterioration was noted in the cirrhotic controls suggesting that this
change may be due to the progression of liver disease rather than the effect
of TIPSS per se. Longer follow up of changes in neuropsychological function
in cirrhotic controls would have been interesting. Significant improvement in
RBMT at 1 month and of the delayed matching to sample memory sub-test of
CANTAB at 15 months is somewhat surprising and suggests that the
mechanism of changes in the memory characteristics in patients with sub
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clinical hepatic encephalopathy is different to the pathogenic mechanisms
associated with the changes in the neuropsychological function.
Patients in the TIPSS group were significantly less anxious at 1 month
but by 3 months became more anxious. This may be related to the security of
the in-hospital stay, regular follow up, familiarity with the medical staff and
ready access to the hospital services. Subsequent deterioration may be due
to the effect of return to the community. Significant improvement in the levels
of anxiety in the control population at 1 month may be related to the
familiarity with the operators.
The psychological component of the quality of life deteriorated
significantly in patients in the TIPSS group, starting at 3 months after the
procedure and continuing up to the duration of follow up. This may be a
surrogate marker of anxiety. No significant change in the physical quality of
life argues against the change in the psychological component being due to a
worsening in the severity of liver disease. Whether this finding is the effect of
TIPSS is difficult to ascertain because of the shorter duration of follow up in
the cirrhotic controls. It is possible that the mechanisms associated with
changes in the neuropsychological function (reflected by changes in
CANTAB) and psychological component of the quality of life are similar.
Of particular interest is the finding of a significant correlation between
changes in ICG clearance and change in the complex and simple reaction
time sub tests of CANTAB. This observation is in keeping with the study by
Lacy et. al. (1992) who demonstrated a similar phenomenon in patients
having distal splenorenal shunts. It is possible that some of the alteration in
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ICG clearance may reflect changes in liver function following TIPSS and
some of the alteration may be due to changes in portal blood flow due to
placement of the shunt.
Somberg et.al. (1992) suggested that the development of
encephalopathy following TIPSS was predicted by the aetiology of the
underlying liver disease (non alcoholic), female sex and low serum albumin.
Our evaluation of the predictors of encephalopathy have failed to confirm this
observation and found that encephalopathy following TIPSS is independently
predicted only by its presence prior to TIPSS (Jalan et.al. 1995). Sanyal et.al.
(1994) have confirmed this finding in an independent study.
Significant deterioration in the markers of hepatocellular injury (ALT)
and function (bilirubin) following TIPSS is not unexpected. Simultaneous
reduction in ICG clearance suggests that this may be the result of the
phenomenon of "sinusoidal steal" in addition to dysfunction of the liver. A
recent abstract suggested that this deterioration in liver function, particularly
in the activity of the microsomal system (P450) may be more prolonged than
that observed in this study (Lotterer et.al. 1994). In extreme cases patients
after TIPSS may develop a fulminant failure like syndrome which is invariably
fatal (Jalan et.al. 1997).
Our results and the incidence of clinically detectable encephalopathy
following TIPSS is at variance with that reported in a study comparing the
development of encephalopathy in patients having TIPSS and those being
treated by sclerotherapy which found that encephalopathy following TIPSS
occurred in about 30% patients (Sanyal et.al. 1994). The population studied
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comprised all comers with a large proportion belonging to Child class C
whereas we have selected the study population excluding patients who were
clinically encephalopathic, in renal failure, had continued bleeding or were
septic. In addition only a small proportion of our patients suffered from severe
liver disease. The purpose of our study was to assess the contribution of
TIPSS to the alteration of neuropsychological function, memory and quality of
life in patients who were not clinically encephalopathic.
In summary, clinical encephalopathy in this selected group of patients
occurred in 3 % patients following TIPSS. Neuropsychological tests were
significantly worse in cirrhotic patients compared with controls, 67 % showing
evidence of subclinical encephalopathy. In this selected group of patients
with no history of encephalopathy, there was a temporary deterioration in the
neuropsychological function both in patients having TIPSS and the cirrhotic
controls. Although temporary deterioration occurred in the levels of anxiety
and the psychological component of the quality of life in patients with TIPSS,
measures of memory improved. Significant deterioration occurred in ALT,
bilirubin and ICG clearance. Changes in ICG clearance following TIPSS
correlated significantly with the changes in the neuropsychological tests.
Further studies should address the mechanism of these changes and the
effect of different prophylactic measures on their prevention. Repeated
access to the portal system provides a unique opportunity to determine the




The Royal Infirmary of Edinburgh is a tertiary referral centre for the treatment
of liver diseases and it is also the only liver transplantation centre in
Scotland. Consequently, we are referred patients from the whole of Scotland
who are often treatment failures. The purpose of this study was to look at the
role of TIPSS in the secondary prophylaxis of variceal haemorrhage in
patients with cirrhosis. Previous studies have suggested that the natural
history of variceal hemorrhage is extremely variable depending upon when
patients are recruited into the studies and how many bleeds they have had at
the time of randomisation (Smith JL and Graham DY, 1981). Therefore, in
this study we randomised the patients who presented with the first episode of
variceal haemorrhage and were not bleeding at the time of randomisation.
Therefore the 12 patients who rebled within 24 hours of the initial endoscopy
were excluded from the study.
Our randomised trial has shown that TIPSS markedly reduces the
frequency and severity of rebleeding in patients presenting with a first
episode of variceal haemorrhage compared with VBL. There are two major
factors which affect rebleeding in patients with cirrhosis after the first episode
of bleeding has been controlled. First, the risk of rebleeding and death is
highest in the first week after the initial haemorrhage and decreases
thereafter (Smith JL and Graham DY 1981, Burroughs et.al. 1992). Second,
the rates of rebleeding within 2 months in different series depends almost
entirely upon the number of patients with advanced liver disease included
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into the study (Smith JL and Graham DY 1981, Burroughs et.al. 1992,
Lebrec et.al. 1984, Burroughs et.al. 1983, Villeneuve et.al. 1986, Quieniet
et.al. 1987, Colombo et.al. 1989, Garden et.al. 1990). These two factors are
crucial when assessing the impact of a new modality of treatment for variceal
bleeding.
There are four fully published randomised controlled clinical trials
comparing TIPSS with endoscopic sclerotherapy (ES) in the management of
variceal hemorrhage (Cabrera et.al. 1996, Rossle et.al. 1997, Sanyal et.al.
1997, Cello et.al. 1997). Interpretation of trials in variceal hemorrhage have
inherent difficulties because of differences in the management of patients in
different parts of the world. TIPSS and endoscopic treatment can be difficult
to compare, for whereas the success of a TIPSS procedure is apparent
immediately from a reduction in portal pressure to less than 12 mmHg, there
is no immediate indicator of a successful endoscopic sclerotherapy
treatment. Furthermore, separation of patients in these trials into those who
are treated by endoscopic therapy and those who had TIPSS is less clear.
Endoscopic therapy was used to treat the index bleed in both groups of
patients. Therefore, most patients in the TIPSS group will have had at least
one session of endoscopic treatment. Cross-over between groups because
of treatment failures also complicate the 'intention to treat' analysis.
All of these trials have built a potential confounding factor into the
study design which, although ethically responsible, makes interpretation of
the mortality data difficult. Rates of rebleeding were significantly lower for
TIPSS than for ES in Cabrera's (p<0.02), Rossle's (p=0.001) and also in
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Cello's study (p<0.01). No significant differences in rebleeding were detected
in Sanyal's study. In Cabrera's study, 51% patients (16 patients) rebled in the
ES group. Of these, 10 patients had uncontrolled variceal hemorrhage and 9
were 'rescued' with TIPSS. In Rossle's study, 45% (29 patients) patients
rebled in the ES group and 9 patients underwent TIPSS rescue'. In Cello's
study, 48% patients (12 patients) rebled in the ES group of whom 6 patients
required TIPSS rescue'. In Sanyal's study only 26% (8 patients) patients
rebled in the ES group, but 6 of them required TIPSS rescue. Although, it is
considered 'valid' to analyse data on an intention to treat basis this does not
reflect the true result. Mortality from uncontrolled variceal hemorrhage in
patients with cirrhosis who are treated with conventional measures
approaches 80%. The use of TIPSS in this situation improves survival (Jalan
et.al. 1995). If these studies were not designed to rescue patients in the ES
arm, each of these studies might have shown a survival benefit for the
patients in the TIPSS group. In fact, Garcia-Villareal (1996) presented a
similar randomised trial in an abstract form in which 'TIPSS rescue' was not
used. Although they randomised only a small number of patients they
showed a significant survival benefit for patients randomised to TIPSS. This
tends to support the suggestion that the lack of significant differences in
mortality in the first 3 studies may be due to rescue TIPSS intervention for
uncontrolled variceal haemorrhage. It could therefore be argued that these
trials are not really TIPSS versus ES but TIPSS versus ES plus rescue
TIPSS trials.
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Of the above trials, the study by Sanyal et.al. stands out in not
reporting a difference in rebleeding. This is probably because of the study
design and the methodology used in this study. One of the most important
factors that determines outcome in clinical trials of variceal bleeding is the
time interval from the episode of the first bleed to randomisation. Graham
and Smith (1981), and Burroughs et.al. (1989) have confirmed in separate
studies that shifting the starting point for analysis (time of randomisation) of
survival and rebleeding from the episode of bleeding by as little as 5 days
significantly alters the rates of rebleeding and mortality. They also showed
that if treatments to prevent rebleeding were used long after control of a first
episode of bleeding then improved survival would not be expected as many
deaths related to bleeding would already have occurred and the risk of death
in the survivors is much lower after this period. The time of randomisation in
the first 3 trials was within 3 days of the bleed (Rossle - within 24 hours of
presentation, Cabrera - within 3 days after control of bleeding, Cello - within
24 hours of admission). In Sanyal's study the exact time of randomisation is
not clear. They state that 'survivors of an episode of active esophageal
variceal hemorrhage were considered for inclusion if they were clinically
stable and were not actively haemorrhaging (absence of hemorrhage was
indicated by a stable hemoglobin level and no need for transfusions) for at
least 72 hours.' They then state that that 'the primary intervention was started
within 72 hours of randomisation.' This suggests that randomisation was
performed within 3 days of the initial hemorrhage but in 'Table V they
describe that 9±2 days elapsed between the time of cessation of bleeding
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and TIPSS insertion, and 11 ±3 days elapsed between the time of cessation
of bleeding and endoscopic sclerotherapy. What is also unclear is that if the
criteria for randomisation were met at 72 hours then why did patients receive
their respective treatments at a mean of 9 and 11 days respectively. The
rebleeding rate in their sclerotherapy group is only 26% which is lower than
that reported in other studies above. This may have been due to a selection
bias whereby they have inadvertently selected survivors likely to do well with
sclerotherapy.
No significant differences were observed in mortality in the first 3
studies, but an essential confounding factor is the TIPSS rescue'. Sanyal's
study however, did show a significantly higher rate of mortality in the TIPSS
group. When a proportional hazards model was constructed using variables
such as age, Child-class, encephalopathy, alcohol use and the primary
intervention (TIPSS or ES), none of these factors were found to be
independent predictors of mortality. It is also interesting to look at the causes
of mortality. In the TIPSS group, of the 12 deaths, 5 were due to variceal
rebleeding. Seven patients died in the ES group. Only 3 deaths were due to
variceal rebleeding. Variceal rebleeding in the TIPSS group accounted for
zero deaths in Cabrera's study and zero deaths in Rossle's study. Data for
Cello's study are not available. Three deaths occurred due to rebleeding in
the ES group in Cabrera's study and 2 deaths were related to variceal
rebleeding in Rossle's study. The possible reason for the higher rate of
variceal hemorrhage in the TIPSS group in Sanyal's study may be related to
the TIPSS procedure itself. TIPSS was either unsuccessful or inadequate in
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5 patients (12%). Furthermore, most authorities would agree that the portal
pressure gradient (PPG) should be reduced to less than 12 mmHg after
TIPSS. If this is not achieved then the procedure should be considered
unsuccessful. Although Sanyal et.al. state that some of their patients had a
PPG of >12mmHg they do not say how many. They did not use a parallel
stent to try and achieve this aim. The mean portal pressure they recorded at
6 months was about 18 mmHg suggesting that their method of surveillance,
i.e. endoscopy and Doppler ultrasonography did not adequately detect an
increase in PPG. These factors may have contributed to the higher rate of
rebleeding and mortality they observed in the TIPSS group.
There is consistency in 3 of the studies about the incidence of
encephalopathy amongst the two groups of patients. Worsening in or the
occurrence of previously absent encephalopathy was significantly higher and
occurred in about 30% patients in the TIPSS group (Cabrera et.al. 33%,
Rossle et.al. 36%, Sanyal et.al. 31%) and about 15% in the sclerotherapy
group (Cabrera et.al. 13%, Rossle et.al. 18%, Sanyal et.al. 13%).
Encephalopathy in Cello's study was not significantly different in the two
groups (TIPSS - 50%, ES - 44%). This observation is at variance with the
other studies and may be due to the patients studied and the method of
diagnosis of encephalopathy. In this study, only patients classified as having
either massive or sub-massive hemorrhage were included into the study.
The authors do not mention any strict criteria for the diagnosis of
encephalopathy which is defined in this study as 'the presence of asterixis,
gross disorientation or agitation, or frank somnolence or coma in the absence
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of any other identifiable cause.' This definition would identify only patients
with severe encephalopathy and overlook patients with milder
encephalopathy. Only in Rossle's study are clear diagnostic criteria set out
for grading the severity of encephalopathy. It is notable that only a handful of
patients in this study did not respond to medical treatment (3%) but
responded quickly to reduction of the shunt. What is even more interesting is
that there were 2 patients in the ES arm who developed encephalopathy that
was refractory to treatment. These two patients had undergone 'TIPSS
rescue'. These observations are important because they highlight that the
introduction of TIPSS is associated with increased incidence of
encephalopathy which is seldom troublesome, but also illustrate the
shortcoming of an intention to treat analysis.
Cello's paper provides the first evaluation of the relative costs incurred
in the management of patients with variceal hemorrhage using TIPSS or ES.
They found no significant differences in either the total health care costs or in
the mean health care cost per day of survival. There were no significant
differences in the mean duration of hospitalisation amongst the groups for
encephalopathy. Sanyal et.al provide some data regarding the reasons for
hospitalisation which was greater for the patients in the ES group for
decompensated ascites, and greater in TIPSS group for encephalopathy and
sepsis. Rossle et.al. found that patients in the TIPSS group spent less time in
the hospital, but this was not statistically significant. Cabrera et.al. found that
although there was no significant difference in the number of days spent in
the hospital by patients in either group for the index admission, patients in the
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ES group spent significantly more time in the hospital for rebleeding. Overall,
the total number of days spent per patient in the hospital was roughly 27
days in the ES group and 25 days in the TIPSS group (mean from Cabrera's,
Cello's and Rossle's study, data from Sanyal's study was not available). It
would have been interesting to see the extent to which patients were
readmitted to intensive care, high dependency care or ward care as these
are important variables that make enormous differences to the overall cost.
We compared TIPSS with variceal band ligation and found that patients in
the banding arm required significantly more admissions for intensive and high
dependency care (Jalan et.al. 1997). Indeed, overall costs/patient were
significantly lower in the TIPSS group. We accept, however, that measuring
costs of different procedures and extrapolating them to different health
systems is fraught with inaccuracies. Despite the differences in the data it is
clear that TIPSS is not more expensive than ES in the management of
variceal hemorrhage in patients with cirrhosis.
Another confounding factor that makes interpretation difficult is that
these studies do not strictly look at secondary prophylaxis of variceal
hemorrhage, but at the role of the two treatments in the management of any
episode of variceal bleeding. By definition, a study of secondary prophylaxis
should include only patients who are presenting with a first episode of
variceal hemorrhage, and build into the study an exclusion for patients who
have bled previously. Patients with second or subsequent variceal bleeding
are the survivors of a first bleed and may intrinsically have a different natural
history. Cabrera randomised about 30% of patients in either group with
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previous variceal bleeding. In Rossle's study about 60% patients had
previous bleeds and in Sanyal's study about 50% patients had previous
bleeds. Cello et.al. do not mention previous bleeds as an exclusion criteria
and do not state how many of the patients in either group had previous
bleeds.
The fundamental principle of power calculations for clinical trials is to
estimate the number of patients that would need to be randomised to show a
difference in the primary end point of the study. The primary end-point of the
studies by Cabrera et.al., Rossle et.al and Sanyal et.al. were rebleeding and
the power calculations were made to this end. Cello et.al. state that the
primary end point of their study was survival, but their power calculations for
estimation of sample size were for rebleeding. If mortality is considered a
secondary end point, as in all these studies, then it is inadvisable to over-
interpret these data and say that 'no differences in mortality were detected'.
A study specifically designed to answer this question needs to be performed
before such a conclusion could be made.
One method for overcoming the problems of sample size is the
performance of a meta-analysis, but this can only be reliable if the studies
are homogenous. According to Friedman and Goldberg (1996),
'heterogeneity is the Achilles heel of a meta-analysis.' The above account
plus other confounding factors such as the use of different treatments in
different studies such as banding, propranolol, vasoactive drugs and
methods for shunt surveillance must make the studies so heterogeneous that
they will be difficult to combine. The interpretation of data from such an
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analysis due to the degree of heterogeneity will be extremely difficult.
Regarding meta-analyses, Bailar (1997) concluded that 'in my own review of
selected meta-analyses, problems were so frequent and so serious, including
bias on the part of the meta-analyst, that it was difficult to trust the overall
"best estimates" that the method often produces'.
These studies are, however, extremely valuable in their own right and
show five important conclusions. There is little doubt that TIPSS substantially
reduces rebleeding, its severity and hospital admissions from this
complication. One of the major problems following TIPSS is shunt
insufficiency which can be prevented and does not translate into increased
rebleeding if shunt surveillance is performed regularly. TIPSS is associated
with increased rates of encephalopathy which is seldom troublesome. There
is no difference in survival between the two treatment modalities but this
must take into account the effect of TIPSS rescue' in patients with
uncontrolled variceal hemorrhage in the patients in the endoscopy arm.
Finally, TIPSS certainly does not cost more to the health service but may in
some centres be associated with reduced costs.
The rate of variceal rebleeding in our VBL group was higher than
reported in studies comparing VBL with sclerotherapy. Most studies report
rates of rebleeding following VBL of 25-35% (Steigmann et.al. 1992, Gimson
et.al. 1993, Lo et.al. 1995, Hou et.al. 1995, Hashizume et.al. 1993, Laine
et.al. 1996) whereas the rate of rebleeding in our VBL group was 51%. This
difference is most likely due to different populations under study. All the
above studies randomised about 30% of patients with Child C liver disease
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and this is reflected by about 30% rebleeding in these studies (Steigmann
et.al. 1992, Gimson et.al. 1993, Lo et.al. 1995, Hou et.al. 1995, Hashizume
et.al. 1993, Laine et.al. 1996). About 50% of patients in our study had Child
class C liver disease, and, as we have outlined earlier the risk of rebleeding
is closely related to the severity of liver disease. The effect of severity of liver
disease upon rebleeding is highlighted in this study as we have shown a
significantly higher rate of rebleeding in patients with Child class C disease
compared with patients with Child class A and B disease. Furthermore, most
of our patients continued to abuse alcohol which is known to have a
detrimental effect upon portal hemodynamics (Silva et.al. 1994). Although
some authorities suggest that earlier eradication of varices would occur if
more than 1 band were placed on an individual varix, this concept is not
universally accepted. At the time this study was set up we decided to follow
the protocol and the method that was described by Steigmann et.al (1992).
The number of sessions of VBL required to achieve variceal eradication was
similar to that reported in other studies.
Data from the retrospective study presented in this thesis have shown
that the outcome of patients with uncontrolled variceal haemorrhage is dismal
and TIPSS in this situation improves survival (Jalan et.al. 1995). This
impression has been confirmed by two other group of investigators and most
authorities believe that TIPSS is the treatment of choice for patients with
uncontrolled variceal hemorrhage (McCormick et.al. 1994, Sanyal et.al.
1996). No significant difference in mortality was detected in the trial
comparing TIPSS with VBL for the secondary prophylaxis of variceal
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haemorrhage despite marked differences in rebleeding (Jalan et al. 1997).
This may be related to the design of the study. The primary object of this
study was to detect differences in rebleeding, and it was not thought ethical
to withhold TIPSS in cases of VBL failure and uncontrolled variceal
haemorrhage. TIPSS rescue of patients in the VBL group with uncontrolled
variceal haemorrhage may have masked a survival benefit, as 6 of the 8
patients thus treated, survived. The primary reason that Garcia-Villareal's
(1996) study comparing TIPSS with sclerotherapy showed a significant
reduction in both rebleeding and mortality in the TIPSS arm was the study
design, by which patients with uncontrolled variceal haemorrhage in the
sclerotherapy arm were not treated with emergency TIPSS. In all the other
trials patients with uncontrolled variceal haemorrhage were rescued with
TIPSS. Furthermore, no significant differences in mortality in patients with
Child A and B or Child class C disease between the two groups highlights the
fact that TIPSS does not adversely affect outcome.
Worsening of encephalopathy after TIPSS is independently predicted
by its presence prior to TIPSS (Jalan et.al. 1995, Sanyal et.al. 1994).
Although insertion of TIPSS precipitated worsening or new onset
encephalopathy in 5 patients, this was not significantly different to the
frequency of encephalopathy occurring in the VBL group (3 patients).
Encephalopathy may be due to progression in liver disease in addition to
increased portacaval shunting. The observation that encephalopathy
developed late in 1 patient in the TIPSS group and 2 patients in the VBL
group suggests that encephalopathy is due at least in part to the deterioration
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in liver function. Furthermore, all the episodes of encephalopathy were
managed successfully using conservative measures. Our results, which show
no significant differences in the incidence of encephalopathy, is at variance
with most of the other data from randomised studies (Cabrera et.al. 1996,
Rossle et.al. 1997, Sanyal et.al. 1997). This is difficult to explain but may be
accounted for by the population under study. 26% and 33% patients in the
TIPSS and VBL groups respectively were encephalopathic at the time of
randomisation. The other reason for this difference may stem from the
definitions of encephalopathy used. We used the simple clinical criteria
defined by Parson-Smith et.al (1957). Use of subtle tests of
neuropsychological function may have yielded different results.
Patients in the VBL group who rebled, spent significantly greater time
in the intensive care unit compared with the patients who did not rebleed.
Although the cost of the procedures was significantly higher in the TIPSS
group, the overall total cost of treatment was significantly less in the patients
treated with TIPSS compared with VBL. This is due to the longer hospital
stay in the patients in the VBL group. Furthermore, if 2.4 patients with
variceal bleeding are treated with TIPSS, one episode of variceal bleeding
would be prevented. In economic terms, the use of TIPSS will generate a
significant saving for every rebleed that is prevented. These results should
however, be taken in context. These costs estimate only the direct costs as
borne by the National Health Service in the UK. These costs do not take into
account the establishment costs, hardware cost, radiology or endoscopy time
and the cost of training personnel that would be required to establish a new
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service. In addition, these costs may not be directly applicable to all health
systems around the world, but in general terms, procedure costs are higher
with TIPSS but hospital admissions are less because of a reduction in
rebleeding.
In conclusion, if we take the primary end point of the study as
rebleeding, this study has shown that TIPSS is superior to variceal band
ligation for the secondary prophylaxis of variceal haemorrhage in patients
with cirrhosis. On the other hand, if mortality is taken as the revised end point
then, the results of this study can also be interpreted to show the TIPSS is as
effective as variceal band ligation plus TIPSS rescue'. It is important to
remember that our trial compares TIPSS with variceal band ligation which
has been shown to be superior to sclerotherapy for prevention of rebleeding.
However, this study was designed to look at differences in rebleeding and not
at mortality. This study has also shown significant reduction in the total cost
of treating a patient with a variceal bleed in patients treated with TIPSS
compared with VBL. Randomised, clinical trials of endoscopic treatment,
comparing VBL with TIPSS need to be performed including large numbers of
patients with the first episode of variceal hemorrhage. Because large
numbers of patients will be required if the primary end-point of the study is to
be mortality, it should be an international multicentre study. The time of
randomisation is crucial as any potential benefit of TIPSS will be
progressively less with increasing time lag between the bleed and definitive




This study comparing TIPSS and surgery in the treatment of uncontrolled
variceal haemorrhage confirms that patients requiring these treatments are
extremely ill and mortality will be high whatever the treatment used. This
study has the limitation of being retrospective and non-randomised.
Nevertheless, factors making this comparison worthwhile and valid are that
during the 7 years there has been no change in the capacity of the hospital in
dealing with these patients, selection criteria were the same in both periods,
the patient groups were similar with respect to the severity of liver disease
and its complications and the only treatment prior to July 1991 was surgery
and since then the only treatment has been TIPSS. We have tried to
eliminate the problem of bias by collection of data by 2 separate observers
(RJ and TJ) and reviewing all possible avenues of patient retrieval
(endoscopy records, surgical audit system and meticulous search through
the ward records).
Seven of the 19 patients in the OT group were thought to be unfit for
surgery. This information is of immense importance because, although the
patients in the TIPSS group had comparable severity and complications of
liver disease the patient was never thought to be too ill for the procedure
reflecting the relatively less traumatic nature of TIPSS. Furthermore, analysis
of the results for the patients in the 2 groups was made on an intention to
treat basis. Early mortality in the TIPSS group was half that of the surgical
group. Forty percent mortality in patients with TIPSS is reminiscent of the
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figure associated with first bleed (Smith JL and Graham DY 1981, Burroughs
et.al. 1989) but rates of 79% (surgical group) is similar to the figures
reported by most groups in this patient population (McCormick et.al. 1994,
Teres et.al. 1987b). Perioperative death in the TIPSS group, related to
puncture of the portal vein is unusual (LaBerge et.al. 1993, Rossle et.al.
1994, Jalan et.al. 1994) and close attention to the depth of puncture in
patients with small fibrotic livers may reduce the risk further. Increase in
intracranial pressure in patients with chronic liver disease is rare (Crippin
et.al. 1992) and its occurrence in 2 patients in our study is noteworthy.
Variceal bleeding, especially if associated with hypotension could cause
deterioration in liver function. The high incidence of sepsis in both groups of
patients is worrying and probably reflects the population of patients being
studied. Most of the patients have advanced forms of liver disease, have
been seriously ill, have had numerous procedures including repeated
sclerotherapy and balloon tamponade and multiple punctures for peripheral
and central venous access for transfusions.
That TIPSS can be used as an effective bridge to transplantation has
been well described by Ring et.al. (1992) and is illustrated by the 2 patients,
one in the OT group who died waiting to be transferred for transplantation
and the other who had a successful TIPSS before transplantation. The case
of the patient who underwent transection and later required TIPSS for
recurrent variceal haemorrhage and the other who died from recurrent
bleeding in the surgical group illustrates the risk of late rebleeding following
transection. The high rates of mortality from variceal rebleeding in the OT
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group is noteworthy and in sharp contrast to the results of rebleeding
following TIPSS which is usually early and due to shunt insufficiency and can
be corrected easily in most cases.
Surgical intervention does however, remain the treatment of choice for
patients with extrahepatic portal vein obstruction. Assessment of the patency
of the portal vein is necessary in all patients with uncontrolled variceal
haemorrhage. The sluggish and reversed portal blood flow may make this
assessment difficult. This is illustrated by the patient who was wrongly
diagnosed as having portal vein obstruction.
The results of this study indicate that TIPSS can be performed
successfully in very ill patients who are not fit to undergo OT and is
associated with significantly lower rates of early mortality. In this group of
very ill patients, it prolongs life and we believe, should be regarded as the
preferred mode of treatment as compared with OT for uncontrolled variceal
haemorrhage. A randomised prospective study comparing these treatments
is needed to answer this question definitively.
6.5 SODIUM HANDLING AND TIPSS
The present study addresses the changes in renal handling of sodium
and the possible mechanisms associated with these changes and shows that
TIPSS is an effective method of treating ascites in patients with cirrhosis.
TIPSS was inserted in the majority of patients for recurrent variceal
haemorrhage refractory to sclerotherapy who also had ascites rather than for
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ascites that was difficult to treat. Although ascites was controlled in the 2
patients having TIPSS for refractory ascites, both patients died of progressive
liver failure within the first 6 months of TIPSS. The experience of TIPSS in
the setting of refractory ascites, remains discouraging. Ochs et.al. (1997) in
an uncontrolled study of 50 patients concluded that, although there were
significant improvements in UNa and CrCI, mortality from the underlying liver
disease was substantial. Quiroga et.al. (1995) showed that the effect of
TIPSS for refractory ascites was also disappointing with about 40% patients
dying within the 6 months without OLT. In a study comparing TIPSS with
paracentesis, Lebrec et.al.(1994) concluded that TIPSS was effective only for
patients with milder forms of liver disease perhaps due to temporary
deterioration in liver failure that often follows insertion of TIPSS. The exact
mechanism of this is unclear although the phenomenon of diversion of blood
from the liver, constituting 'sinusoidal steal' has been blamed (Jalan et.al.
1995).
The mechanism whereby sodium handling improves after TIPSS is
multifactorial. We have shown that although there is a significant reduction in
PRA, All and PPG, none of these correlate with the changes in UNa and
CrCI. LiCI was used as a measure of sodium reabsorption proximal to the
inner medullary collecting duct. The mechanism by which TIPSS may
modulate changes in LiCI and ANP is suggested in a study by Quiroga et.al.
(1995) who showed that there was an increase in the pre-load and that the
norepinephrine concentrations were reduced after TIPSS. The former
observation would account for the change in ANP and the latter for an
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increase in LiCI (Morali et.al. 1991). It is unlikely that the improvement in LiCI
was due to the change in CrCI following TIPSS because there was no
significant correlation between these following TIPSS.
cGMP measurements in this study probably reflects the activity of
other unmeasured natriuretic factors and probably nitric oxide activity (Billiar
et.al. 1992) because the change in ANP which is the other major determinant
of cGMP levels were both not significantly different prior to TIPSS and did not
change significantly thereafter.
This study has failed to demonstrate any relationship between the
change in UNa and CrCI and Pugh score. This finding is supported by
Moreau et.al. (1993) who found no correlation between renal blood flow and
the severity of liver disease as assessed by antipyrine clearance. Wong et.al.
(1994) do however, suggest a relationship between the ability of the kidneys
to handle a sodium load due to a specific tubular defect and the severity of
liver disease.
It would have been interesting to study serial changes in the renal
sodium, hormonal profile and the portal pressure gradient. It was however,
thought unethical to catheterise the shunt outside of routine surveillance
procedure. A recent abstract (Wong et.al. 1995) did however, address the
issue of serial changes in UNa and concluded that portal hypertension and
renin-angiotensin axis are important in the pathogenesis of sodium retention
in cirrhosis and changes in the renal handling of sodium are not due to
changes in the renal haemodynamics, implicating a renal tubular defect. This
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study did however have the limitation of not having concurrent
measurements of the portal pressure gradient.
We have failed to demonstrate any direct relationship between the
degree of change in UNa and the change in PPG. Support for this
observation is provided by Moreau et.al (1993) although differing opinions
exist (Epstein et.al. 1977). It does appear that although there is a role for
portal hypertension in the aetiology of renal dysfunction in liver disease, the
absolute PPG does not appear to be important. It is likely that the renal
dysfunction in cirrhosis is multifactorial.
In conclusion, we have demonstrated that significant changes in UNa
and CrCI after TIPSS is due both to changes in the renal proximal tubular
function and a reduction in the neurohumoral factors that are involved in
sodium retention. The degree of improvement in UNa and CrCI were
independent of the severity of underlying liver disease and the change in
PPG.
6.6 HEPATORENAL REFLEX
This study shows that there is a dramatic reduction in RBF following
acute increase in the PAG. This change is not related to alteration in the
mean arterial pressure, heart rate or the right atrial pressure. The relationship
between changes in RBF and cardiac output would ideally have been studied
in the same patient but the introduction of a third line for central venous
access was thought to be unethical. Although changes in cardiac output (-
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10.9% (±6.9)) were statistically significant this change was not sufficient to
explain the magnitude of the change in RBF (-43.5% (±25.3)). Furthermore,
the changes in cardiac output were not associated with any significant
disturbance in the mean arterial pressure which is of paramount importance
in the perfusion of the kidneys.
Several theories regarding the initiation of renal vasoconstriction in
cirrhosis have been proposed. The underfill hypothesis (Witte et.al. 1971)
gave way to the overfill hypothesis (Leiberman et.al. 1970), which has been
replaced by the peripheral vasodilatation theory (Schrier et.al. 1988). The
initiating event according to the peripheral vasodilatation theory, is splanchnic
vasodilatation and portal hypertension produced by the action of splanchnic
vasodilators upon the portal and systemic circulation due to reduced
clearance and shunting of these substances from the portal to systemic
circulation through the collaterals. This causes relative underfilling of the
arterial vascular compartment, thereby activating compensatory mechanisms
which are responsible for reduction in renal blood flow and sodium retention.
RBF is regulated by intrarenal, humoral and neural factors. The
intrarenal factors that have been implicated include the kallikrein-kinin system
(MacGilchrist et.al. 1994), prostaglandins (Rimola et.al. 1986), thromboxane,
leukotrienes (Moore et.al. 1990), platelet activating factor (Caramelo et.al.
1987), endothelin (Uchihara et.al. 1992), nitric oxide (Lee et.al. 1993) and
adenosine (Llach et.al. 1993). Flumoral factors that have significant
relationship to sodium retention include changes in the renin-aldosterone-
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angiotensin axis (Bosch et.al. 1980), antidiuretic hormone (Moreau et.al.
1994) and the atrial natriuretic peptide (Gines et.al. 1988).
The kidneys are innervated by sympathetic nerves derived from T11,
T12 and L1 via the coeliac and the aortorenal ganglia. These are distributed
both to the renal microvasculature and to the different parts of the nephron
(Bajaras et.al. 1984). Stimulation of the sympathetic system produces an
increase in the renal vascular resistance thereby reducing RBF (Dibona GF
1987, DiBona GF and Swain LL 1985). The importance of lumbar
sympathetic discharge in the pathogenesis of the hepatorenal syndrome is
reflected by marked improvement in effective plasma flow following
sympathectomy (Solis-Herruzo et.al. 1987). The inverse relationship between
portal vein flow and RBF, and the reduction in RBF with acute increase in
PAG and renal resistance suggests the existence of a signaling mechanism
between the liver and the kidney.
TIPSS has been shown to be effective in the treatment of the
hepatorenal syndrome (Ochs et.al 1994, Alam et.al. 1995). The mechanism
of this improvement is not entirely clear but the results of this study provides
some clues. The reduction in portal pressure gradient by the introduction of
TIPSS may be envisaged to increase RBF through the hepatorenal axis and
therefore improve renal perfusion, creatinine clearance and sodium
excretion.
Ideally, the systemic samples for the measurement of neurohumoral
factors should have been collected from the pulmonary artery to avoid the
problems of streaming and inadequate mixing. This would involve the
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introduction of a third catheter, which was considered unethical. This
streaming effect and poor mixing may be responsible for the higher values of
ANP found in the renal vein rather than in the right atrium (ANP is produced
in orificium of the coronary sinus and then secreted into the right atrium).
Similarly, the kidneys are important in the production of renin. Higher levels
of renin are therefore expected in the renal circulation. The finding of higher
values of renin in the right atrium in this study may be related to the mixing
problem.
Higher cGMP concentration in the systemic circulation probably
reflects increased nitric oxide activity because the ANP levels were normal.
Normal adrenaline and noradrenaline concentrations in these patients may
reflect adequate shunt function and the absence of ascites. Significantly
higher concentrations of noradrenaline (vasoconstrictor) and cGMP
(reflecting nitric oxide activity - vasodilator) in the renal circulation may
represent the reciprocal role of these substances in the regulation of RBF.
Insignificant change in the ANP argues against the change in RBF being due
to a significant alteration in the circulating volume. Similarly, the renin -
angiotensin system has not been implicated in the reduction in renal blood
flow following acute increase in portal pressure gradient. These observations
are against a significant role of these humoral factors in modulating the
change in RBF and point to the existence of a hepatorenal axis in the
mediation of this phenomenon.
It was therefore somewhat surprising that the levels of adrenaline and
noradrenaline were not significantly different prior to and following shunt
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occlusion. This may either be due to the limit of detectability of the assay
used or to the rapid uptake and breakdown of these catecholamines by
synaptic mono-amine-oxidase inhibitors and catecholamine-o-methyl
transferases. The problems of streaming and inadequate mixing of blood in
the renal vein and the right atrium may be partially responsible for the normal
values of adrenaline and noradrenaline observed. Electrophysiological or
pharmacological studies are required for the confirmation of the role of the
sympathetic system as an effector arm of this phenomenon. It is also
possible that this phenomenon may be mediated by other intrarenal factors
described above. Further studies are required to ascertain the role of these
factors in the mediation of this phenomenon which may be important in the
pathogenesis of the hepatorenal syndrome.
The contribution of the reduction in cardiac output following shunt
occlusion to the reduction in RBF cannot be disregarded. Occlusion of TIPSS
appears to induce a decrease in venous return and therefore, possibly re¬
distribution in blood flow. Flowever, the change in cardiac output did not
produce any significant haemodynamic disturbance. The transient increase in
RBF between 2 and 4 minutes in 3 patients following inflation of the balloon
is difficult to explain but further argues against a significant role of reduction
in CO being important in the change in RBF. Unfortunately, in this study we
have not measured changes in CO at these time points. The statistical
insignificance of the change in mean arterial pressure is unlikely to be due to
the number of patients studied in each group because the difference
remained inconsequential even when changes in both groups were
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considered together. Finally, as pointed out above, the degree of reduction in
CO cannot fully explain the changes in RBF.
In conclusion, we have demonstrated a dramatic reduction in RBF with
acute increase in PAG which is compatible with the existence of hepatorenal
reflex in man, although other mechanisms may also be contributory. This is a
reproducible model which can be used to study this phenomenon further,
enhance our understanding of the changes in renal circulation in liver disease
thereby, providing clues for the development of newer treatments.
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6.7 OVERALL CONCLUSIONS
The introduction of TIPSS into clinical practice has provided an
exciting new modality of treatment that is widely applicable to treat the most
dreaded complication of portal hypertension, i.e. variceal haemorrhage.
Although there is little doubt about the role of TIPSS in the management of
uncontrolled variceal haemorrhage in patients with cirrhosis, further larger
studies are needed to determine the role of TIPSS in the secondary
prophylaxis of variceal haemorrhage in patients with cirrhosis. TIPSS
produces significant improvement in sodium excretion in patients with
cirrhosis but its use in patients with refractory ascites and hepatorenal failure
require further evaluation.
The 'Achilles heel' of TIPSS is shunt insufficiency. Innovative
methods such as the use of 'covered stents' and shunt brachytherapy require
further evaluation. Transient deterioration of liver function after TIPSS occurs
in about 40% patients and patient selection to determine which patients are
likely to die within a few weeks of TIPSS requires clarification. The incidence
of encephalopathy after TIPSS is elevated and the use of further
modifications of the type of stent, such as those that can produce an end-to-
side portacaval shunt may be necessary to prevent this complication.
Finally, and perhaps most importantly, TIPSS provides repeated
access to the portal system and will allow understanding of the pathogenesis
of portal hypertension and hepatic encephalopathy.
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